UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20541
FORM 10-K
ý ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2018
o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 001-36007 (Physicians Realty Trust)
Commission file number: 333-205034-01 (Physicians Realty L.P.)
(Exact Name of Registrant as Specified in Its Charter)
Maryland (Physicians Realty Trust) Delaware (Physicians Realty L.P.) | 46-2519850 80-0941870 | |
(State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) | |
309 N. Water Street Suite 500 Milwaukee, Wisconsin | 53202 | |
(Address of Principal Executive Offices) | (Zip Code) | |
(414) 367-5600
(Registrant’s telephone number, including area code)
Securities registered under Section 12(b) of the Act:
Registrant | Title of Each Class | Name of Each Exchange On Which Registered | ||
Physicians Realty Trust | Common Shares, $0.01 par value | New York Stock Exchange | ||
Securities registered under Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Physicians Realty Trust Yes ý No o Physicians Realty L.P. Yes o No ý
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
Physicians Realty Trust Yes o No ý Physicians Realty L.P. Yes o No ý
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Physicians Realty Trust Yes ý No o Physicians Realty L.P. Yes ý No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Physicians Realty Trust Yes ý No o Physicians Realty L.P. Yes ý No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Physicians Realty Trust | Large accelerated filer ý Accelerated filer o Non-accelerated filer o Smaller reporting company o Emerging growth company o |
Physicians Realty L.P. | Large accelerated filer o Accelerated filer o Non-accelerated filer ý Smaller reporting company o Emerging growth company o |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Physicians Realty Trust o Physicians Realty L.P. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Physicians Realty Trust Yes o No ý Physicians Realty L.P. Yes o No ý
The aggregate market value of Physicians Realty Trust’s common shares held by non-affiliates as of June 30, 2018 was approximately $2,886,115,067 based upon the closing price reported for such date on the New York Stock Exchange. There is no established trading market for units of Physicians Realty L.P.
As of February 22, 2019, there were 182,417,778 shares of Physicians Realty Trust’s common shares outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
The information required by Part III of this Annual Report on Form 10-K, to the extent not set forth in this Form 10-K, is incorporated herein by reference from Physicians Realty Trust’s definitive proxy statement relating to the annual meeting of shareholders to be held on April 30, 2019, to be filed with the Securities and Exchange Commission within 120 days after the end of the Registrant’s fiscal year ended December 31, 2018.
EXPLANATORY NOTE
This Annual Report on Form 10-K combines the Annual Reports on Form 10-K for the year ended December 31, 2018 of Physicians Realty Trust (the “Trust”), a Maryland real estate investment trust, and Physicians Realty L.P. (the “Operating Partnership”), a Delaware limited partnership. Unless otherwise indicated or unless the context requires otherwise, all references in this report to “we,” “us,” “our,” the “Company,” and “Physicians Realty” refer to the Trust, together with its consolidated subsidiaries, including the Operating Partnership. References to the “Operating Partnership” mean collectively the Operating Partnership together with its consolidated subsidiaries. In this report, all references to “common shares” refer to the common shares of the Trust and references to “our shareholders” refer to shareholders of the common shares of the Trust, the term “OP Units” refers to partnership interests of the Operating Partnership and the term “Series A Preferred Units” refers to Series A Participating Redeemable Preferred Units of the Operating Partnership. As of February 22, 2019, 104,172 Series A Preferred Units were outstanding.
The Trust is a self-managed real estate investment trust (“REIT”) formed primarily to acquire, selectively develop, own, and manage healthcare properties that are leased to physicians, hospitals, and healthcare delivery systems. The Trust operates in an umbrella partnership REIT structure (“UPREIT”) in which the Operating Partnership and its subsidiaries hold substantially all of the assets. The Trust’s operations are conducted through the Operating Partnership and wholly-owned and majority-owned subsidiaries of the Operating Partnership. The Trust, as the general partner of the Operating Partnership, controls the Operating Partnership and consolidates the assets, liabilities, and results of operations of the Operating Partnership.
The Trust conducts substantially all of its operations through the Operating Partnership. As of December 31, 2018, the Trust held a 97.2% interest in the Operating Partnership and owns no Series A Preferred Units. Apart from this ownership interest, the Trust has no independent operations.
Noncontrolling interests in the Operating Partnership, and shareholders’ equity of the Trust and partners’ capital of the Operating Partnership are the primary areas of difference between the consolidated financial statements of the Trust and those of the Operating Partnership. OP Units not owned by the Trust are accounted for as limited partners’ capital in the Operating Partnership’s consolidated financial statements and as noncontrolling interests in the Trust’s consolidated financial statements. The differences between the Trust’s shareholders’ equity and the Operating Partnership’s partners’ capital are due to the differences in the equity issued by the Trust and the Operating Partnership, respectively.
The Company believes combining the Annual Reports of the Trust and the Operating Partnership, including the notes to the consolidated financial statements, into this single report results in the following benefits:
• | a combined report enhances investors’ understanding of the Trust and the Operating Partnership by enabling investors to view the business as a whole in the same manner as management views and operates the business; |
• | a combined report eliminates duplicative disclosure and provides a more streamlined and readable presentation, as a substantial portion of the Company’s disclosure applies to both the Trust and the Operating Partnership; and |
• | a combined report creates time and cost efficiencies through the preparation of one combined report instead of two separate reports. |
To help investors understand the significant differences between the Trust and the Operating Partnership, this report presents the following separate sections for each of the Trust and the Operating Partnership:
• | the market for registrant’s common equity, related stockholder matters and issuer purchases of equity securities in Item 5 of this report; |
• | selected financial data in Item 6 of this report; |
• | the consolidated financial statements in Item 8 and Item 15 of this report; |
• | certain accompanying notes to the consolidated financial statements, including Note 14 (Earnings Per Share and Earnings Per Unit) and Note 16 (Quarterly Data); |
• | controls and procedures in Item 9A of this report; and |
• | the certifications of the Chief Executive Officer and the Chief Financial Officer included as Exhibits 31 and 32 to this report. |
PHYSICIANS REALTY TRUST AND PHYSICIANS REALTY L.P.
Annual Report on Form 10-K for the Year Ended December 31, 2018
Table of Contents
Page | |
Forward-Looking Statements
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K contains forward-looking statements made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts may be forward-looking statements within the meaning of the federal securities laws. In particular, statements pertaining to our capital resources, property performance and results of operations contain forward-looking statements. Likewise, all of our statements regarding anticipated growth in our funds from operations and anticipated market conditions, demographics and results of operations are forward-looking statements. You can identify forward-looking statements by the use of forward-looking terminology such as “believe,” “expect,” “outlook,” “continue,” “project,” “may,” “will,” “should,” “seek,” “approximately,” “intend,” “plan,” “pro forma,” “estimate,” or “anticipate” or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. You can also identify forward-looking statements by discussions of strategy, plans, expectations, or intentions.
These forward-looking statements reflect the views of our management regarding current expectations and projections about future events and are based on currently available information. These forward-looking statements are not guarantees of future performance and involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data, or methods which may be incorrect or imprecise and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:
• | general economic conditions; |
• | adverse economic or real estate developments, either nationally or in the markets where our properties are located; |
• | our failure to generate sufficient cash flows to service our outstanding indebtedness, or our ability to pay down or refinance our indebtedness; |
• | fluctuations in interest rates and increased operating costs; |
• | the availability, terms and deployment of debt and equity capital, including our unsecured revolving credit facility; |
• | our ability to make distributions on our common shares; |
• | general volatility of the market price of our common shares; |
• | our increased vulnerability economically due to the concentration of our investments in healthcare properties; |
• | our geographic concentration in Texas causes us to be particularly exposed to downturns in the Texas economy or other changes in Texas market conditions; |
• | changes in our business or strategy; |
• | our dependence upon key personnel whose continued service is not guaranteed; |
• | our ability to identify, hire, and retain highly qualified personnel in the future; |
• | the degree and nature of our competition; |
• | changes in governmental regulations or interpretations thereof, such as real estate and zoning laws and increases in real property tax rates, taxation of REITs, and similar matters; |
• | defaults under or non-renewal of leases by tenants; |
• | decreased rental rates or increased vacancy rates; |
• | difficulties in identifying healthcare properties to acquire and completing acquisitions; |
2
• | competition for investment opportunities; |
• | any adverse effects to the business, financial position or results of operations of Catholic Health Initiatives (“CHI”), or one or more of the CHI-affiliated tenants, that impact the ability of CHI-affiliated tenants to pay us rent; |
• | the impact of our investments in joint ventures we may make in the future; |
• | the financial condition and liquidity of, or disputes with, any joint venture and development partners with whom we may make co-investments in the future; |
• | cybersecurity incidents could disrupt our business and result in the compromise of confidential information; |
• | our ability to operate as a public company; |
• | changes in healthcare laws or government reimbursement rates; |
• | changes in accounting principles generally accepted in the United States (GAAP); |
• | lack of or insufficient amounts of insurance; |
• | other factors affecting the real estate industry generally; |
• | our failure to maintain our qualification as a REIT for U.S. federal income tax purposes; |
• | limitations imposed on our business and our ability to satisfy complex rules in order for us to qualify as a REIT for U.S. federal income tax purposes; and |
• | Other factors that may materially adversely affect us, or the per share trading price of our common shares, including: |
• | the number of our common shares available for future issuance or sale; |
• | our issuance of equity securities or the perception that such issuance might occur; |
• | future debt; |
• | failure of securities analysts to publish research or reports about us or our industry; and |
• | securities analysts’ downgrade of our common shares or the healthcare-related real estate sector. |
While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. We disclaim any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this report, except as required by applicable law. You should not place undue reliance on any forward-looking statements that are based on information currently available to us or the third parties making the forward-looking statements. For a further discussion of these and other factors that could impact our future results, performance or transactions, see Part I, Item 1A. “Risk Factors” of this report.
3
PART I
ITEM 1. BUSINESS
Overview
Physicians Realty Trust, a Maryland real estate investment trust, and Physicians Realty L.P., a Delaware limited partnership, were organized in April 2013 to acquire, selectively develop, own and manage healthcare properties that are leased to physicians, hospitals and healthcare delivery systems. Unless otherwise indicated or unless the context requires otherwise, all references in this report to “we,” “us,” “our,” the “Company,” and “Physicians Realty” refer to the Trust, together with its consolidated subsidiaries, including the Operating Partnership. References to the “Operating Partnership” mean collectively the Operating Partnership together with its consolidated subsidiaries. We completed our initial public offering (“IPO”) in July 2013. The Trust’s common shares are listed on the New York Stock Exchange (“NYSE”) and it is included in the MSCI US REIT Index.
We have grown our portfolio of gross real estate investments from approximately $124 million at the time of our IPO to approximately $4.4 billion as of December 31, 2018. As of December 31, 2018, our portfolio consisted of 252 healthcare properties located in 30 states with approximately 13,624,598 net leasable square feet, which were approximately 96% leased with a weighted average remaining lease term of approximately 7.9 years. As of December 31, 2018, approximately 90% of the net leasable square footage of our portfolio was either on campus with a hospital or other healthcare facility or strategically affiliated with a hospital or other healthcare facility.
We receive a cash rental stream from healthcare providers under our leases. Approximately 93.0% of the annualized base rent payments from our properties as of December 31, 2018 are from absolute and triple-net leases, pursuant to which the tenants are responsible for all operating expenses relating to the property, including but not limited to real estate taxes, utilities, property insurance, routine maintenance and repairs, and property management. This structure helps insulate us from increases in certain operating expenses and provides relatively predictable cash flow. We seek to structure our leases to generate attractive returns on a long-term basis. Our leases typically have initial terms of 5 to 15 years and include annual rent escalators of approximately 1.5% to 3.0%. Our operating results depend significantly upon the ability of our tenants to make required rental payments. We believe that our portfolio of medical office buildings and other healthcare facilities will enable us to generate stable cash flows over time because of the diversity of our tenants, staggered lease expiration schedule, long-term leases, and low historical occurrence of tenants defaulting under their leases. As of December 31, 2018, leases representing a percentage of our portfolio on the basis of leased square feet will expire as follows:
Year | Portfolio Lease Expirations | |
MTM (1) | 0.9% | |
2019 | 2.7% | |
2020 | 3.6% | |
2021 | 4.4% | |
2022 | 4.9% | |
2023 | 4.7% | |
2024 | 5.9% | |
2025 | 7.1% | |
2026 | 27.5% | |
2027 | 9.2% | |
2028 | 10.1% | |
Thereafter | 19.0% | |
Total | 100.0% | |
(1) | “MTM” means month-to-month. This line also includes 5 leases which expired on December 31, 2018, representing 0.2% of portfolio leasable square feet. |
We invest in real estate that is integral to providing high quality healthcare services. Our properties are typically located on a campus with a hospital or other healthcare facilities or strategically affiliated with a hospital or other healthcare system. We believe the impact of government programs and continuing trends in the healthcare industry create attractive opportunities for us to invest in healthcare-related real estate. Our management team has significant public healthcare REIT experience and has long established relationships with physicians, hospitals, and healthcare delivery system decision makers that we believe will provide quality investment and growth opportunities. Our principal investments include medical office
4
buildings, outpatient treatment facilities, and other real estate integral to health care providers. We seek to generate attractive risk-adjusted returns for our shareholders through a combination of stable and increasing dividends and potential long-term appreciation in the value of our properties and our common shares.
The Trust is a Maryland real estate investment trust and has elected to be taxed as a REIT for U.S. federal income tax purposes. We conduct our business through an umbrella partnership REIT structure in which our properties are owned by the Operating Partnership directly or through limited partnerships, limited liability companies, or other subsidiaries. The Trust is the sole general partner of the Operating Partnership and, as of February 22, 2019, owned approximately 97.2% of the OP Units.
Our Objectives and Growth Strategy
Overview
Our principal business objective is to provide attractive risk-adjusted returns to our shareholders through a combination of (i) sustainable and increasing rental revenue and cash flow that generate reliable, increasing dividends, and (ii) potential long-term appreciation in the value of our properties and common shares. Our primary strategies to achieve our business objective are to leverage our physician and hospital relationships nationwide to invest in off-market assets that maximize risk-adjusted returns to our shareholders, to invest in, own, and manage a diversified portfolio of high quality healthcare properties, and to understand our tenants’ real estate strategies, which we believe will drive high retention, high occupancy and reliable, increasing rental revenue and cash flow.
We intend to grow our portfolio of high-quality healthcare properties leased to physicians, hospitals, healthcare delivery systems, and other healthcare providers primarily through acquisitions of existing healthcare facilities that provide stable revenue growth and predictable long-term cash flows. We may also selectively finance the development of new healthcare facilities through joint venture or fee arrangements with premier healthcare real estate developers. Generally, we expect to make investments in new development properties when approximately 80% or more of the development property has been pre-leased before construction commences. We seek to invest in properties where we can develop strategic alliances with financially sound healthcare providers and healthcare delivery systems that offer need-based healthcare services in sustainable healthcare markets. We focus our investment activity on the following types of healthcare properties:
• | medical office buildings; |
• | outpatient treatment and diagnostic facilities; |
• | physician group practice clinics; |
• | ambulatory surgery centers; and |
• | specialty hospitals and treatment centers. |
We believe that shifting consumer preferences, limited space in hospitals, the desire of patients and healthcare providers to limit non-essential services provided in a hospital setting, and cost considerations, among other trends, continue to drive the industry trend of performing procedures in outpatient facilities that have traditionally been performed in hospitals, such as surgeries and other invasive medical procedures. As these trends continue, we believe that demand for medical office buildings and similar healthcare properties will continue to rise, and that our investment strategy accounts for these trends.
We may invest opportunistically in life science facilities, assisted living facilities, independent senior living facilities, senior housing properties, and skilled nursing facilities. Consistent with the Trust’s qualification as a REIT, we may also opportunistically invest in companies that provide healthcare services, and in joint venture entities with operating partners structured to comply with the REIT Investment Diversification Act of 2007 (“RIDEA”).
In connection with our review and consideration of healthcare real estate investment opportunities, we generally take into account a variety of market considerations, including:
• | whether the property is anchored by a financially-sound healthcare delivery system or whether tenants have strong affiliation to a healthcare delivery system; |
• | the performance of the local healthcare delivery system and its future prospects; |
• | property location, with a particular emphasis on proximity to healthcare delivery systems; |
• | demand for medical office buildings and healthcare related facilities, current and future supply of competing properties, and occupancy and rental rates in the market; |
• | population density and growth potential; |
5
• | ability to achieve economies of scale with our existing medical office buildings and healthcare related facilities or anticipated investment opportunities; and |
• | existing and potential competition from other healthcare real estate owners and operators. |
In addition, our management team has maintained a conservative balance sheet while investing over $4.4 billion as of December 31, 2018 in real estate assets since our IPO in July 2013. For short-term purposes, we may borrow on our primary unsecured credit facility. From time to time, we replace these borrowings with long-term capital such as senior unsecured notes and equity, or alternative securities (i.e. debt convertible to equity). We selectively utilize capital market transactions in furtherance of our investment strategy, including, amending our Credit Agreement (as hereinafter defined) to extend the maturity date of the revolving credit facility and to reduce the interest rate margin applicable to borrowings, and the raising of an additional $9.9 million of equity through sales under our ATM Program (as hereinafter defined).
Business Strategy
We are focused on building and maintaining a portfolio of high-quality healthcare properties leased to physicians, hospitals, healthcare delivery systems, and other healthcare providers. Our investment strategy includes a focus on investments with the following key attributes:
• | We seek to invest in properties serving healthcare systems with dominant market share, high credit quality and those who are investing capital into their campuses. In particular, we seek to own off-market or selectively marketed assets with attractive demographics, economic growth, and high barriers to entry. We seek to invest in and maintain well occupied properties that we believe are critical to the delivery of healthcare. |
• | We emphasize ensuring an appropriate and balanced mix of tenants to provide synergies within both individual buildings and the broader health system campus. Our primary tenants are healthcare systems, academic medical centers and leading physician groups. These groups typically have strong and stable financial performance. We believe this helps ensure stability in our rental income and tenant retention over time. |
• | We seek to maintain a core, critical portfolio of properties and to build our reputation as a dedicated leading MOB owner and operator. |
• | We seek to maintain or increase our average rental rates, and focus on actively leasing our vacant space and reducing leasing concessions. |
In addition, we seek to invest in properties where we can develop strategic alliances with financially sound healthcare providers and healthcare delivery systems that offer need-based healthcare services in sustainable healthcare markets, and consider the potential for long-term relationships and repeat business when assessing acquisition potential.
We actively manage our balance sheet to maintain our investment grade credit rating, to maintain an appropriate level of leverage and to preserve financing flexibility for funding of future acquisitions. In particular, we:
• | Continue to maintain a high level of liquidity, including borrowing availability under our unsecured revolving credit facility. |
• | Maintain access to multiple sources of capital, including private debt issuances, public bond offerings, public equity offerings, and unsecured bank loans. |
• | Periodically review our portfolio to consider potential dispositions of relatively lower quality properties to reinvest the proceeds into high quality properties. |
• | Closely monitor our existing debt maturities and average interest rates. |
6
2018 Highlights and Other Recent Developments
Investment Activity
• | For the full year 2018, we completed acquisitions of 4 operating healthcare properties and 1 land parcel. These properties are located in 5 states for an aggregate purchase price of approximately $252.8 million. In addition, we funded $18.2 million of other investments, including the issuance of loans and buyouts of noncontrolling interests, resulting in total investments of $271.0 million. We also acquired 2 properties and an adjacent land parcel through the conversion and satisfaction of a previously outstanding construction loan, valued at an aggregate $18.8 million. Additionally, we acquired 2 parcels of land, which we had previously ground leased, as the result of a lease restructuring arrangement and equity recapitalization. |
• | During 2018, we sold 34 medical office buildings located in 9 states for approximately $220.4 million and recognized a net gain of approximately $11.7 million. |
• | On January 18, 2019, the Company made a construction loan to finance the construction of a 27,000 square foot cancer center in Denton, Texas up to $15.5 million. The loan bears interest at a rate of 5.50% on the outstanding principal balance during construction and 6.25% following substantial completion. The loan is secured by a first deed of trust on the real estate and a completion guaranty, and includes a purchase option that is exercisable upon the first anniversary of substantial completion. The 100% pre-leased development is located across the street from the 208-bed Texas Health Presbyterian Hospital Denton campus, and is expected to include expanded radiation oncology services, CT, PET-CT, and a state of the art infusion center with direct access to a healing garden. As of February 22, 2019, $5.0 million has been funded under the construction loan facility. |
• | On February 13, 2019, the Company funded a $15.0 million term loan that is secured by a first mortgage on real estate being developed in Columbus, Ohio and by a full recourse guaranty. The loan bears interest at a rate of 8.5% during its one-year term. |
Assets Slated for Disposition
• | We consider 6 properties in three states, representing an aggregate of approximately 320,270 square feet of gross leasable area, to be slated for disposition as of December 31, 2018. These assets consist of five assets formerly affiliated with Foundation Healthcare, Inc. (formerly OTC: FDNH) (“Foundation Healthcare”) and one additional property which we believe no longer meets our core business strategy from a geography and line of business perspective. |
Capital Markets and Dividends
• | In August 2016, we entered into separate At Market Issuance Sales Agreements (the “Sales Agreements”) with each of KeyBanc Capital Markets Inc., Credit Agricole Securities (USA) Inc., JMP Securities LLC, Raymond James & Associates, Inc., and Stifel Nicolaus & Company, Incorporated (the “Agents”), pursuant to which we may issue and sell, from time to time, our common shares having an aggregate offering price of up to $300.0 million, through the Agents (the “ATM Program”). During the fiscal year-ended December 31, 2018, we issued and sold pursuant to the ATM Program 570,551 common shares at a weighted average price of $17.50 per share, resulting in net proceeds to us of approximately $9.9 million. |
Our Industry and Market Opportunity
The nature of healthcare delivery continues to evolve due to the impact of government programs, regulatory changes and consumer preferences. We believe these changes have increased the need for capital among healthcare providers and increased pressure on these providers to integrate more efficient real estate solutions in order enhance the delivery of quality healthcare. In particular, we believe the following factors and trends are creating an attractive environment in which to invest in healthcare properties.
7
$3.3 Trillion Healthcare Industry Projected to Grow to $5.7 Trillion (and 19.7% of U.S. GDP) by 2026
According to the U.S. Department of Health and Human Services (“HHS”), healthcare spending accounted for 17.9% of U.S. gross domestic product (“GDP”) in 2016. The general aging of the population, driven by the Baby Boomer generation and advances in medical technology and services which increase life expectancy, are key drivers of the growth in healthcare expenditures. The anticipated continuing increase in demand for healthcare services, together with an evolving complex and costly regulatory environment, changes in medical technology and reductions in government reimbursements are expected to pressure capital-constrained healthcare providers to find cost effective solutions for their real estate needs.
We believe the demand by healthcare providers for healthcare real estate will increase as healthcare spending in the United States continues to increase. According to the Centers for Medicare & Medicaid Services’ National Health Expenditure Projections 2017-2026, national healthcare expenditures continue to rise and are projected to grow from an estimated $3.5 trillion in 2017 to $5.7 trillion by 2026, representing an average annual rate of growth of 5.5%, reaching a projected 19.7% of GDP in 2026.
Source: Centers for Medicare & Medicaid Services, Office of the Actuary
Aging Population
The aging of the U.S. population has a direct effect on the demand for healthcare as older persons generally utilize healthcare services at a rate well in excess of younger people. According to the U.S. Census Bureau, the U.S. population over 65 years of age is projected to more than double from 49.2 million to nearly 94.7 million and the 85 and older population is expected to more than triple, from 6.4 million to 19.0 million, between 2016 and 2060. Also according to the U.S. Census Bureau, the number of older Americans is growing as a percentage of the total U.S. population with the number of persons older than 65 estimated to comprise 15.2% of the total U.S. population in 2016 and projected to grow to 23.5% by 2060.
We believe that healthcare expenditures for the population over 65 years of age will continue to rise as a disproportionate share of healthcare dollars is spent on older Americans. To illustrate, in 2012 the elderly (65+ years old) represented only 14% of the population while accounting for 34% of all healthcare-related spending. We believe the older population group increasingly will require treatment and management of chronic and acute health ailments and that this increased demand for healthcare services will create a substantial need for additional medical office buildings and other facilities that serve the healthcare industry in many regions of the United States. Additionally, we believe there will likely be a focus on lowering the cost of outpatient care to support the aging U.S. population, which will continue to support medical office and outpatient facility property demand in the long term. For example, beginning in 2019, CMS expanded the list of procedures that can be performed and reimbursed in outpatient surgery centers to include 12 cardiac catherization diagnostic procedures and 5 ancillary procedures. We believe these trends will result in a substantial increase in the number of properties meeting our investment criteria.
8
We believe advances in medical technology will continue to enable healthcare providers to identify and treat once fatal illnesses and improve the survival rate of critically ill and injured patients who will require continuing medical care. Along with these technical innovations, the U.S. population is growing older and living longer.
Source: U.S. Census Bureau
Affordable Care Act
The Affordable Care Act (as hereinafter defined) constituted a significant overhaul of many aspects of healthcare regulations and health insurance, and created the framework for healthcare services over the near term. It required every American to have health insurance or be subjected to a tax. Those who cannot afford health insurance are offered insurance subsidies or Medicaid coverage. On December 14, 2018, a federal district court in Texas ruled that the Affordable Care Act’s individual mandate was unconstitutional. However, the Affordable Care Act will remain in place pending an appeal.
The U.S. Census Bureau estimated that approximately 50 million Americans did not have healthcare insurance in 2009, before the Affordable Care Act was enacted. The HHS reported that approximately 28.1 million Americans did not have health insurance in 2016. The Affordable Care Act and subsequent legislation, executive orders and events, as well as their potential impact on our business, are discussed more fully under Item 1, “Business,” under the caption “Certain Government Regulations.”
We believe the increase in the number of Americans with access to health insurance will result in an increase in physician office visits and an overall rise in healthcare utilization which in turn will drive a need for expansion of medical, outpatient, and smaller specialty hospital facilities. We also believe the increased dissemination of health research through media outlets, marketing of healthcare products, and availability of advanced screening techniques and medical procedures have contributed to a more engaged population of healthcare users and has created increased demand for customized facilities providing specialized, preventive and integrative healthcare services.
We further believe the provisions of the Affordable Care Act that are designed to lower certain reimbursement amounts under Medicare and tie reimbursement levels to the quality of services provided will increase the pressure on healthcare providers to become more efficient in their business models, invest capital in their businesses, lower costs and improve the quality of care, which in turn will drive healthcare systems to monetize their real estate assets and create demand for new, modern and specialized facilities.
9
Clinical Care Continues to Shift to Outpatient Care
According to the American Hospital Association, procedures traditionally performed in hospitals, such as certain types of surgery, are increasingly moving to outpatient facilities driven by advances in clinical science, shifting consumer preferences, limited or inefficient space in existing hospitals, and lower costs in the outpatient environment. This continuing shift toward delivering healthcare services in an outpatient environment rather than a traditional hospital environment increases the need for additional outpatient facilities and smaller, more specialized and efficient hospitals. Studies by the Medicare Payment Advisory Commission and others have shown that healthcare is delivered more cost effectively and with higher patient satisfaction when it is provided on an outpatient basis. Increasingly, hospital admissions are reserved for the critically ill, and less critical patients are treated on an outpatient basis with recuperation in their own homes. We believe healthcare market trends toward outpatient care will continue to push healthcare services out of larger, older, inefficient hospitals and into newer, more efficient and conveniently located outpatient facilities and smaller specialized hospitals. We believe that increased specialization within the medical field is also driving demand for medical facilities designed specifically for particular specialties and that physicians want to locate their practices in medical office space that is in or adjacent to these facilities.
Impact of BBA on Outpatient Care
Section 603 Assets: Section 603 of the Bipartisan Budget Act of 2015 (the “2015 BBA”) generally prohibits hospital outpatient departments (“HOPDs”) from charging preferential hospital outpatient department rates for Medicare patients treated in “off-campus” locations on or after January 1, 2017, potentially impacting their profitability. These preferential Medicare rates are only permitted if the hospital provides HOPD services in a building within 250 yards of the hospital’s main inpatient location. A hospital HOPD can be grandfathered by the 2015 BBA even if the location is outside the 250 yard distance. Under the statutory authority, an off-campus HOPD facility in existence as of November 2, 2015 can be “grandfathered” and can continue to be paid at the preferential HOPD rates, if, among other things, the hospital was billing HOPD services in that location on a HOPD basis as of November 2, 2015 and continues to provide those services in that location. On November 21, 2018, the Secretary issued a final rule, effective January 1, 2019, that eliminates the higher, Outpatient Prospective Payment System reimbursement rate for evaluation and management services provided by Grandfathered HOPD locations. The Secretary, instead, will only reimburse for evaluation and management services at the lower, Medicare Physician Fee Schedule rate that new non-grandfathered off-campus HOPD locations receive. See Centers for Medicare & Medicaid Services, Medicare Program: Changes to Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs, Department of Health and Human Services, 83 Fed. Reg. 58,818 (November 21, 2018) (“Final Rule”). The American Hospital Association (the “AHA”) and a number of hospitals have sued the Secretary in federal court to enforce the plain meaning of Section 603 of the BBA and restore the right to Grandfathered HOPD reimbursement rates. “Grandfathered” hospitals providing HOPD services in our portfolio are referred to as 603 assets in our SEC reports and other public disclosures.
We own a number of assets that will continue to be reimbursed at hospital inpatient rates, which we refer to as “603 assets” after the applicable section of the BBA. Rent derived from these 603 assets accounts for approximately 18% of our total portfolio annualized base rent as of December 31, 2018. Depending upon the implementation of the regulations, the BBA may enhance the value of these 603 assets because existing HOPDs may lose their higher reimbursements rates should they choose to change locations.
Portfolio Summary
Please see “Item 2. Properties” for a table that summarizes our portfolio as of December 31, 2018.
Geographic Concentration
As of December 31, 2018, approximately 15.4% of our total annualized base rent was derived from properties located in Texas.
As a result of this geographic concentration, we are particularly exposed to downturns in the Texas economy or other changes in local real estate market conditions. Any material change in the current payment programs or regulatory, economic, environmental, or competitive conditions in Texas could have a disproportionate effect on our overall business results. In the event of negative economic or other changes in the Texas market, our business, financial condition, and results of operations, our ability to make distributions to our shareholders and the market price of our common shares may be adversely affected. See the discussion under Item 1A, “Risk Factors,” under the caption, “Economic and other conditions that negatively affect geographic areas in which we conduct business, and in particular Texas, and other areas to which a greater percentage of our revenue is attributed could materially adversely affect our business, results of operations, and financial condition.”
10
Customer Concentration
We receive substantially all of our revenue as rent payments from tenants under leases of space in our healthcare properties, with our five largest tenants based upon rental revenue representing approximately $54.9 million, or 19.2%, of the annualized base rent from our properties as of December 31, 2018. No one tenant represents more than 5.7% of our total annualized base rent; however, 19.2% of our total annualized base rent as of December 31, 2018 is from tenants affiliated with CHI. We have no control over the success or failure of our tenants’ businesses and, at any time, any of our tenants may experience a downturn in its business that may weaken its financial condition. Our business, financial position, or results of operation could be materially adversely affected if CHI were to experience a material adverse effect on its business, financial position, or results of operations.
Competition
We compete with many other entities engaged in real estate investment activities for acquisitions of healthcare properties, including national, regional and local operators, acquirers, and developers of healthcare-related real estate properties and other investors such as private equity firms, some of whom may have greater financial resources and lower costs of capital than we do. The competition for healthcare-related real estate properties may significantly increase the price that we must pay for healthcare properties or other assets that we seek to acquire, and our competitors may succeed in acquiring those properties or assets themselves. In addition, our potential acquisition targets may find our competitors to be more attractive because they may have greater resources, may be willing to pay more for the properties or may have a more compatible operating philosophy. In particular, larger REITs that target healthcare properties may enjoy significant competitive advantages that result from, among other things, a lower cost of capital, enhanced operating efficiencies, more personnel, and market penetration and familiarity with markets. In addition, the number of entities and the amount of funds competing for suitable investment properties may increase. Increased competition would result in increased demand for the same assets and therefore increase prices paid for them. Those higher prices for healthcare properties or other assets may adversely affect our returns from our investments.
We also face competition in leasing available MOBs and other facilities that serve the healthcare industry to prospective tenants. As a result, we may have to provide rent concessions, incur charges for tenant improvements, offer other inducements, or we may be unable to timely lease vacant space in our properties, all of which may have a material adverse impact on our results of operations.
Seasonality
Our business has not been, and we do not expect it to become, subject to material seasonal fluctuations.
Employees
At December 31, 2018, we had 70 full-time employees, none of whom are subject to a collective bargaining agreement. We believe that relations with our employees are positive.
Environmental Matters
As an owner of real estate, we are subject to various federal, state, and local environmental laws, regulations, and ordinances and also could be liable to third parties as a result of environmental contamination or noncompliance at our properties even if we no longer own such properties. See the discussion under Item 1A, “Risk Factors,” under the caption “Environmental compliance costs and liabilities associated with owning, leasing, developing and operating our properties may affect our results of operations.”
11
Certain Government Regulations
Overview
Our tenants and operators are typically subject to extensive and complex federal, state, and local healthcare laws and regulations relating to fraud and abuse practices, government reimbursement, licensure, protection of patient health information, and certificate of need and similar laws governing the operation of healthcare facilities, and we expect that the healthcare industry, in general, will continue to face increased regulation and pressure in the areas of fraud, waste and abuse, cost control, healthcare management, and provision of services, among others. These regulations are wide-ranging and can subject our tenants and operators to civil, criminal and administrative sanctions. Affected tenants and operators may find it increasingly difficult to comply with this complex and evolving regulatory environment because of a relative lack of guidance in many areas as certain of our healthcare properties are subject to oversight from several government agencies and the laws may vary from one jurisdiction to another. Changes in laws and regulations, reimbursement enforcement activity and regulatory non-compliance by our tenants and operators can all have a significant effect on their operations and financial condition, which in turn may adversely impact us, as detailed below and set forth under Item 1A, “Risk Factors,” under the caption “The healthcare industry is heavily regulated, and new laws or regulations, changes to existing laws or regulations, enforcement of these laws, loss of licensure, or failure to obtain licensure could adversely impact our company and result in the inability of our tenants to make rent payments to us.”
In 2017, Congress came within a single vote of repealing of the Affordable Care Act and substantially reducing funding to the Medicaid program. New legislation may be introduced in the future, proposing changes, if not full repeal of the Affordable Care Act. Beyond this, significant changes to commercial health insurance and government-sponsored insurance (i.e., Medicare and Medicaid) remain possible. Commercial and government payors are likely to continue imposing larger discounts and tighter cost controls upon operators, through reductions in reimbursement rates and changes in payment methodologies, discounted fee structures, the assumption by healthcare providers of all or a portion of the financial risk or otherwise. A shift toward less comprehensive health insurance coverage and increased consumer cost-sharing on health expenditures could have a material adverse effect on certain of our operators’ liquidity, financial condition, and results of operations and, in turn, their ability to satisfy their contractual obligations, including making rental payments under and otherwise complying with the terms of our leases.
The following is a discussion of certain laws and regulations generally applicable to our operators, and in certain cases, to us.
Healthcare Legislation
Health Reform Laws. On March 23, 2010, President Obama signed into law the Patient Protection and Affordable Care Act of 2010 (the “Affordable Care Act”) and the Health Care and Education Reconciliation Act of 2010, which amends the Affordable Care Act (collectively with other subsequently enacted federal health care laws and regulations, the “Health Reform Laws”). The Health Reform Laws contain various provisions that may directly impact us or the operators and tenants of our properties. Some provisions of the Health Reform Laws may have a positive impact on our operators’ or tenants’ revenues, by, for example, increasing coverage of uninsured individuals, while others may have a negative impact on the reimbursement of our operators or tenants by, for example, altering the market basket adjustments for certain types of health care facilities. The Health Reform Laws also enhance certain fraud and abuse penalty provisions that could apply to our operators and tenants, in the event of one or more violations of the federal health care regulatory laws. In addition, there are provisions that impact the health coverage that we and our operators and tenants provide to our respective employees. The Health Reform Laws also provide additional Medicaid funding to allow states to carry out the expansion of Medicaid coverage to certain financially-eligible individuals beginning in 2014, and have also permitted states to expand their Medicaid coverage to these individuals since April 1, 2010, if certain conditions are met. On June 28, 2012, the United States Supreme Court upheld the individual mandate of the Health Reform Laws but partially invalidated the expansion of Medicaid. The ruling on Medicaid expansion allows states not to participate in the expansion-and to forego funding for the Medicaid expansion-without losing their existing Medicaid funding. As of December 31, 2017, 18 states have pursued this option. The participation by states in the Medicaid expansion could have the dual effect of increasing our tenants’ revenues, through new patients, but could also further strain state budgets. While the federal government paid for approximately 100% of those additional costs from 2014 to 2016, states now are expected to pay for part of those additional costs.
Challenges to the Health Reform Laws and Potential Repeal and/or Further Reforms under Trump Administration. Since the enactment of the Health Care Laws, there have been multiple attempts through legislative action and legal challenge to repeal or amend the Health Reform Laws, including the case that was before the U.S. Supreme Court, King v. Burwell. Although the Supreme Court in Burwell upheld the use of subsidies to individuals in federally-facilitated health care exchanges
12
on June 25, 2015, which ultimately did not disrupt significantly the implementation of the Health Reform Laws, we cannot predict whether other current or future efforts to repeal, amend or challenge the validity of all or part of the Health Reform Laws will be successful, nor can we predict the impact that such a repeal, amendment or challenge would have on our operators or tenants and their ability to meet their obligations to us.
In 2017, President Trump and Congress unsuccessfully sought to repeal and replace the Affordable Care Act. On January 20, 2017, President Trump issued an Executive Order stating that it is the administration’s official policy to repeal the Affordable Care Act and instructing the Secretary of Health and Human Services and the heads of all other executive departments and agencies with authority and responsibility under the Affordable Care Act to, among other matters, delay implementation of or grant an exemption from any provision of the Affordable Care Act that would impose a fiscal burden on any state or a cost, fee, tax, penalty, or regulatory burden on individuals, families, healthcare providers, health insurers, patients, and others. On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was signed into law. The Tax Act, among other things, reduces the Affordable Care Act’s individual mandate penalty to zero beginning in 2019. The elimination of the penalties does not remove the requirement to obtain healthcare coverage; however, without penalties there effectively will be no enforcement. On December 14, 2018, a federal district court in Texas ruled that the Affordable Care Act’s individual mandate was unconstitutional. The court also ruled that the provisions of the individual mandate were not severable from the remainder of the Affordable Care Act, rendering the remainder of the Affordable Care Act invalid as well. The Affordable Care Act will remain in place pending an appeal of the court’s decision to the United States Court of Appeals for the Fifth Circuit.
It is possible that Congress will continue to consider other legislation to repeal the Affordable Care Act or repeal and replace some or all elements of the Affordable Care Act.
We cannot predict the effect of the Executive Order, the Tax Act’s 2019 repeal of the individual mandate penalty on the Affordable Care Act, or the Texas court’s decision or any appeal thereof, other state-based litigation, or whether Congress’ attempt to repeal or repeal and replace the law will be successful. Further, we cannot predict how the Affordable Care Act might be amended or modified, either through the legislative or judicial process, and how any such modification might impact our tenants’ operations or the net effect of this law on us. If the operations, cash flows or financial condition of our operators and tenants are materially adversely impacted by any repeal or modification of the law, our revenue and operations may be materially adversely affected as well.
Fraud and Abuse Enforcement
There are various extremely complex federal and state laws and regulations governing healthcare providers’ relationships and arrangements and prohibiting fraudulent and abusive practices by such providers. These laws include (i) federal and state false claims acts, which, among other things, prohibit providers from filing false claims or making false statements to receive payment from Medicare, Medicaid or other federal or state healthcare programs, (ii) federal and state anti-kickback and fee-splitting statutes, including the Medicare and Medicaid anti-kickback statute, which prohibit the payment or receipt of remuneration to induce referrals or recommendations of healthcare items or services, (iii) federal and state physician self-referral laws (commonly referred to as the “Stark Law”), which generally prohibit referrals by physicians to entities with which the physician or an immediate family member has a financial relationship, (iv) the federal Civil Monetary Penalties Law, which prohibits, among other things, the knowing presentation of a false or fraudulent claim for certain healthcare services and (v) federal and state privacy laws, including the privacy and security rules contained in the Health Insurance Portability and Accountability Act of 1996, which provide for the privacy and security of personal health information. Violations of healthcare fraud and abuse laws carry civil, criminal and administrative sanctions, including punitive sanctions, monetary penalties, imprisonment, denial of Medicare and Medicaid reimbursement, and potential exclusion from Medicare, Medicaid, or other federal or state healthcare programs. These laws are enforced by a variety of federal, state, and local agencies and can also be enforced by private litigants through, among other things, federal and state false claims acts, which allow private litigants to bring qui tam or “whistleblower” actions. Many of our operators and tenants are subject to these laws, and some of them may in the future become the subject of governmental enforcement actions if they fail to comply with applicable laws.
Reimbursement
Sources of revenue for many of our tenants and operators include, among other sources, governmental healthcare programs, such as the federal Medicare program and state and Medicaid program, and non-governmental payors, such as insurance payors, managed care organizations (MCOs), health maintenance organizations (HMOs), and Accountable Care Organizations (ACOs). As federal and state governments focus on healthcare reform initiatives, and as the federal government and many states face significant budget deficits, efforts to reduce costs by these payors will likely continue, which may result in reduced or slower growth in reimbursement for certain services provided by some of our tenants and operators.
13
We cannot predict whether future Congressional proposals will seek to reduce physician reimbursements. Efforts by other payors to reduce healthcare costs are likely to continue, which may result in reductions or slower growth in reimbursement for certain services provided by some of our tenants. Further, revenue realizable under third-party payor agreements can change after examination and retroactive adjustment by payors during the claims settlement process or as a result of post-payment audits. For example, payors may disallow requests for reimbursement based on determinations that certain costs are not reimbursable or reasonable, because additional documentation is necessary or because certain services were not covered or were not medically necessary. The Healthcare Reform Laws and regulatory changes could impose further limitations on government and private payments to healthcare providers. In some cases, states have enacted or are considering enacting measures designed to reduce their Medicaid expenditures and to make changes to private healthcare insurance. In addition, the failure of any of our tenants to comply with various laws and regulations could jeopardize their ability to continue participating in Medicare, Medicaid, and other government sponsored payment programs. The financial impact on our tenants’ failure to comply with such laws and regulations could restrict their ability to make rent payments to us.
Healthcare Licensure and Certificate of Need
Certain healthcare facilities in our portfolio are subject to extensive federal, state and local licensure, certification and inspection laws, and regulations. In addition, various licenses and permits are required to dispense narcotics, operate pharmacies and laboratories, handle radioactive materials, and operate equipment. Many states require certain healthcare providers to obtain a certificate of need, which requires prior approval for the construction, expansion, and closure of certain healthcare facilities. The approval process related to state certificate of need laws may impact some of our tenants’ and operators’ abilities to expand or change their businesses.
Available Information
Our website address is www.docreit.com. We make available, free of charge through the Investor Relations portion of the website, annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (the “SEC” or the “Commission”). Reports of beneficial ownership filed pursuant to Section 16(a) of the Exchange Act are also available on our website. These reports and other information are also available, free of charge, at www.sec.gov.
In addition, the Trust’s Board of Trustees has established a Code of Business Conduct and Ethics that applies to our officers, including our Chief Executive Officer and President and Chief Financial Officer, trustees, and employees. The Code of Business Conduct and Ethics provides a statement of the Company’s policies and procedures for conducting business legally and ethically. A copy of the Code of Business Conduct and Ethics is available in the Investor Relations section of our website (www.docreit.com) under the tab “Governance Documents.” Any amendments to or waivers from the Code of Business Conduct and Ethics will be disclosed on our website. Information contained on our website is not part of this report.
14
ITEM 1A. RISK FACTORS
The following summarizes the material risks of purchasing or owning our securities. Additional unknown risks may also impair our financial performance and business operations. Our business, financial condition, and/or results of operation may be materially adversely affected by the nature and impact of these risks. In such case, the market value of our securities could be detrimentally affected, and investors may lose part or all of the value of their investment. You should carefully consider the risks and uncertainties described below.
We have grouped these risk factors into the following general categories:
• | Risks related to our business; |
• | Risks related to the healthcare industry; |
• | Risks related to the real estate industry; |
• | Risks related to financings; |
• | Risks related to our portfolio and structure; and |
• | Risks related to our qualification and operation as a REIT. |
Risks Related To Our Business
Our real estate investments are concentrated in healthcare properties, and any downturn in the healthcare industry could materially affect our business.
We acquire, own, manage, operate, and selectively develop properties for lease primarily to physicians, hospitals, and healthcare delivery systems. We are subject to risks inherent in concentrating investments in real estate, and further from the concentration of our investments in the healthcare sector. Any adverse effects that result from these risks could be more pronounced than if we diversified our investments outside of healthcare properties. Given our concentration in this sector, our tenant base is especially concentrated and dependent upon the healthcare industry generally, and any industry downturn could adversely affect the ability of our tenants to make lease payments and our ability to maintain current rental and occupancy rates. Our tenant mix could become even more concentrated if a significant portion of our tenants practice in a particular medical field or are reliant upon a particular healthcare delivery system. Accordingly, a downturn in the healthcare industry generally, or in the healthcare-related facility specifically, could adversely affect our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares.
Economic and other conditions that negatively affect geographic areas in which we conduct business, and in particular Texas, and other areas to which a greater percentage of our revenue is attributed could materially adversely affect our business, results of operations, and financial condition.
Our operating results depend upon our ability to maintain and increase occupancy levels and rental rates at our properties. Adverse economic or other conditions in the geographic markets in which we operate, including periods of economic slowdown or recession, industry slowdowns, periods of deflation, relocation of businesses, changing demographics, earthquakes and other natural disasters, fires, terrorist acts, civil disturbances or acts of war, and other man-made disasters which may result in uninsured or underinsured losses, and changes in tax, real estate, zoning, and other laws and regulations, may lower our occupancy levels and limit our ability to increase rents or require us to offer rental concessions.
As of December 31, 2018, approximately 1.9 million square feet of our gross leasable area and $44.1 million of our total annualized base rent was derived from properties located in Texas (13.8% of our gross leasable area and 15.4% of our total annualized base rent). As a result of these geographic concentrations, we are particularly exposed to downturns in the Texas economy or other changes in local real estate market conditions. Any material change in the current payment programs or regulatory, economic, environmental, or competitive conditions in Texas could have a disproportionate effect on our overall business results. In the event of negative economic or other changes in any of the markets in which we conduct business, our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares may be adversely affected.
15
We may in the future make investments in joint ventures, which could be adversely affected by our lack of decision-making authority, our reliance upon our joint venture partners’ financial condition, any disputes that may arise between us and our joint venture partners and our exposure to potential losses from the actions of our joint venture partners.
We may in the future make co-investments with third parties through partnerships, joint ventures, or other entities, acquiring noncontrolling interests in or sharing responsibility for the management of the affairs of a property, partnership, joint venture or other entity. Joint ventures generally involve risks not present with respect to our wholly-owned properties, including the following:
• | our joint venture partners may make decisions with which we disagree or that are not in our best interest; |
• | we may be prevented from taking actions that are opposed by our joint venture partners; |
• | our ability to transfer our interest in a joint venture to a third party may be restricted; |
• | our joint venture partners might become bankrupt or fail to fund their share of required capital contributions which may delay construction or development of a healthcare related facility or increase our financial commitment to the joint venture; |
• | our joint venture partners may have economic or business interests or goals with respect to the healthcare related facility or the joint venture that conflict with our business interests and goals which could increase the likelihood of disputes regarding the ownership, management or disposition of the healthcare related facility or the joint venture may compete with us for property acquisitions; |
• | disputes may develop with our joint venture partners over decisions affecting the healthcare related facility or the joint venture which may result in litigation or arbitration that would increase our expenses and distract our officers and/or trustees from focusing their time and effort on our business and possibly disrupt the daily operations of the healthcare related facility; and |
• | we may suffer losses as a result of the actions of our joint venture partners with respect to our joint venture investments. |
Joint venture investments involve risks that may not be present with other methods of ownership. In addition to those risks identified above, our partners may be in a position to take action or withhold consent contrary to our instructions or requests. In the future, in certain instances, we or our partners may have the right to trigger a buy-sell arrangement, which could cause us to sell our interest, or acquire our partners’ interest, at a time when we otherwise would not have initiated such a transaction. Our ability to acquire our partners’ interest may be limited if we do not have sufficient cash, available borrowing capacity, or other capital resources. In such event, we may be forced to sell our interest in the joint venture when we would otherwise prefer to retain it. Joint ventures may require us to share decision-making authority with our partners, which could limit our ability to control the properties in the joint ventures. Even when we have a controlling interest, certain major decisions may require partner approval, such as the sale, acquisition or financing of a property.
Our healthcare properties and tenants face competition from nearby hospitals and other healthcare properties, and we may not realize the benefits that we anticipate from focusing on healthcare properties that are strategically aligned with a healthcare delivery system and from the relationships established through such strategic alignments. Further, we may not be able to maintain or expand our relationships with our existing and future hospital and healthcare delivery system clients.
As part of our business strategy, we focus on healthcare properties that are strategically aligned with a healthcare delivery system by (i) seeking to acquire, own, manage, and develop healthcare properties that are located on medical campuses where the underlying land is owned by a healthcare delivery system or by us, or (ii) seeking to acquire, own, manage, and develop healthcare properties located in close proximity to a healthcare delivery system or strategically aligned with a healthcare delivery system through leasing or other arrangements. We may not realize the benefits that we anticipate as a result of these strategic relationships, such as increased rents and reduced tenant turnover rates as compared to healthcare properties that are not strategically aligned. Moreover, building a portfolio of healthcare properties that are strategically aligned does not assure the success of any given property. The associated healthcare delivery system may not be successful and the strategic alignment that we seek for our healthcare properties could dissolve, and we may not succeed in replacing them. In addition, our healthcare properties, the associated healthcare delivery systems with which our healthcare properties are strategically aligned, and our tenants may be unable to compete successfully with nearby hospitals, medical practices, other healthcare properties that provide comparable services, pharmacies and other retailers that may initiate or expand healthcare clinic operations and
16
services to compete with our tenants. Any of our properties may be materially and adversely affected if the healthcare delivery system with which it is strategically aligned is unable to compete successfully. If we do not realize the benefits that we anticipate from our business strategy and our strategic alignments dissolve and we are not successful in replacing them, our reputation, business, financial results, and prospects may be adversely affected.
The success of our business depends, to a large extent, on our current and future relationships with hospital and healthcare delivery system clients. We invest a significant amount of time to develop, maintain, and be responsive to these relationships, and our relationships have helped us to secure acquisition and development opportunities, as well as other advisory, property management, and projects, with both new and existing clients. If our relationships with hospital or health system clients deteriorate, if a conflict of interest or non-compete arrangement prevents us from expanding these relationships, or if a hospital on or near whose campus one of our properties is located fails or becomes unable to meet its financial obligations, the business of our tenants could be adversely affected or our ability to secure new acquisition and development opportunities or other advisory, property management, and hospital project management projects could be adversely impacted and our professional reputation within the industry could be damaged.
Any failure, inability, or unwillingness by our tenants to pay rent or other amounts under leases could materially adversely affect our financial results; we may have difficulty finding suitable replacement tenants in the event of a tenant default or non-renewal of our leases, especially for our properties located in smaller markets.
Our portfolio of healthcare properties is leased to physicians, hospitals, healthcare delivery systems, and other healthcare providers. We cannot provide assurance that our tenants will have sufficient assets, income, and access to financing to enable them to satisfy their respective obligations to us, and any failure, inability or unwillingness by our tenants to do so could adversely affect our financial results. We have had tenants pay us rent late or fail to pay rent, which has adversely affected our financial results.
We cannot predict whether our tenants will renew or extend existing leases beyond their current terms. Nearly all of our properties are subject to leases which have multi-year terms. As of December 31, 2018, leases representing 2.7% and 3.6% of leased square feet at our properties will expire in 2019 and 2020, respectively, and leases representing 0.2% of leased square feet had expired as of December 31, 2018. If any of our leases are not renewed or extended, or if a tenant defaults under the terms of its lease or becomes insolvent, we would attempt to relet those spaces or properties to other tenants or new tenants. In case of non-renewal, we generally have advance notice before expiration of the lease term to arrange for reletting or repositioning of the spaces or the properties and our tenants are required to continue to perform all of their obligations (including the payment of all rental amounts) under the non-renewed leases until such expiration. However, following expiration of a lease term or if we exercise our right to replace a tenant in default, rental payments on the related properties could decline or cease altogether while we relet or reposition the spaces or the properties with suitable replacement tenants. We also might not be successful in identifying suitable replacement tenants or entering into leases with new tenants on a timely basis or on terms as favorable to us as our current leases, or at all, and we may be required to fund certain expenses and obligations (e.g., real estate taxes, debt costs, and maintenance expenses) to preserve the value of, and avoid the imposition of liens on, our properties while they are being relet or repositioned. Our ability to relet or reposition our properties, or spaces within our properties, with suitable tenants could be significantly delayed or limited by state licensing, receivership, certificate of need or other laws, as well as by the Medicare and Medicaid change-of-ownership rules. We could also incur substantial additional expenses in connection with any licensing, receivership, or change-of-ownership proceedings. In addition, our ability to locate suitable replacement tenants could be impaired by the specialized healthcare uses or contractual restrictions on use of the properties, and we may be required to spend substantial amounts to adapt the properties to other uses. Any such delays, limitations and expenses could adversely impact our ability to collect rent, obtain possession of leased properties, or otherwise exercise remedies for tenant default and could have a material adverse effect on us or cause us to take an impairment charge on a property.
All of these risks may be greater in smaller markets, where there may be fewer potential replacement tenants, making it more difficult to replace tenants, especially for specialized spaces, like hospital or outpatient treatment facilities located in our properties, and could have a material adverse effect on us.
If the business, financial position or results of operations of CHI or one or more of our CHI-affiliated tenants suffer or are adversely affected, it could have a material adverse effect on our business, financial position, or results of operations.
As of December 31, 2018, after giving effect to the merger of CHI and Dignity Health on February 1, 2019, tenants affiliated with the surviving corporation, CommonSpirit Health (“CommonSpirit”), represented approximately 20.8% of our total annualized base rent. Although CommonSpirit is not a party to nor a guarantor of the related lease agreements, it controls each of the subsidiaries and affiliates that are parties to a master lease agreement we have with the CommonSpirit tenants.
17
Given this control, if CommonSpirit’s business, financial position or results of operations suffer or are adversely affected, it could adversely affect its ability to provide any financial or operational support for the subsidiaries and affiliates it controls, which could adversely affect one or more of the CommonSpirit-affiliated tenants’ ability to pay rent to us. Additionally, if CommonSpirit’s business, financial position or results of operations were to suffer or its credit ratings were to be downgraded, it could cause investors to lose confidence in our ability to collect rent from the CHI-affiliated tenants and could cause our stock price to decline. Moreover, there can be no assurance that CommonSpirit’s subsidiaries and affiliates will have sufficient assets, income, and access to financing to enable them to satisfy their payment obligations under their lease agreements. The inability of any of these subsidiaries and affiliates to meet their rent obligations could materially adversely affect our business, financial position, or results of operations including our ability to pay dividends to our stockholders as required to maintain our status as a REIT. The inability of CommonSpirit’s subsidiaries and affiliates to satisfy their other obligations under their lease agreements such as the payment of taxes, insurance, and utilities could have a material adverse effect on the condition of the leased properties as well as on our business, financial position, and results of operations. For these reasons, if CommonSpirit were to experience a material adverse effect on its business, financial position, or results of operations, our business, financial position, or results of operations could also be materially adversely affected.
CommonSpirit, which resulted from the merger of Dignity Health and CHI, may have different plans or objectives than CHI with respect to the services its physicians provide or the locations in which those services are provided. If CommonSpirit were to cause its subsidiaries or affiliates to terminate any of their leases, vacate the leased premises, or consolidate, downsize or relocate their operations from any of our premises, or if the subsidiaries and affiliates do not comply with the healthcare regulations to which the leased properties and operations are subject, we may be required to find other lessees for any affected leased properties and there could be a decrease or cessation of rental payments by CommonSpirit’s subsidiaries and affiliates. In such event, we may be unable to locate suitable replacement lessees willing to pay similar rental rates or at all, which would have the effect of reducing our rental revenues and could materially adversely affect our business, financial position, or results of operations.
We may not be successful in identifying and completing off-market acquisitions and other suitable acquisitions or investment opportunities, which may impede our growth and adversely affect our business, financial condition, and results of operations.
An important component of our growth strategy is to acquire “off-market” properties before they are widely marketed by the owners. Facilities that are acquired off-market are typically more attractive to us as a purchaser because of the absence of a formal marketing process, which could lead to higher prices or other unattractive terms. If we cannot obtain off-market deal flow in the future, our ability to locate and acquire facilities at attractive prices could be adversely affected. We expect to compete with many other entities engaged in real estate investment activities for acquisitions of healthcare properties, including national, regional, and local operators, acquirers and developers of healthcare-related real estate properties, and other investors such as private equity firms, some of whom may have greater financial resources and lower costs of capital than we do. The competition for healthcare-related real estate properties may significantly increase the price that we must pay for healthcare properties or other assets that we seek to acquire, and our competitors may succeed in acquiring those properties or assets themselves. In addition, our potential acquisition targets may find our competitors to be more attractive because they may have greater resources, may be willing to pay more for the properties, or may have a more compatible operating philosophy. In particular, larger REITs that target healthcare properties may enjoy significant competitive advantages that result from, among other things, a lower cost of capital, enhanced operating efficiencies, more personnel and market penetration, and familiarity with markets. In addition, the number of entities and the amount of funds competing for suitable investment properties may increase. Increased competition would result in increased demand for these assets and therefore likely would increase prices paid for them. Those higher prices for healthcare properties or other assets may adversely affect our returns from our investments.
We may in the future make investments in development projects, which may not yield anticipated returns which could directly affect our operating results and reduce the amount of funds available for distributions.
A component of our growth strategy is exploring development opportunities, some of which may arise through strategic joint ventures. In deciding whether to make an investment in a particular development, we make certain assumptions regarding the expected future performance of that property. To the extent that we consummate development opportunities, our investment in these projects will be subject to the following risks:
• | we may be unable to obtain financing for development projects on favorable terms or at all; |
• | we may not complete development projects on schedule or within budgeted amounts; |
18
• | we may encounter delays in obtaining or fail to obtain all necessary zoning, land use, building, occupancy, environmental and other governmental permits and authorizations, or underestimate the costs necessary to develop the property to market standards; |
• | development or construction delays may provide tenants the right to terminate preconstruction leases or cause us to incur additional costs; |
• | volatility in the price of construction materials or labor may increase our development costs; |
• | hospitals or health systems may maintain significant decision-making authority with respect to the development schedule; |
• | we may incorrectly forecast risks associated with development in new geographic regions; |
• | tenants may not lease space at the quantity or rental rate levels projected; |
• | demand for our development project may decrease prior to completion, including due to competition from other developments; and |
• | lease rates and rents at newly developed properties may fluctuate based on factors beyond our control, including market and economic conditions. |
If our investments in development projects do not yield anticipated returns for any reason, including those set forth above, our business, financial condition and results of operations, our ability to make distributions to our shareholders and the trading price of our common shares may be adversely affected.
Some of our existing properties and properties we acquire in the future are and may be subject to ground lease or other restrictions on the use of the space. If we are required to undertake significant capital expenditures to procure new tenants, then our business and results of operations may suffer.
76 of our properties, representing approximately 40.4% of our total leasable square feet and 38.4% of our annualized revenue based on rental payments for the month ended December 31, 2018, are subject to ground leases that contain certain restrictions. These restrictions include limits on our ability to re-lease our initial properties to tenants not affiliated with the healthcare delivery system that owns the underlying property, rights of purchase and rights of first offer and refusal with respect to sales of the property and limits on the types of medical procedures that may be performed. In addition, lower than expected rental rates upon re-leasing could impede our growth. We may not be able to re-lease space on terms that are favorable to us or at all. Further, we may be required to undertake significant capital expenditures to renovate or reconfigure space to attract new tenants. If we are unable to promptly re-lease our initial properties, if the rates upon such re-leasing are significantly lower than expected, or if we are required to undertake significant capital expenditures in connection with re-leasing, our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares may be adversely affected.
Uninsured losses or losses in excess of our insurance coverage could adversely affect our financial condition and our cash flows.
We maintain comprehensive liability, fire, flood, earthquake, wind (as deemed necessary or as required by our lenders), extended coverage, and rental loss insurance with respect to our properties. Certain types of losses, however, may be either uninsurable or not economically insurable, such as losses due to riots, acts of war, or terrorism. Should an uninsured loss occur, we could lose both our investment in and anticipated profits and cash flows from a healthcare-related facility. If any such loss is insured, we may be required to pay a significant deductible on any claim for recovery of such a loss prior to our insurer being obligated to reimburse us for the loss, or the amount of the loss may exceed our coverage for the loss. In addition, future lenders may require such insurance, and our failure to obtain such insurance could constitute a default under loan agreements. We may determine not to insure some or all of our properties at levels considered customary in our industry, which would expose us to an increased risk of loss. As a result, our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares may be adversely affected.
19
Environmental compliance costs and liabilities associated with owning, leasing, developing, and operating our properties may affect our results of operations.
Under various U.S. federal, state, and local laws, ordinances, and regulations, current and prior owners and tenants of real estate may be jointly and severally liable for the costs of investigating, remediating, and monitoring certain hazardous substances or other regulated materials on or in such property. In addition to these costs, the past or present owner or tenant of a property from which a release emanates could be liable for any personal injury or property damage that results from such releases, including for the unauthorized release of asbestos-containing materials and other hazardous substances into the air, as well as any damages to natural resources or the environment that arise from such releases. These environmental laws often impose such liability without regard to whether the current or prior owner or tenant knew of, or was responsible for, the presence or release of such substances or materials. Moreover, the release of hazardous substances or materials, or the failure to properly remediate such substances or materials, may adversely affect the owner’s or tenant’s ability to lease, sell, develop, or rent such property or to borrow by using such property as collateral. Persons who transport or arrange for the disposal or treatment of hazardous substances or other regulated materials may be liable for the costs of removal or remediation of such substances at a disposal or treatment facility, regardless of whether or not such facility is owned or operated by such person.
Certain environmental laws impose compliance obligations on owners and tenants of real property with respect to the management of hazardous substances and other regulated materials. For example, environmental laws govern the management and removal of asbestos-containing materials and lead-based paint. Failure to comply with these laws can result in penalties or other sanctions. If we incur substantial costs to comply with these environmental laws or we are held liable under these laws, our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares may be adversely affected.
We may be unable to make distributions which could result in a decrease in the market price of our common shares.
Substantially all of our assets are held through the Operating Partnership, which holds substantially all of its properties and assets through subsidiaries. Our Operating Partnership’s cash flow is dependent upon cash distributions to it by its subsidiaries, and in turn, substantially all of the Trust’s cash flow is dependent upon cash distributions to it by the Operating Partnership. The creditors of each of our direct and indirect subsidiaries are entitled to payment of that subsidiary’s obligation to them, as and when due and payable, before distributions may be made by that subsidiary to its equity holders. Therefore, our Operating Partnership’s ability to make distributions to holders of OP Units depends on its subsidiaries’ ability first to satisfy their obligations to their creditors and then to make distributions to the Operating Partnership. Furthermore, holders of Series A Preferred Units are entitled to receive preferred distributions before payment of distributions to OP Unit holders, including the Trust. Finally, the Trust’s ability to pay dividends to holders of common shares depends upon our Operating Partnership’s ability to first satisfy its obligations to its creditors and then to make distributions to the Trust.
While we expect to make regular quarterly distributions to the holders of our common shares, if sufficient cash is not available for distribution from our operations, we may have to fund distributions from working capital, borrow to provide funds for such distributions, or reduce the amount of such distributions. To the extent we borrow to fund distributions, our future interest costs would increase, thereby reducing our earnings and cash available for distributions from what they otherwise would have been. If cash available for distribution generated by our assets is less than expected, or if such cash available for distribution decreases in future periods from expected levels, our inability to make distributions could result in a decrease in the market price of our common shares. All distributions are made at the discretion of our board of trustees. Any inability to make distributions, or to make distributions at expected levels in the future, could result in a decrease in the market price of our common shares.
Cybersecurity incidents could disrupt our business and result in the compromise of confidential information.
Our business is at risk from and may be impacted by cybersecurity attacks, including attempts to gain unauthorized access to our confidential data, and other electronic security breaches. Such cyber attacks can range from individual attempts to gain unauthorized access to our information technology systems to more sophisticated security threats. While we employ a number of measures to prevent, detect and mitigate these threats, there is no guarantee such efforts will be successful in preventing a cyber attack. Cybersecurity incidents could disrupt our business and compromise confidential information of ours and third parties, including our tenants.
20
We may not be able to sustain our growth rate level.
We have grown our portfolio of gross real estate investments from approximately $124 million at the time of our IPO in July 2013 to approximately $4.4 billion as of December 31, 2018. This long-term growth rate has contributed significantly to our growth in revenue. While we expect to continue to grow through property acquisitions and investments as our asset base continues to increase, we expect our historic growth rate to continue to decelerate in the future as a result of various factors, including the size of our portfolio, changes in the economic and other conditions in geographic markets in which we conduct business, changes in the real estate market, changes in healthcare regulations, and the competitiveness of the real estate market. Additionally, our significant growth has resulted in increased levels of responsibility for our management, who may experience additional demands related to managing our current properties portfolio.
Our ability to issue equity to expand our business will depend, in part, upon the market price of our common shares, and our failure to meet market expectations with respect to our business could negatively affect the market price of our common shares and thereby limit our ability to raise capital and our issuance of equity securities could decrease the per share market price of our common shares.
The availability of equity capital to us will depend, in part, upon the market price of our common shares which, in turn, will depend upon various market conditions and other factors that may change from time to time. Our failure to meet the market’s expectation with regard to future earnings and cash distributions would likely adversely affect the market price of our common shares and, as a result, the cost and availability of equity capital to us.
In addition, the vesting of any restricted shares granted to trustees, executive officers, and other employees under our 2013 Equity Incentive Plan, the issuance of our common shares or OP Units in connection with future property, portfolio or business acquisitions, and other issuances of our common shares may cause dilution to our shareholders and could have an adverse effect on the per share market price of our common shares and may adversely affect the terms upon which we may be able to obtain additional capital through the sale of equity securities.
Increases in interest rates may increase our interest expense and adversely affect our cash flows, our ability to service our indebtedness and our ability to make distributions to our shareholders, and could cause our stock price to decline. Failure to hedge effectively against interest rate changes may adversely affect our results of operations.
One of the factors that influences the market price of our common shares is the dividend yield on common shares (as a percentage of the price of our common shares) relative to market interest rates. In response to the global financial crisis, the U.S. Federal Reserve took actions which resulted in low interest rates prevailing in the marketplace for a historically long period of time. Since December 2015, the U.S. Federal Reserve has raised its benchmark interest rate by a quarter of a percentage point nine times to a range of 2.25% to 2.50% and may raise its benchmark interest rate in the future. Further increases in market interest rates may lead prospective purchasers of our common shares to expect a higher dividend yield (with a resulting decline in the market price of our common shares) and higher interest rates would likely increase our borrowing costs for both our existing and future indebtedness and potentially decrease funds available for distribution. Thus, higher market interest rates could cause the market price of our common shares to decrease.
Additionally, as of December 31, 2018, we had approximately $221.8 million of variable-rate indebtedness outstanding that has not been swapped for a fixed interest rate and we expect that more of our indebtedness in the future, including borrowings under our unsecured revolving credit facility since December 31, 2018 and thereafter, will be subject to variable interest rates. Increases in interest rates on any variable rate indebtedness will increase our interest expense, which could adversely affect our cash flow and our ability to pay distributions to our shareholders.
In certain cases, we may seek to manage our exposure to interest rate volatility by using interest rate hedging arrangements. Hedging involves risks, such as the risk that the counterparty may fail to honor its obligations under an arrangement, that the arrangements may not be effective in reducing our exposure to interest rate changes, and that a court could rule that such an agreement is not legally enforceable. In addition, we may be limited in the type and amount of hedging transactions that we may use in the future by our need to satisfy the REIT income tests under the Code. Failure to hedge effectively against interest rate changes may have an adverse effect on our business, financial condition, results of operations, our ability to make distributions to our shareholders, and the market price of our common shares.
21
The income from certain of our properties is dependent on the ability of our property managers to successfully manage those properties.
We depend upon the performance of our property managers to effectively manage certain of our properties and real estate assets. We do not control these third party property managers, and are accordingly subject to various risks generally associated with outsourcing of management of day-to-day activities. The income we recognize from any properties managed by third party property managers is dependent on the ability of the property manager of such property to successfully manage the property, which such property management is not within our control. Property managers generally compete with other companies in the management of properties, with respect to the quality of care provided, reputation, physical appearance of the property, and price and location, among other attributes. A property manager’s inability to successfully compete with other companies on one or more of the foregoing aspects could adversely impact our business and results of operations. Additionally, because we do not control third party property managers, any adverse events such as issues related to insufficient internal controls, cybersecurity incidents, or other adverse events may impact the income we recognize from properties managed by such third party property managers. We may be unable to anticipate such events or properly assess the magnitude of any such events because we do not control third party property managers who provide property management services to us.
Risks Related to the Healthcare Industry
The healthcare industry is heavily regulated, and new laws or regulations, changes to existing laws or regulations, loss of licensure, or failure to obtain licensure could adversely impact our company and result in the inability of our tenants to make rent payments to us.
The healthcare industry is heavily regulated by U.S. federal, state and local governmental authorities. Our tenants generally are subject to laws and regulations covering, among other things, licensure, certification for participation in government programs, billing for services, privacy and security of health information, and relationships with physicians and other referral sources. In addition, new laws and regulations, changes in existing laws and regulations or changes in the interpretation of such laws or regulations could negatively affect our financial condition and the financial condition of our tenants. These changes, in some cases, could apply retroactively. The enactment, timing, or effect of legislative or regulatory changes cannot be predicted.
The Affordable Care Act is changing how healthcare services are covered, delivered, and reimbursed through expanded coverage of uninsured individuals and reduced Medicare program spending. In addition, it reforms certain aspects of health insurance, expands existing efforts to tie Medicare and Medicaid payments to performance and quality, and contains provisions intended to strengthen fraud and abuse enforcement. The complexities and ramifications of the Affordable Care Act are significant and are being implemented in a phased approach which began in 2010. It remains difficult to predict the full effects of the Affordable Care Act and its impact on our business, our revenues, and financial condition and those of our tenants due to the law’s complexity, lack of implementing regulations or interpretive guidance, gradual implementation, partial repeal, and possible full repeal. Further, we are unable to foresee how individuals and businesses will respond to the choices afforded them by the Affordable Care Act, or the effect of any potential changes made to the Affordable Care Act or other healthcare laws and programs. The Affordable Care Act could adversely affect the reimbursement rates received by our tenants, the financial success of our tenants and strategic partners and consequently us.
In 2012, the United States Supreme Court upheld the individual mandate of the Affordable Care Act but partially invalidated the expansion of Medicaid. The ruling on Medicaid expansion allow states not to participate in the expansion (and to forego funding for the Medicaid expansion) without losing their existing Medicaid funding. While the U.S. federal government paid for approximately 100% of those additional costs from 2014 to 2016, states now are expected to pay a small percentage of those additional costs. Because the U.S. federal government substantially funds the Medicaid expansion, it is unclear how many states ultimately will elect this option. As of January 2018, 32 states and Washington, D.C. have elected to participate in the Medicaid expansion. The participation by states in the Medicaid expansion could have the effect of increasing some of our tenants’ revenues but also could be a strain on U.S. federal government and state budgets.
In 2017, President Trump and Congress unsuccessfully sought to repeal and replace the Affordable Care Act. On January 20, 2017, President Trump issued an Executive Order stating that it is the administration’s official policy to repeal the Affordable Care Act and instructing the Secretary of Health and Human Services and the heads of all other executive departments and agencies with authority and responsibility under the Affordable Care Act to, among other matters, delay implementation of or grant an exemption from any provision of the Affordable Care Act that would impose a fiscal burden on any state or a cost, fee, tax, penalty, or regulatory burden on individuals, families, healthcare providers, health insurers, patients, and others. On December 22, 2017, the Tax Act was signed into law. The Tax Act, amongst other things, repeals the Affordable Care Act’s individual mandate penalty beginning in 2019. The elimination of the penalties does not remove the requirement to obtain healthcare coverage; however,
22
without penalties there effectively will be no enforcement. On December 14, 2018, a federal district court in Texas ruled that the Affordable Care Act’s individual mandate was unconstitutional. The court also ruled that the provisions of the individual mandate were not severable from the remainder of the Affordable Care Act, rendering the remainder of the Affordable Care Act invalid as well. The Affordable Care Act will remain in place pending an appeal of the court’s decision to the United States Court of Appeals for the Fifth Circuit.
It is possible that Congress will continue to consider other legislation to repeal the Affordable Care Act or repeal and replace some or all elements of the Affordable Care Act.
We cannot predict the effect of the Executive Order, the Tax Act’s 2019 repeal of the individual mandate penalty on the Affordable Care Act, or the Texas court’s decision or any appeal thereof, other state-based litigation, or whether Congress’ attempt to repeal or repeal and replace the law will be successful. Further, we cannot predict how the Affordable Care Act might be amended or modified, either through the legislative or judicial process, and how any such modification might impact our tenants’ operations or the net effect of this law on us. If the operations, cash flows, or financial condition of our operators and tenants are materially adversely impacted by any repeal or modification of the law, our revenue and operations may be materially adversely affected as well.
Recent changes to healthcare laws and regulations, including to government reimbursement programs such as Medicare and reimbursement rates applicable to our current and future tenants, could have a material adverse effect on the financial condition of our tenants and, consequently, their ability to meet obligations to us.
Statutory and regulatory policy changes and decisions may impact one or more specific providers that lease space in any of our facilities. In particular, the following recent changes to healthcare laws and regulations may apply to our tenants:
• | The Medicare Access and CHIP Reauthorization Act of 2015 (“MACRA”) reforms Medicare payment policy for services paid under the Medicare physician fee schedule and adopts a series of policy changes affecting a wide range of providers and suppliers. MACRA repeals the sustainable growth rate formula effective January 1, 2015, and establishes a new payment framework which may impact payment rates for our tenants, including long-term care hospitals (“LTCH”). |
• | The Bipartisan Budget Act of 2013 establishes new payment limits for Medicare patients discharged from an LTCH who do not meet specified criteria. For any Medicare patient who does not meet the new criteria, the LTCH will be paid a lower “site-neutral” payment rate, which may impact the financial condition of tenants affected by the lower payment rate. Additionally, new rules may cause all discharges from LTCHs to be paid at the site-neutral rate if the number of discharges for which payment is made under the site-neutral payment rate is greater than 50% of the total number of discharges from the LTCH. |
• | The 2015 BBA provides changes to the requirements for providers who seek HOPD reimbursement under Medicare. The 2015 BBA generally requires providers who seek to qualify for HOPD to be located on the campus of the hospital that seeks such HOPD, which generally is higher than reimbursement for providers that do not qualify as HOPD providers. The 2015 BBA specifically grandfathers HOPD providers in existence as of November 2, 2015 and does not change such HOPD providers’ eligibility for HOPD reimbursement. |
We have a number of existing tenants that may be reimbursed as HOPD providers and but for the grandfathering protection of the 2015 BBA, may not be eligible for HOPD reimbursement in the future. Any provider who establishes a new HOPD location after November 2, 2015 will be subject to the 2015 BBA requirements and if any such provider does not satisfy the new requirements, then such provider will be reimbursed for claims billed on or after January 1, 2017 at generally lower reimbursement levels. Failure to comply with the 2015 BBA requirements could adversely affect the ability of certain of our tenants to make rent payments to us, which may have an adverse effect on our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares.
• | The Affordable Care Act instituted a market basket payment adjustment to LTCHs. In fiscal years 2017 through 2019, the market basket update will be reduced by 0.75%. The Affordable Care Act specifically allows these market basket reductions to result in a less than 0% payment update and payment rates that are less than the prior year. MACRA sets the annual update for fiscal year 2018 at 1% after taking into account the market basket payment reduction of 0.75% mandated by the Affordable Care Act. |
• | The Bipartisan Budget Act of 2018 (Pub. L. 115-123) makes numerous changes to Medicare payment to physicians under the Medicare Part B program. These changes include, for example, the removal of certain restrictions on payment for telehealth services associated with clinical assessments for end-stage renal dialysis patients and acute stroke patients. This legislation also repealed the payment caps for certain physical therapy and speech language |
23
therapy services, while reducing payment for these services if provided by therapy assistants. The Bipartisan Budget Act of 2018 amended policies related to the Merit-based Incentive Payment System (MIPS) which, as part of the CMS Quality Payment Program, is intended to tie payments to quality and cost-efficient care, drive improvement in care processes and health outcomes, increase the use of healthcare information, and reduce the cost of care.
• | Every year, the Centers for Medicare and Medicaid Services (CMS) adjusts payment levels and policies for physician services through rulemaking, in compliance with statutory requirements, and other budget decisions by the Executive Branch. In November 2018, CMS issued a final rule for the Medicare physician fee schedule effective for 2019. Among other things, the final rule increases payment levels during 2019 for many physician services, although payment for some procedures may be reduced based on recalculations of the practice expense component of the physician relative value units. Medicare payment for certain drugs may be reduced from 6% to 3% of the wholesale acquisition cost, if an average sales price is not available. |
• | On November 21, 2018, the Secretary issued a final rule, effective January 1, 2019, that eliminates the higher, Outpatient Prospective Payment System reimbursement rate for evaluation and management services provided by Grandfathered HOPD locations. The Secretary, instead, will only reimburse for evaluation and management services at the lower, Medicare Physician Fee Schedule rate that new non-grandfathered off-campus HOPD locations receive. See Centers for Medicare & Medicaid Services, Medicare Program: Changes to Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs, Department of Health and Human Services, 83 Fed. Reg. 58,818 (November 21, 2018). The AHA and a number of hospitals have sued the Secretary in federal court to enforce the plain meaning of Section 603 of the BBA and restore the right to Grandfathered HOPD reimbursement rates. |
These reimbursement and regulatory changes may have an adverse financial impact on the net operating revenues and profitability of many LTCHs for cost reporting periods beginning on or after July 1, 2016, which could have an impact on their ability to pay rent due to us. Similarly, these payment changes for physicians under Medicare Part B may have an adverse financial impact on the revenues and profitability of many physician practices in future years, which could adversely affect their ability to pay rent.
Many states also regulate the establishment and construction of healthcare facilities and services, and the expansion of existing healthcare facilities and services through certificate of need, or CON, laws, which may include regulation of certain types of beds, medical equipment, and capital expenditures. Under such laws, the applicable state regulatory body must determine a need exists for a project before the project can be undertaken. If any of our tenants seeks to undertake a CON-regulated project, but are not authorized by the applicable regulatory body to proceed with the project, these tenants could be prevented from operating in their intended manner and could be materially adversely affected.
The application of lower reimbursement rates to our tenants or failure to qualify for existing rates under certain exceptions, the failure to comply with these laws and regulations, or the failure to secure CON approval to undertake a desired project could adversely affect our tenants’ ability to make rent payments to us which may have an adverse effect on our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares.
Adverse trends in healthcare provider operations may negatively affect our lease revenues and our ability to make distributions to our shareholders.
The healthcare industry is currently experiencing, among other things:
• | changes in the demand for and methods of delivering healthcare services; |
• | changes in third party reimbursement methods and policies; |
• | consolidation and pressure to integrate within the healthcare industry through acquisitions, joint ventures, and managed service organizations; and |
• | increased scrutiny of billing, referral, and other practices by U.S. federal and state authorities. |
These factors may adversely affect the economic performance of some or all of our tenants and, in turn, our lease revenues, which may have a material adverse effect on our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares.
24
Reductions in reimbursement from third party payors, including Medicare and Medicaid, could adversely affect the profitability of our tenants and hinder their ability to make rent payments to us or renew their leases.
Sources of revenue for our tenants typically include the U.S. federal Medicare program, state Medicaid programs, private insurance payors, MCOs, HMOs, and ACOs. Healthcare providers continue to face increased government and private payor pressure to control or reduce healthcare costs and significant reductions in healthcare reimbursement, including reduced reimbursements and changes to payment methodologies under the Affordable Care Act. In some cases, private insurers rely upon all or portions of the Medicare payment systems to determine payment rates which may result in decreased reimbursement from private insurers.
The slowdown in the United States economy has negatively affected state budgets, thereby putting pressure on states to decrease spending on state programs including Medicaid. The need to control Medicaid expenditures may be exacerbated by the potential for increased enrollment in state Medicaid programs due to unemployment and declines in family incomes. Historically, states have often attempted to reduce Medicaid spending by limiting benefits and tightening Medicaid eligibility requirements. Many states have adopted, or are considering the adoption of, legislation designed to enroll Medicaid recipients in managed care programs and/or impose additional taxes on hospitals to help finance or expand the states’ Medicaid systems. Potential reductions to Medicaid program spending in response to state budgetary pressures could negatively impact the ability of our tenants to successfully operate their businesses.
Efforts by payors to reduce healthcare costs will likely continue which may result in reductions or slower growth in reimbursement for certain services provided by some of our tenants. A reduction in reimbursements to our tenants from third party payors for any reason could adversely affect our tenants’ ability to make rent payments to us which may have a material adverse effect on our businesses, financial condition and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares.
Our tenants and our company are subject to fraud and abuse laws, the violation of which by a tenant may jeopardize the tenant’s ability to make rent payments to us.
There are various federal and state laws prohibiting fraudulent and abusive business practices by healthcare providers who participate in, receive payments from, or are in a position to make referrals in connection with government-sponsored healthcare programs, including the Medicare and Medicaid programs. Our lease arrangements with certain tenants may also be subject to these fraud and abuse laws.
Violations of these laws may result in criminal and/or civil penalties that range from punitive sanctions, damage assessments, penalties, imprisonment, denial of Medicare and Medicaid payments, and/or exclusion from the Medicare and Medicaid programs. In addition, the Affordable Care Act clarifies that the submission of claims for items or services generated in violation of the Anti-Kickback Statute constitutes a false or fraudulent claim under the False Claims Act. The federal government has taken the position, and some courts have held, that violations of other laws, such as the Stark Law, can also be a violation of the False Claims Act. Additionally, certain laws, such as the False Claims Act, allow for individuals to bring whistleblower actions on behalf of the government for violations thereof. Imposition of any of these penalties upon one of our tenants or strategic partners could jeopardize that tenant’s ability to operate or to make rent payments or affect the level of occupancy in our healthcare properties, which may have a material adverse effect on our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares. Further, we enter into leases and other financial relationships with healthcare delivery systems that are subject to or impacted by these laws. We also have other investors who are healthcare providers in certain of our subsidiaries that own our healthcare properties. If any of our relationships, including those related to the other investors in our subsidiaries, are found not to comply with these laws, we and our healthcare provider investors may be subject to civil and/or criminal penalties.
Our healthcare-related tenants may be subject to significant legal actions that could subject them to increased operating costs and substantial uninsured liabilities, which may affect their ability to pay their rent payments to us, and we could be subject to healthcare industry violations.
As is typical in the healthcare industry, our tenants may become subject to claims that their services have resulted in patient injury or other adverse effects. Many of these tenants may have experienced an increasing trend in the frequency and severity of professional liability and general liability insurance claims and litigation asserted against them. The insurance coverage maintained by these tenants may not cover all claims made against them nor continue to be available at a reasonable cost, if at all. In some states, insurance coverage for the risk of punitive damages arising from professional liability and general liability claims and/or litigation may not, in certain cases, be available to these tenants due to state law prohibitions or limitations of availability. As a result, these types of tenants of our healthcare properties and healthcare-related facilities
25
operating in these states may be liable for punitive damage awards that are either not covered or are in excess of their insurance policy limits.
We also believe that there has been, and will continue to be, an increase in governmental investigations of certain healthcare providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Insurance is not available to cover such losses. Any adverse determination in a legal proceeding or governmental investigation, any settlements of such proceedings, or investigations in excess of insurance coverage, whether currently asserted or arising in the future, could have a material adverse effect on a tenant’s financial condition. If a tenant is unable to obtain or maintain insurance coverage, if judgments are obtained or settlements reached in excess of the insurance coverage, if a tenant is required to pay uninsured punitive damages, or if a tenant is subject to an uninsurable government enforcement action or investigation, the tenant could be exposed to substantial additional liabilities, which may affect the tenant’s ability to pay rent, which in turn could have a material adverse effect on our business, financial condition, and results of operations, our ability to pay distributions to our shareholders, and the market price of our common shares. We could also be subject to costly government investigations or other enforcement actions which could have a material adverse effect on our business, financial condition, and results of operations, our ability to pay distributions to our shareholders, and the market price of our common shares.
The Health Insurance Portability and Accountability Act, commonly referred to as HIPAA, was established in 1996 to set national standards for the confidentiality, security, and transmission of personal health information (PHI). Healthcare providers are required, under HIPAA and its implementing regulations, to protect and keep confidential any PHI. HIPAA also sets limits and conditions on use and disclosure of PHI without patient authorization. The law gives patients specific rights to their health information, including rights to obtain a copy of or request corrections to their medical records. The physician or the medical practice can be liable if there are improper disclosures of PHI, including from employee mishandling of PHI, medical records security breaches, lost or stolen electronic devices, hacking, social media breaches or failure to get patient authorizations. Violations could result in multi-million dollar penalties. Actual or potential violations of HIPAA could subject our tenants to government investigations, litigation or other enforcement actions which could adversely affect our tenants’ ability to pay rent and could have a material adverse effect on our business, financial condition, and results of operations, our ability to pay distributions to our shareholders, and the market price of our common shares.
Risks Related to the Real Estate Industry
Our operating performance is subject to risks associated with the real estate industry.
Real estate investments are subject to various risks and fluctuations and cycles in value and demand, many of which are beyond our control. Certain events may decrease cash available for distributions as well as the value of our properties. These events include, but are not limited to:
• | vacancies or our inability to rent space on favorable terms, including possible market pressures to offer tenants rent abatements, tenant improvements, early termination rights, or tenant-favorable renewal options; |
• | inability to collect rent from tenants; |
• | competition from other real estate investors with significant capital, including other real estate operating companies, REITs, and institutional private equity or other investment funds; |
• | reductions in the level of demand for healthcare properties and changes in the demand for certain healthcare-related properties; |
• | increases in the supply of medical office space; |
• | increases in expenses associated with our real estate operations, including, but not limited to, insurance costs, third party management fees, energy prices, real estate assessments, and other taxes and costs of compliance with laws, regulations and governmental policies, and restrictions on our ability to pass such expenses on to our tenants; and |
• | changes in, and changes in interpretation or enforcement of, laws, regulations, and governmental policies associated with real estate, including, without limitation, health, safety, environmental, real estate and zoning and tax laws, increases in real property tax rates and taxation of REITs, governmental fiscal policies, and the ADA. |
In addition, periods of economic slowdown or recession, such as the recent U.S. economic downturn, rising interest rates or declining demand for real estate, or the public perception that any of these events may occur, could result in a general decline in rents or an increased incidence of defaults under existing leases. If we cannot operate our properties to meet our financial expectations, our business, financial condition, results of operations, cash flow, per share market price of our common
26
shares, and ability to satisfy our debt service obligations and to make distributions to our shareholders could be adversely affected.
Illiquidity of real estate investments could significantly impede our ability to respond to adverse changes in the performance of any of our properties.
Because real estate investments are relatively illiquid, our ability to promptly sell one or more of our properties in response to changing economic, financial, and investment conditions is limited. The real estate market is affected by many factors, such as general economic conditions, availability of financing, interest rates, and other factors, including supply and demand, that are beyond our control. We cannot predict whether we will be able to sell any of our properties for the price or on the terms set by us or whether any price or other terms offered by a prospective purchaser would be acceptable to us. We also cannot predict the length of time needed to find a willing purchaser and to close the sale of any of our properties. We may be required to expend funds to correct defects or to make improvements before a property can be sold. We cannot assure that we will have funds available to correct those defects or to make those improvements.
In acquiring a property, we may agree to transfer restrictions that materially restrict us from selling that property for a period of time or impose other restrictions, such as a limitation on the amount of debt that can be placed on that property. These transfer restrictions would impede our ability to sell a property even if we deem it necessary or appropriate. These facts and any others that would impede our ability to respond to adverse changes in the performance of our properties may have an adverse effect on our business, financial condition, results of operations, or ability to make distributions to our shareholders and the market price of our common shares.
Uncertain market conditions could cause us to sell our healthcare properties at a loss in the future.
We intend to hold our various real estate investments until such time as we determine that a sale or other disposition appears to be advantageous to achieve our investment objectives. Our senior management team and the Trust’s board of trustees may exercise their discretion as to whether and when to sell a healthcare related facility, and we will have no obligation to sell our buildings at any particular time. We generally intend to hold our healthcare properties for an extended period of time, and we cannot predict with any certainty the various market conditions affecting real estate investments that will exist at any particular time in the future. Because of the uncertainty of market conditions that may affect the future disposition of our healthcare properties, we may not be able to sell our properties at a profit in the future or at all. In addition, if we are unable to access the capital markets for financing in the future, we may need to sell some of our properties to raise capital. We may incur prepayment penalties in the event that we sell a property subject to a mortgage earlier than we otherwise had planned. Additionally, we could be forced to sell healthcare properties at inopportune times which could result in us selling the affected property at a substantial loss. Accordingly, the extent to which we will pay cash distributions and realize potential appreciation on our real estate investments will, among other things, be dependent upon fluctuating market conditions. Any inability to sell a healthcare property could adversely impact our ability to make debt payments and distributions to our shareholders.
Our assets may be subject to impairment charges.
We will periodically evaluate our real estate investments and other assets for impairment indicators. The judgment regarding the existence of impairment indicators is based upon factors such as market conditions, tenant performance, and legal structure. For example, the termination of a lease by a major tenant may lead to an impairment charge. If we determine that an impairment has occurred, we would be required to make an adjustment to the net carrying value of the asset, which could have an adverse effect on our results of operations in the period in which the impairment charge is recorded. We have had tenant defaults that have caused us to record impairment charges in the past, and it is possible we may have tenant defaults in the future, which could lead to impairment charges.
Our investments in, or originations of, mezzanine and term loans will be subject to specific risks relating to the particular company, and our loan assets will involve greater risks of loss than senior loans secured by income-producing properties.
As of December 31, 2018, we have 10 mezzanine loans and one term loan outstanding, and in the future, we may originate further loans. These investments involve special risks relating to the particular borrower, including its financial condition, liquidity, results of operations, business, and prospects. We may also originate other real estate-related investments which take the form of subordinated loans secured by second mortgages on the underlying property or loans secured by a pledge of the ownership interests of either the entity owning the property or a pledge of the ownership interests of the entity that owns the interest in the entity owning the property or other properties. These types of assets involve a higher degree of risk than long-term senior mortgage lending secured by income producing real property because the loan may become unsecured as a result of foreclosure by the senior lender and because it is in a subordinated position and there may not be adequate equity in
27
the property. In the event of a bankruptcy of the entity providing the pledge of its ownership interests as security, we may not have full recourse to the assets of such entity, or the assets of the entity may not be sufficient to satisfy such loan. If a borrower defaults on a loan or debt senior to our loan, or in the event of a borrower bankruptcy, such loan will be satisfied only after the senior debt. We may be unable to enforce guaranties of payment and/or performance given as security for some loans. As a result, we may not recover some or all of our initial expenditure. Mezzanine and term loans may partially finance the construction of real estate projects and so involve additional risks inherent in the construction process, such as adherence to budgets and construction schedules. In addition, mezzanine and term loans may have higher loan-to-value ratios than conventional mortgage loans, resulting in less equity in the property and increasing the risk of loss of principal. Significant losses related to our mezzanine and term loans would result in operating losses for us and may limit our ability to make distributions to our shareholders.
Risks Related to Financings
Required payments of principal and interest on borrowings may leave us with insufficient cash to operate our properties or to pay the distributions currently contemplated or necessary to qualify as a REIT and may expose us to the risk of default under our debt obligations.
We historically borrow on our unsecured revolving credit facility to acquire properties. Then, as market conditions dictate, we have issued equity or long-term fixed rate debt to repay borrowings under our unsecured revolving credit facility. We are subject to risks associated with debt financing, including the risk that existing indebtedness may not be refinanced or that the terms of refinancing may not be as favorable as the terms of current indebtedness. The majority of our borrowings were completed under indentures or contractual agreements that limit the amount of indebtedness we may incur. Accordingly, in the event that we are unable to raise additional equity or borrow money because of these limitations, our ability to acquire additional properties may be limited.
As of December 31, 2018, we had approximately $108.7 million of mortgage debt on individual properties and approximately $465.0 million of borrowings outstanding under our unsecured credit facility. In addition, in January 2016, August 2016, March 2017, and December 2017 we issued and sold $150.0 million, $75.0 million, $400.0 million, and $350.0 million, respectively, aggregate principal amount of senior notes. We expect to incur additional debt in the future. We do not anticipate that our internally generated cash flow will be adequate to repay our existing indebtedness upon maturity, and, therefore, we expect to repay our indebtedness through refinancings and future offerings of equity and debt securities, either of which we may be unable to secure on favorable terms or at all. Our level of debt and the limitations imposed upon us by our debt agreements could have adverse consequences, including the following:
• | our cash flow may be insufficient to meet our required principal and interest payments; |
• | we may be unable to borrow additional funds as needed or on favorable terms, including to make acquisitions; |
• | we may be unable to refinance our indebtedness at maturity or the refinancing terms may be less favorable than the terms of our original indebtedness; |
• | because a portion of our debt bears, or is expected to bear, interest at variable rates, an increase in interest rates could materially increase our interest expense; |
• | we may fail to effectively hedge against interest rate volatility; |
• | we may be forced to dispose of one or more of our properties, possibly on disadvantageous terms if we are able to do so at all; |
• | our leverage could place us at a competitive disadvantage compared to our competitors who have less debt; |
• | we may experience increased vulnerability to economic and industry downturns, reducing our ability to respond to changing business and economic conditions; |
• | we may default on our obligations and the lenders or mortgagees may foreclose on our properties that secure their loans and receive an assignment of rents and leases; |
• | we may violate financial covenants contained in our various loan documents which would cause a default on our obligations, giving lenders various remedies, including increased interest rates, foreclosure, and liability for additional expenses; |
• | we may inadvertently violate non-financial restrictive covenants in our loan documents, such as covenants that require us to maintain the existence of entities, maintain insurance policies and provide financial statements, which would entitle the lenders to accelerate our debt obligations; and |
28
• | our default under any of our mortgage loans with cross-default or cross-collateralization provisions could result in default on other indebtedness and result in the foreclosures of other properties. |
The realization of any or all of these risks may have an adverse effect on our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares.
In addition, in July 2017, the U.K. Financial Conduct Authority announced that it would phase out LIBOR as a benchmark by the end of 2021. It is unclear whether new methods of calculating LIBOR will be established after 2021. We are unable to predict the effect of any changes, any alternative reference rates, or any other reforms to LIBOR or any replacement of LIBOR that may be enacted in the United Kingdom or elsewhere. Such changes, reforms, or replacements relating to LIBOR could have a material adverse impact on the market for, or value of, any of our LIBOR-linked loans, derivatives, and other indebtedness or on our financial condition or results of operations.
As of December 31, 2018, we had approximately $465.0 million of borrowings outstanding under our unsecured credit facility (including the term loan feature of our unsecured credit facility), during 2016 and 2017, we issued an aggregate of $975.0 million of debt, and in January 2018 we issued 104,172 Series A Preferred Units of the Operating Partnership (“Series A Preferred Units”), all of which is senior to our common shares upon liquidation, and we may in the future make offerings of debt or preferred equity securities which may be senior to our common shares for purposes of dividend distributions or upon liquidation, any of which may materially adversely affect the per share market price of our common shares.
As of December 31, 2018, there were approximately $465.0 million of borrowings outstanding under our unsecured credit facility (including the term loan feature of our unsecured credit facility), and during 2016 and 2017, we issued $975.0 million of aggregate principal amount of senior notes. In January 2018, we issued 104,172 Series A Preferred Units. In the future, we may attempt to increase our capital resources by making additional offerings of debt or equity securities (or causing the Operating Partnership to issue debt securities), including medium-term notes, senior or subordinated notes, and classes or series of preferred shares. Upon liquidation, holders of our debt securities and preferred shares and lenders with respect to other borrowings will be entitled to receive our available assets prior to distribution to the holders of our common shares. Additionally, any convertible or exchangeable securities that we issue in the future may have rights, preferences, and privileges more favorable than those of our common shares and may result in dilution to owners of our common shares. Holders of our common shares are not entitled to preemptive rights or other protections against dilution. Our preferred shares would have a preference on liquidating distributions or a preference on dividend payments that could limit our ability pay dividends or other distributions to the holders of our common shares. Because our decision to issue securities in any future offering will depend on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing, or nature of our future offerings. Thus, our shareholders bear the risk that our future offerings could reduce the per share market price of our common shares and dilute their interest in us.
The derivative instruments that we may use to hedge against interest rate fluctuations may not be successful in mitigating our risks associated with interest rates and could reduce the overall returns on our shareholders’ investment.
We may use derivative instruments to hedge exposure to changes in interest rates on certain of our variable rate loans, but no hedging strategy can protect us completely. We cannot assure our shareholders that our hedging strategy and the derivatives that we use will adequately offset the risk of interest rate volatility or that our hedging of these transactions will not result in losses. Any settlement charges incurred to terminate unused derivative instruments may result in increased interest expense, which may reduce the overall return on our investments. These instruments may also generate income that may not be treated as qualifying REIT income for purposes of the 75% or 95% REIT income tests.
We rely upon external sources of capital to fund future capital needs, and, if we encounter difficulty in obtaining such capital, we may not be able to make future acquisitions necessary to grow our business or meet maturing obligations.
In order to qualify as a REIT under the Internal Revenue Code of 1986, as amended (the “Code”), we are required, among other things, to distribute each year to our shareholders at least 90% of our taxable income, without regard to the deduction for dividends paid and excluding net capital gain. Because of this distribution requirement, we may not be able to fund all of our future capital needs from cash retained from operations, including capital needed to make investments and to satisfy or refinance maturing obligations. As a result, we expect to rely upon external sources of capital, including debt and equity financing, to fund future capital needs. If we are unable to obtain needed capital on satisfactory terms or at all, we may not be able to make the investments needed to expand our business or to meet our obligations and commitments as they mature. Our access to capital will depend upon a number of factors over which we have little or no control, including general stock and bond market conditions and investor interest, the market’s perception of our current and potential future earnings, analyst
29
reports about us and the REIT industry, cash distributions and the market price of our common shares, and other factors such as governmental regulatory action and changes in REIT tax laws. We may not be in a position to take advantage of attractive investment opportunities for growth if we are unable to access the capital markets on a timely basis on favorable terms. Moreover, additional equity offerings may result in substantial dilution of our shareholders’ interests, and additional debt financing may substantially increase our leverage, either of which could cause the per share price of our common shares to decline.
If we become highly leveraged in the future, the resulting increase in outstanding debt could adversely affect our ability to make debt service payments, to pay our anticipated distributions, and to make the distributions required to qualify as a REIT.
As of December 31, 2018, our indebtedness represented approximately 37.4% of our total assets. If we become more highly leveraged, the resulting increase in outstanding debt could adversely affect our ability to make debt service payments, to pay our anticipated distributions, and to make the distributions required to qualify as a REIT. The occurrence of any of the foregoing risks could adversely affect our business, financial condition, and results of operations, our ability to make distributions to our shareholders, and the market price of our common shares.
We are subject to covenants in our debt agreements that may restrict or limit our operations and acquisitions and our failure to comply with the covenants in our debt agreements could have a material adverse impact on our business, results of operations, and financial condition.
The terms of the instruments governing our existing indebtedness require us to comply with a number of customary financial and other covenants, such as maintaining certain leverage and coverage ratios and minimum tangible net worth requirements. Our continued ability to incur additional debt and to conduct business in general is subject to our compliance with these covenants, which limit our operational flexibility. Breaches of these covenants could result in defaults under the instruments governing the applicable indebtedness, in addition to any other indebtedness cross-defaulted against such instruments. Any such default could have a material adverse impact on our business, results of operations, and financial condition or our ability to make distributions to our shareholders.
A downgrade in our credit ratings could materially adversely affect our business and financial condition.
Our credit rating and the credit ratings assigned to our debt securities could change based upon, among other things, our results of operations and financial condition. These ratings are subject to ongoing evaluation by credit rating agencies, and any rating could be changed or withdrawn by a rating agency in the future if, in its judgment, circumstances warrant such action.
If any of the credit rating agencies that have rated our securities downgrades or lowers its credit rating, or if any credit rating agency indicates that it has placed any such rating on a “watch list” for a possible downgrade or lowering, or otherwise indicates that its outlook for that rating is negative, such action could have a material adverse effect on our costs and availability of funding, which could in turn have a material adverse effect on our financial condition, results of operations, cash flows, the market price of our securities, and our ability to satisfy our debt service obligations, among other obligations.
If securities analysts do not publish research or reports about our industry or if they downgrade our common shares or the healthcare-related real estate sector, the market price of our common shares could decline.
The market for our common shares depends in part upon the research and reports that industry or financial analysts publish about us and our industry. We have no control over these analysts. Furthermore, if one or more of the analysts who do cover us downgrades our shares or our industry, or the stock of any of our competitors, the price of our common shares could decline. If one or more of these analysts ceases coverage of our company, we could lose attention in the market which in turn could cause the market price of our common shares to decline.
Risks Related to Our Portfolio and Structure
We have no direct operations and rely upon funds received from the Operating Partnership to meet our obligations.
The Trust conducts substantially all of its operations through the Operating Partnership. As of February 22, 2019, the Trust owned approximately 97.2% of the OP Units and apart from this ownership interest, the Trust does not have any independent operations. As a result, the Trust relies upon distributions from the Operating Partnership to pay any distributions that the Trust might declare on the Trust’s common shares. We also rely upon distributions from the Operating Partnership to
30
the Trust to meet our obligations, including tax liability on taxable income allocated to the Trust from the Operating Partnership (which might make distributions to the Trust not equal to the tax on such allocated taxable income). Shareholders’ claims will consequently be structurally subordinated to all existing and future liabilities and obligations (whether or not for borrowed money) of the Operating Partnership and its subsidiaries. Therefore, in the event of bankruptcy, liquidation or reorganization of the Trust, claims of the Trust’s shareholders will be satisfied only after all of the Trust’s and the Operating Partnership’s and its subsidiaries’ liabilities and obligations have been paid in full.
Our business could be harmed if key personnel terminate their employment with us or if we are unsuccessful in integrating new personnel into our operations.
Our success depends, to a significant extent, on the continued services of Mr. Thomas, our President and Chief Executive Officer; Mr. Theiler, our Executive Vice President and Chief Financial Officer; Mr. Taylor, our Executive Vice President – Investments; Mr. Lucey, our Senior Vice President – Chief Accounting and Administrative Officer; Mr. Theine, our Senior Vice President of Asset and Investment Management; Mr. Page, our Senior Vice President and General Counsel; and Mr. Klein, our Senior Vice President – Investments and Deputy Chief Investment Officer. We do not maintain key person life insurance on any of our officers. Our ability to continue to acquire and develop healthcare properties depends upon the significant relationships that our senior management team has developed over many years.
Although the Trust has entered into employment agreements with Messrs. Thomas, Theiler, Taylor, Lucey, Theine, Page, and Klein, we cannot provide any assurance that any of them will remain employed by the Trust. Our ability to retain our senior management team, or to attract suitable replacements should any member of the senior management team leave, is dependent on the competitive nature of the employment market. The loss of services of, or the failure to successfully integrate one or more new members of, our senior management team could adversely affect our business and our prospects.
The Trust’s declaration of trust restricts the ownership and transfer of our outstanding shares of beneficial interest which may have the effect of delaying, deferring, or preventing a transaction or change of control of our company.
In order for us to qualify as a REIT, no more than 50% of the value of the Trust’s outstanding shares of beneficial interest may be owned, beneficially or constructively, by five or fewer individuals at any time during the last half of each taxable year. Subject to certain exceptions, the Trust’s declaration of trust prohibits any shareholder from owning beneficially or constructively more than 9.8% in value or number of shares, whichever is more restrictive, of the outstanding shares of any class or series of our shares of beneficial interest, although the Trust has granted, and may in the future grant, a waiver from the ownership limitations. The constructive ownership rules under the Code are complex and may cause the outstanding shares owned by a group of related individuals or entities to be deemed to be constructively owned by one individual or entity. As a result, the acquisition of less than 9.8% of our outstanding shares of any class or series by an individual or entity could cause that individual or entity to own constructively in excess of 9.8% of the outstanding shares of any class or series of our shares of beneficial interest and to be subject to the Trust’s declaration of trust’s ownership limit. The Trust’s declaration of trust also prohibits, among other prohibitions, any person from owning our shares of beneficial interest that would result in our being “closely held” under Section 856(h) of the Code or otherwise cause us to fail to qualify as a REIT. Any attempt to own or transfer shares of our beneficial interest in violation of these restrictions may result in the shares being automatically transferred to a charitable trust or may be void. The share ownership restrictions of the Code for REITs and the 9.8% share ownership limit and other restrictions on ownership and transfer of our shares contained in the Trust’s declaration of trust may inhibit market activity in our shares of beneficial interest and restrict our business combination opportunities.
Certain provisions of Maryland law could inhibit changes of control, which may discourage third parties from conducting a tender offer or seeking other change of control transactions that could involve a premium price for our common shares or that our shareholders otherwise believe to be in their best interests.
Certain provisions of the Maryland General Corporation Law, or MGCL, applicable to Maryland real estate investment trusts may have the effect of inhibiting a third party from making a proposal to acquire the Trust (and, indirectly, the Operating Partnership) or of impeding a change of control under circumstances that otherwise could provide the Trust’s common shareholders with the opportunity to realize a premium over the then-prevailing market price of such shares, including:
31
• | “business combination” provisions that, subject to limitations, prohibit certain business combinations between us and an “interested shareholder” (defined generally as any person who beneficially owns 10% or more of the voting power of our shares or an affiliate or associate of ours who was the beneficial owner, directly or indirectly, of 10% or more of the voting power of our shares at any time within the two-year period immediately prior to the date in question) or an affiliate thereof for five years after the most recent date on which the shareholder becomes an interested shareholder, and thereafter imposes certain minimum price and/or supermajority shareholder voting requirements on these combinations; and |
• | “control share” provisions that provide that holders of “control shares” of our Trust (defined as shares that, when aggregated with all other shares controlled by the shareholder, entitle the shareholder to exercise one of three increasing ranges of voting power in electing trustees) acquired in a “control share acquisition” (defined as the direct or indirect acquisition of ownership or control of issued and outstanding “control shares,” subject to certain exceptions) have no voting rights with respect to their control shares, except to the extent approved by our shareholders by the affirmative vote of at least two-thirds of all the votes entitled to be cast on the matter, excluding all interested shares. |
The Trust’s board of trustees has by resolution exempted any business combination between us and any other person from the business combination provisions of the MGCL, provided that the business combination is first approved by the board of trustees (including a majority of trustees who are not affiliates or associates of such person). In addition, the Trust’s bylaws contain a provision exempting any and all acquisitions of our shares from the control share provisions of the MGCL. However, the board of trustees may at any time alter or repeal the resolution exempting certain businesses from the business combination provisions of the MGCL and we may at any time amend or eliminate the provision of our bylaws exempting acquisitions of our shares from the control share provisions of the MGCL.
Certain provisions of the MGCL permit the board of trustees, without shareholder approval and regardless of what is currently provided in the Trust’s declaration of trust or bylaws, to implement certain corporate governance provisions with respect to the Trust, some of which (for example, a classified board) are not currently applicable to us. If implemented, these provisions may have the effect of limiting or precluding a third party from making an unsolicited acquisition proposal for us or of delaying, deferring, or preventing a change in control of us under circumstances that otherwise could provide our common shareholders with the opportunity to realize a premium over the then current market price. Pursuant to our declaration of trust, we have elected to be subject to the provisions of Title 3, Subtitle 8 of the MGCL relating to the filling of vacancies on our board of trustees.
We could increase the number of authorized shares, classify and reclassify unissued shares, and issue shares without shareholder approval.
The Trust’s board of trustees, without shareholder approval, has the power under the Trust’s declaration of trust to amend our declaration of trust to increase or decrease the aggregate number of shares or the number of shares of any class or series of the Trust that we are authorized to issue, and to authorize us to issue authorized but unissued common shares or preferred shares. In addition, under the declaration of trust, the board of trustees has the power to classify or reclassify any unissued common or preferred shares into one or more classes or series of shares and set or change the preference, conversion or other rights, voting powers, restrictions, limitations as to dividends and other distributions, qualifications or terms or conditions of redemption for such newly classified or reclassified shares. As a result, we may issue series or classes of common shares or preferred shares with preferences, dividends, powers, and rights, voting or otherwise, that are senior to, or otherwise conflict with, the rights of holders of our common shares. Although the board of trustees has no such intention at the present time, it could establish a class or series of preferred shares that could, depending on the terms of such class or series, delay, defer, or prevent a transaction or a change of control that might involve a premium price for our common shares or that our shareholders otherwise believe to be in their best interests.
Certain provisions in the partnership agreement of the Operating Partnership may delay or prevent unsolicited acquisitions of us.
Provisions in the partnership agreement of the Operating Partnership may delay, or make more difficult, unsolicited acquisitions of us or changes of our control. These provisions could discourage third parties from making proposals involving an unsolicited acquisition of us or change of our control, although some shareholders might consider such proposals, if made, desirable. These provisions include, among others:
• | redemption rights; |
32
• | a requirement that the Trust may not be removed as the general partner of the Operating Partnership without our consent; |
• | transfer restrictions on OP Units; |
• | the Trust’s ability, as general partner, in some cases, to amend the partnership agreement and to cause the Operating Partnership to issue units with terms that could delay, defer, or prevent a merger or other change of control of the Trust or the Operating Partnership without the consent of the limited partners; and |
• | the right of the limited partners to consent to direct or indirect transfers of the general partnership interest, including as a result of a merger or a sale of all or substantially all of our assets, in the event that such transfer requires approval by our common shareholders. |
The Trust’s declaration of trust and bylaws, Maryland law, and the partnership agreement of the Operating Partnership also contain other provisions that may delay, defer, or prevent a transaction or a change of control that might involve a premium price for our common shares or that our shareholders otherwise believe to be in their best interest.
Risks Related to Our Qualification and Operation as a REIT
If we fail to qualify as a REIT in any taxable year, we will face serious tax consequences that would substantially reduce funds available for distributions to our shareholders.
Since our formation, the Trust has been organized and has operated in such a manner as to qualify for taxation as a REIT under the U.S. federal income tax laws, and we intend to continue to operate in such a manner, but no assurances can be given that we will operate in a manner so as to qualify or remain qualified as a REIT.
Failure to qualify as a REIT, or failure to remain qualified as a REIT, would cause us to be taxed as a regular corporation, which would substantially reduce funds available for distribution to our shareholders. If we fail to qualify as a REIT in any taxable year, we would face serious tax consequences that will substantially reduce the funds available for distribution to our shareholders because:
• | we would not be allowed a deduction for dividends paid to shareholders in computing our taxable income and would be subject to U.S. federal income tax at regular corporate rates; |
• | we could possibly be subject to increased state and local taxes; and |
• | unless we are entitled to relief under certain U.S. federal income tax laws, we could not re-elect REIT status until the fifth calendar year after the year in which we failed to qualify as a REIT. |
In addition, if we fail to qualify as a REIT, we will no longer be required to make distributions. As a result of all these factors, our failure to qualify as a REIT could impair our ability to expand our business and raise capital, and it would adversely affect the value of our shares of beneficial interest.
Failure to make required distributions would subject us to U.S. federal corporate income tax.
We intend to operate in a manner so as to qualify as a REIT for U.S. federal income tax purposes. In order to qualify as a REIT, we generally are required to distribute at least 90% of our REIT taxable income, determined without regard to the dividends paid deduction and excluding any net capital gain, each year to our shareholders. To the extent that we satisfy this distribution requirement, but distribute less than 100% of our REIT taxable income, we will be subject to U.S. federal corporate income tax on our undistributed taxable income. In addition, we will be subject to a 4% nondeductible excise tax if the actual amount that we pay out to our shareholders in a calendar year is less than a minimum amount specified under the Code.
Complying with REIT requirements may cause us to forego otherwise attractive opportunities or liquidate otherwise attractive investments.
To qualify as a REIT for federal income tax purposes, we must continually satisfy tests concerning, among other things, the sources of our income, the nature and diversification of our assets, the amounts we distribute to our shareholders, and the ownership of our shares of beneficial interest. In order to meet these tests, we may be required to forego investments we might otherwise make. Thus, compliance with the REIT requirements may hinder our performance.
33
In particular, we must ensure that at the end of each calendar quarter, at least 75% of the value of our assets consists of cash, cash items, government securities, and qualified real estate assets. The remainder of our investment in securities (other than government securities, securities of taxable REIT subsidiaries (“TRS”), and qualified real estate assets) generally cannot include more than 10% of the outstanding voting securities of any one issuer or more than 10% of the total value of the outstanding securities of any one issuer. In addition, in general, no more than 5% of the value of our assets (other than government securities, securities of TRSs, and qualified real estate assets) can consist of the securities of any one issuer, and no more than 20% of the value of our total assets can be represented by the securities of one or more TRSs. Further, debt instruments that do not otherwise qualify as real estate assets issued to us by publicly offered REITs will be treated as qualified real estate assets for purposes of the asset test, but no more than 25% of the value of our total assets may be represented by such debt instruments. If we fail to comply with these requirements at the end of any calendar quarter, we must correct the failure within 30 days after the end of the calendar quarter or qualify for certain statutory relief provisions to avoid losing our REIT qualification and suffering adverse tax consequences. As a result, we may be required to liquidate otherwise attractive investments. These actions could have the effect of reducing our income and amounts available for distribution to our shareholders.
The prohibited transactions tax may limit our ability to dispose of our properties.
A REIT’s net income from prohibited transactions is subject to a 100% tax. In general, prohibited transactions are sales or other dispositions of property other than “foreclosure property,” held primarily for sale to customers in the ordinary course of business. We may be subject to the prohibited transactions tax equal to 100% of net gain upon a disposition of real property. Although a safe harbor to the characterization of the sale of real property by a REIT as a prohibited transaction is available, we cannot assure you that we can comply with the safe harbor or that we will avoid owning property that may be characterized as held primarily for sale to customers in the ordinary course of business. Consequently, we may choose not to engage in certain sales of our properties or may conduct such sales through any TRS that we may form, which would be subject to federal and state income taxation.
Any ownership of a TRS will be subject to limitations and our transactions with a TRS will cause us to be subject to a 100% penalty tax on certain income or deductions if those transactions are not conducted on arm’s-length terms.
Overall, no more than 20% of the value of a REIT’s assets may consist of stock or securities of one or more TRSs. In addition, the Code also imposes a 100% excise tax on certain transactions between a TRS and its parent REIT that are not conducted on an arm’s-length basis. We will monitor the value of our respective investments in any TRS for the purpose of ensuring compliance with TRS ownership limitations and will structure our transactions with any TRS on terms that we believe are arm’s-length to avoid incurring a 100% excise tax on such transactions. There can be no assurance, however, that we will be able to comply with the 20% limitation or avoid application of the 100% excise tax.
If leases of our properties are not respected as true leases for federal income tax purposes, we would fail to qualify as a REIT and would be subject to higher taxes and have less cash available for distribution to our shareholders.
To qualify as a REIT, we must satisfy two gross income tests, under which specified percentages of our gross income must be derived from certain sources, such as “rents from real property.” Rents paid to the Operating Partnership by third party lessees and any TRS lessee pursuant to the leases of our properties will constitute substantially all of our gross income. In order for such rent to qualify as “rents from real property” for purposes of the gross income tests, the leases must be respected as true leases for federal income tax purposes and not be treated as service contracts, joint ventures, or some other type of arrangement. If our leases are not respected as true leases for federal income tax purposes, we would fail to qualify as a REIT.
Dividends payable by REITs do not qualify for the reduced tax rates available for some dividends.
The maximum tax rate applicable to “qualified dividend income” payable to U.S. shareholders who are taxed at individual rates is 23.8%. Dividends payable by REITs, however, generally are not eligible for the reduced rates on qualified dividend income. The more favorable rates applicable to regular corporate qualified dividends could cause investors who are taxed at individual rates to perceive investments in REITs to be relatively less attractive than investments in the stocks of non-REIT corporations that pay dividends, which could adversely affect the value of the shares of REITs, including our common shares.
34
We may be subject to adverse legislative or regulatory tax changes that could reduce the market price of our common shares.
At any time, the U.S. federal income tax laws governing REITs or the administrative interpretations of those laws may be amended. We cannot predict when or if any new U.S. federal income tax law, regulation, or administrative interpretation, or any amendment to any existing U.S. federal income tax law, regulation, or administrative interpretation, will be adopted, promulgated or become effective and any such law, regulation, or interpretation may take effect retroactively. We and our shareholders could be adversely affected by any such change in the U.S. federal income tax laws, regulations, or administrative interpretations.
ITEM 1B. UNRESOLVED STAFF COMMENTS
None.
35
ITEM 2. PROPERTIES
Geographic Diversification/Concentration
The following table lists the states in which our properties are located and provides certain information regarding our portfolio’s geographic diversification/concentration as of December 31, 2018:
State | Number of Properties | GLA (1) (square feet) | Percent of GLA | Annualized Base Rent (2) (thousands) | Percent of Annualized Base Rent | |||||||||||
Alabama | 10 | 488,709 | 3.6 | % | $ | 10,096 | 3.5 | % | ||||||||
Arizona | 13 | 733,791 | 5.4 | % | 15,931 | 5.6 | % | |||||||||
Arkansas | 8 | 283,440 | 2.1 | % | 4,515 | 1.6 | % | |||||||||
Colorado | 5 | 129,620 | 1.0 | % | 2,815 | 1.0 | % | |||||||||
Connecticut | 1 | 72,022 | 0.5 | % | 1,734 | 0.6 | % | |||||||||
Florida | 20 | 361,468 | 2.7 | % | 9,078 | 3.2 | % | |||||||||
Georgia | 7 | 1,042,328 | 7.7 | % | 24,716 | 8.6 | % | |||||||||
Illinois | 3 | 139,450 | 1.0 | % | 2,795 | 1.0 | % | |||||||||
Indiana | 21 | 998,831 | 7.3 | % | 19,824 | 6.9 | % | |||||||||
Kentucky | 12 | 976,620 | 7.2 | % | 16,552 | 5.8 | % | |||||||||
Louisiana | 3 | 150,777 | 1.1 | % | 5,856 | 2.0 | % | |||||||||
Maine | 1 | 44,677 | 0.3 | % | 894 | 0.3 | % | |||||||||
Maryland | 3 | 166,594 | 1.2 | % | 3,876 | 1.4 | % | |||||||||
Michigan | 6 | 250,456 | 1.8 | % | 6,202 | 2.2 | % | |||||||||
Minnesota | 19 | 810,301 | 5.9 | % | 17,154 | 6.0 | % | |||||||||
Mississippi | 2 | 97,294 | 0.7 | % | 2,429 | 0.8 | % | |||||||||
Missouri | 2 | 69,184 | 0.5 | % | 1,857 | 0.6 | % | |||||||||
Montana | 3 | 185,085 | 1.4 | % | 5,357 | 1.9 | % | |||||||||
Nebraska | 13 | 979,303 | 7.2 | % | 17,739 | 6.2 | % | |||||||||
New Mexico | 2 | 53,029 | 0.4 | % | 1,404 | 0.5 | % | |||||||||
New York | 13 | 613,520 | 4.5 | % | 14,393 | 5.0 | % | |||||||||
North Dakota | 8 | 434,215 | 3.2 | % | 7,795 | 2.7 | % | |||||||||
Ohio | 12 | 650,319 | 4.8 | % | 13,451 | 4.7 | % | |||||||||
Oklahoma | 1 | 52,000 | 0.4 | % | 504 | 0.2 | % | |||||||||
Pennsylvania | 11 | 403,811 | 3.0 | % | 5,512 | 1.9 | % | |||||||||
Tennessee | 8 | 689,498 | 5.1 | % | 12,451 | 4.4 | % | |||||||||
Texas | 28 | 1,880,974 | 13.8 | % | 44,064 | 15.4 | % | |||||||||
Virginia | 1 | 72,255 | 0.5 | % | 1,787 | 0.6 | % | |||||||||
Washington | 10 | 589,141 | 4.3 | % | 10,286 | 3.6 | % | |||||||||
Wisconsin (3) | 6 | 205,886 | 1.4 | % | 4,947 | 1.8 | % | |||||||||
Total | 252 | 13,624,598 | 100.0 | % | $ | 286,014 | 100.0 | % | ||||||||
(1) | “GLA” means gross leasable area. |
(2) | Annualized base rent is calculated by multiplying (a) base rental payments for the month ended December 31, 2018, by (b) 12. |
(3) | Excludes leases related to the Company’s 108,843 square foot corporate office building. |
36
Scheduled Lease Expirations
The following table provides a summary of lease expirations for our properties owned as of December 31, 2018, for the periods indicated:
Expiration (1) | Number of Leases Expiring | GLA | Percent of GLA | Annualized Base Rent (thousands) | Percent of Annualized Base Rent | Annualized Base Rent Leased per Square Foot (2) | ||||||||||||||
2019 | 103 | 345,677 | 2.5 | % | 7,752 | 2.7 | % | $ | 22.43 | |||||||||||
2020 | 111 | 466,063 | 3.4 | % | 9,963 | 3.5 | % | 21.38 | ||||||||||||
2021 | 148 | 575,475 | 4.2 | % | 12,240 | 4.3 | % | 21.27 | ||||||||||||
2022 | 100 | 633,649 | 4.7 | % | 16,070 | 5.6 | % | 25.36 | ||||||||||||
2023 | 110 | 606,918 | 4.5 | % | 13,627 | 4.8 | % | 22.45 | ||||||||||||
2024 | 65 | 767,566 | 5.6 | % | 15,859 | 5.5 | % | 20.66 | ||||||||||||
2025 | 134 | 926,790 | 6.8 | % | 22,114 | 7.7 | % | 23.86 | ||||||||||||
2026 | 121 | 3,580,117 | 26.3 | % | 72,165 | 25.2 | % | 20.16 | ||||||||||||
2027 | 69 | 1,192,916 | 8.8 | % | 25,143 | 8.8 | % | 21.08 | ||||||||||||
2028 | 70 | 1,316,431 | 9.7 | % | 30,826 | 10.8 | % | 23.42 | ||||||||||||
Thereafter | 73 | 2,507,308 | 18.3 | % | 57,642 | 20.2 | % | 22.99 | ||||||||||||
Month to month (3) | 49 | 117,602 | 0.9 | % | 2,613 | 0.9 | % | 22.22 | ||||||||||||
Vacant | — | 588,086 | 4.3 | % | — | — | — | |||||||||||||
Total / Weighted average | 1,153 | 13,624,598 | 100.0 | % | $ | 286,014 | 100.0 | % | $ | 21.94 | ||||||||||
(1) | Excludes leases related to the Company’s 108,843 square foot corporate office building. |
(2) | Annualized base rent per leased square foot is calculated by dividing (a) annualized base rent as of December 31, 2018 by (b) square footage under executed leases as of December 31, 2018. |
(3) | Includes 5 leases which expired on December 31, 2018, representing 0.2% of portfolio leasable square feet. |
Tenants
As of December 31, 2018, our properties were approximately 96% leased. No single tenant accounted for more than 5.7% of our total annualized base rent or 5.5% of total base revenue as of December 31, 2018; however, 19.2% of our total annualized base rent as of December 31, 2018 were from tenants affiliated with CHI.
The following table sets forth certain information about the 10 largest tenants in our portfolio based on total annualized base rent as of December 31, 2018:
Tenant | # of Properties | Leased GLA | % GLA | Annualized Base Rent (thousands) | % of Portfolio Annualized Rent | ||||||||||
CHI - Nebraska | 13 | 895,138 | 6.6 | % | $ | 16,336 | 5.7 | % | |||||||
CHI - KentuckyOne Health | 11 | 752,480 | 5.5 | % | 13,577 | 4.8 | % | ||||||||
Northside Hospital | 5 | 475,571 | 3.5 | % | 10,086 | 3.5 | % | ||||||||
Baylor Scott and White Health | 2 | 268,639 | 2.0 | % | 7,583 | 2.7 | % | ||||||||
Ascension - St. Vincent's - Indianapolis | 4 | 357,110 | 2.6 | % | 7,291 | 2.5 | % | ||||||||
US Oncology | 5 | 254,939 | 1.9 | % | 6,810 | 2.4 | % | ||||||||
CHI - St. Alexius (ND) | 7 | 362,284 | 2.7 | % | 6,391 | 2.2 | % | ||||||||
HonorHealth | 6 | 243,482 | 1.8 | % | 5,953 | 2.1 | % | ||||||||
CHI - Franciscan (WA) | 8 | 332,089 | 2.4 | % | 5,780 | 2.0 | % | ||||||||
Great Falls Clinic | 3 | 185,085 | 1.3 | % | 5,357 | 1.9 | % | ||||||||
Total | 64 | 4,126,817 | 30.3 | % | $ | 85,164 | 29.8 | % | |||||||
Before entering into a lease and during the lease term, we seek to manage our exposure to significant tenant credit issues. In most instances, we seek to obtain tenant financial information, including credit reports, financial statements, and tax returns. Where appropriate, we seek to obtain financial commitments in the form of letters of credit, security deposits, or
37
personal guarantees from tenants. On an ongoing basis, we monitor accounts receivable and payment history for both tenants and properties and seek to identify any credit concerns as quickly as possible. In addition, we keep in close contact with our tenants in an effort to identify and address negative changes to their businesses prior to such adverse changes affecting their ability to pay rent to us.
Ground Leases
We lease the land upon which 76 of our properties are built, representing approximately 40.4% of our total leasable square feet and 38.4% of our annualized base revenue as of December 31, 2018. The ground leases subject these properties to certain restrictions. These restrictions may limit our ability to re-let such facilities to tenants not affiliated with the healthcare delivery system that owns the underlying land. Restrictions may also include rights of first offer and refusal with respect to sales of the properties and may limit the types of medical procedures that may be performed at the facilities.
ITEM 3. LEGAL PROCEEDINGS
From time to time, we are party to various lawsuits, claims and other legal proceedings that arise in the ordinary course of our business. We are not currently a party, as plaintiff or defendant, to any legal proceedings which, individually or in the aggregate, would be expected to have a material effect on our business, financial condition, or results of operations if determined adversely to us.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
38
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Physicians Realty Trust
The Trust’s common shares are traded on the NYSE under the symbol “DOC.” As of February 22, 2019, the Trust had 322 registered shareholders of record of the Trust’s common shares.
It has been the Trust’s policy to declare quarterly dividends to its shareholders so as to comply with applicable provisions of the Code governing REITs. The declaration and payment of quarterly dividends remains subject to the review and approval of the Board of Trustees.
Physicians Realty L.P.
There is no established public market for the Operating Partnership’s OP Units or Series A Preferred Units. As of February 22, 2019, there were no holders of record and 187,719,170 OP Units outstanding, 182,645,051 of which were held by the Trust. As of February 22, 2019, there were an additional 104,172 Series A Preferred Units outstanding.
It has been the Operating Partnership’s policy to declare quarterly distributions so as to allow the Trust to comply with applicable provisions of the Code governing REITs. The declaration and payment of quarterly distributions remains subject to the review and approval of the Trust’s Board of Trustees.
39
Stock Performance Graph
This performance graph shall not be deemed “soliciting material” or to be “filed” with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any filing of Physicians Realty Trust under the Securities Act or the Exchange Act.
The graph below compares the cumulative total return of our common shares, the Standard & Poor’s 500, and the MSCI US REIT Index (RMS), from December 31, 2013 through December 31, 2018. The comparison assumes $100 was invested on December 31, 2013 in our common shares and in each of the foregoing indexes and assumes reinvestment of dividends, as applicable. The MSCI US REIT Index consists of equity REITs that are included in the MSCI US Investable Market 2500 Index, except for specialty equity REITS that do not generate a majority of their revenue and income from real estate rental and leasing operations. We have included the MSCI US REIT Index because we joined the MSCI US REIT Index in November 2014 and therefore we believe that it is representative of the industry in which we compete and is relevant to an assessment of our performance.
Period Ending | ||||||||||||||||||||||||
Index | 12/31/2013 | 12/31/2014 | 12/31/2015 | 12/31/2016 | 12/31/2017 | 12/31/2018 | ||||||||||||||||||
Physicians Realty Trust | $ | 100.00 | $ | 139.18 | $ | 149.29 | $ | 176.09 | $ | 175.26 | $ | 165.28 | ||||||||||||
Standard & Poor’s 500 | $ | 100.00 | $ | 113.69 | $ | 115.26 | $ | 129.05 | $ | 157.22 | $ | 150.33 | ||||||||||||
MSCI US REIT (RMS) | $ | 100.00 | $ | 130.38 | $ | 133.67 | $ | 145.16 | $ | 152.52 | $ | 145.55 | ||||||||||||
Recent Sales of Unregistered Securities
From time to time, the Operating Partnership issues OP Units to the Trust, as required by the Partnership Agreement, to reflect additional issuances of common shares by the Trust and to preserve equitable ownership ratios.
40
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
The following table sets forth information relating to repurchases of our common shares of beneficial interest and OP Units during the three months ended December 31, 2018:
ISSUER PURCHASES OF EQUITY SECURITIES
Period | (a) Total Number of Shares (or Units) Purchased | (b) Average Price Paid per Share (or Unit) | (c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs | (d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs | |||||||||
October 1, 2018 - October 31, 2018 | 72,029 | (1) | $ | 16.64 | N/A | N/A | |||||||
November 1, 2018 - November 30, 2018 | — | — | N/A | N/A | |||||||||
December 1, 2018 - December 31, 2018 | — | — | N/A | N/A | |||||||||
Total | 72,029 | $ | 16.64 | — | — | ||||||||
(1) | Represents OP Units redeemed by holders in exchange for common shares of the Trust. |
ITEM 6. SELECTED FINANCIAL DATA
The following selected financial data should be read together with the discussion under the caption Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and the consolidated financial statements and related notes thereto included in this report.
41
Physicians Realty Trust
Year Ended December 31, | |||||||||||||||||||
(in thousands, except per share data) | 2018 | 2017 | 2016 | 2015 | 2014 | ||||||||||||||
Statement of Operations Data | |||||||||||||||||||
Revenues: | |||||||||||||||||||
Rental revenues | $ | 313,006 | $ | 259,673 | $ | 186,301 | $ | 103,974 | $ | 46,397 | |||||||||
Expense recoveries | 97,989 | 75,425 | 45,875 | 21,587 | 5,871 | ||||||||||||||
Interest income on real estate loans and other | 11,556 | 8,486 | 8,858 | 3,880 | 1,066 | ||||||||||||||
Total revenues | 422,551 | 343,584 | 241,034 | 129,441 | 53,334 | ||||||||||||||
Expenses: | |||||||||||||||||||
Interest expense | 66,183 | 47,008 | 23,864 | 10,636 | 6,907 | ||||||||||||||
General and administrative | 28,816 | 22,957 | 18,397 | 14,908 | 11,440 | ||||||||||||||
Operating expenses | 122,620 | 97,035 | 65,999 | 31,026 | 10,154 | ||||||||||||||
Depreciation and amortization | 158,389 | 125,159 | 86,589 | 45,471 | 16,731 | ||||||||||||||
Acquisition expenses | — | 16,744 | 14,778 | 14,893 | 10,897 | ||||||||||||||
Impairment loss | — | 965 | — | — | 1,750 | ||||||||||||||
Total expenses | 376,008 | 309,868 | 209,627 | 116,934 | 57,879 | ||||||||||||||
Income (loss) before equity in income of unconsolidated entities and net gain on sale of investment properties | 46,543 | 33,716 | 31,407 | 12,507 | (4,545 | ) | |||||||||||||
Equity in income of unconsolidated entities | 114 | 183 | 115 | 104 | 95 | ||||||||||||||
Gain on sale of investment properties, net | 11,664 | 5,874 | — | 130 | 32 | ||||||||||||||
Net income (loss) | 58,321 | 39,773 | 31,522 | 12,741 | (4,418 | ) | |||||||||||||
Net (income) loss attributable to noncontrolling interests: | |||||||||||||||||||
Operating Partnership | (1,576 | ) | (1,136 | ) | (825 | ) | (576 | ) | 695 | ||||||||||
Partially owned properties (1) | (515 | ) | (491 | ) | (716 | ) | (377 | ) | (314 | ) | |||||||||
Net income (loss) attributable to controlling interest | 56,230 | 38,146 | 29,981 | 11,788 | (4,037 | ) | |||||||||||||
Preferred distributions | (1,340 | ) | (731 | ) | (1,857 | ) | (1,189 | ) | — | ||||||||||
Net income (loss) attributable to common shareholders | $ | 54,890 | $ | 37,415 | $ | 28,124 | $ | 10,599 | $ | (4,037 | ) | ||||||||
Net income (loss) per share: | |||||||||||||||||||
Basic | $ | 0.30 | $ | 0.23 | $ | 0.22 | $ | 0.15 | $ | (0.12 | ) | ||||||||
Diluted | $ | 0.30 | $ | 0.23 | $ | 0.22 | $ | 0.15 | $ | (0.12 | ) | ||||||||
Dividends and distributions declared per common share and OP Unit | $ | 0.920 | $ | 0.915 | $ | 0.900 | $ | 0.900 | $ | 0.900 | |||||||||
Balance Sheet Data (as of end of period): | |||||||||||||||||||
Assets: | |||||||||||||||||||
Net real estate investments | $ | 3,970,033 | $ | 4,045,388 | $ | 2,767,624 | $ | 1,579,483 | $ | 773,650 | |||||||||
Cash and cash equivalents | 19,161 | 2,727 | 15,491 | 3,143 | 15,923 | ||||||||||||||
Tenant receivables, net | 8,881 | 9,966 | 9,790 | 2,977 | 1,324 | ||||||||||||||
Other assets | 144,759 | 106,302 | 95,187 | 53,283 | 15,806 | ||||||||||||||
Total assets | $ | 4,142,834 | $ | 4,164,383 | $ | 2,888,092 | $ | 1,638,886 | $ | 806,703 | |||||||||
Liabilities and Equity: | |||||||||||||||||||
Credit facility | $ | 457,388 | $ | 324,394 | $ | 643,742 | $ | 389,375 | $ | 134,144 | |||||||||
Notes payable | 966,961 | 966,603 | 224,330 | — | — | ||||||||||||||
Mortgage debt | 108,504 | 186,471 | 123,083 | 94,240 | 77,091 | ||||||||||||||
Accounts payable | 3,886 | 11,023 | 4,423 | 644 | 700 | ||||||||||||||
Dividends and distributions payable | 43,821 | 43,804 | 32,179 | 20,783 | 16,548 | ||||||||||||||
Accrued expenses and other liabilities | 76,282 | 56,405 | 42,287 | 24,473 | 6,140 | ||||||||||||||
Acquired lease intangible, net | 13,585 | 15,702 | 9,253 | 5,950 | 2,871 | ||||||||||||||
Total liabilities | 1,670,427 | 1,604,402 | 1,079,297 | 535,465 | 237,494 | ||||||||||||||
Redeemable noncontrolling interest – Series A Preferred Units (2018, 2016, and 2015) and partially owned properties | 24,747 | 12,347 | 26,477 | 26,960 | — | ||||||||||||||
Total shareholders’ equity | 2,379,505 | 2,473,172 | 1,738,451 | 1,021,132 | 534,730 | ||||||||||||||
Total noncontrolling interests | 68,155 | 74,462 | 43,867 | 55,329 | 34,479 | ||||||||||||||
Total liabilities and equity | $ | 4,142,834 | $ | 4,164,383 | $ | 2,888,092 | $ | 1,638,886 | $ | 806,703 | |||||||||
(1) | Includes amounts attributable to redeemable noncontrolling interests for the years ended December 31, 2018, 2017, and 2016. No such adjustment was required for the years ended December 31, 2015 and 2014. |
42
Physicians Realty L.P.
Year Ended December 31, | |||||||||||||||||||
(in thousands, except per unit data) | 2018 | 2017 | 2016 | 2015 | 2014 | ||||||||||||||
Statement of Operations Data | |||||||||||||||||||
Revenues: | |||||||||||||||||||
Rental revenues | $ | 313,006 | $ | 259,673 | $ | 186,301 | $ | 103,974 | $ | 46,397 | |||||||||
Expense recoveries | 97,989 | 75,425 | 45,875 | 21,587 | 5,871 | ||||||||||||||
Interest income on real estate loans and other | 11,556 | 8,486 | 8,858 | 3,880 | 1,066 | ||||||||||||||
Total revenues | 422,551 | 343,584 | 241,034 | 129,441 | 53,334 | ||||||||||||||
Expenses: | |||||||||||||||||||
Interest expense | 66,183 | 47,008 | 23,864 | 10,636 | 6,907 | ||||||||||||||
General and administrative | 28,816 | 22,957 | 18,397 | 14,908 | 11,440 | ||||||||||||||
Operating expenses | 122,620 | 97,035 | 65,999 | 31,026 | 10,154 | ||||||||||||||
Depreciation and amortization | 158,389 | 125,159 | 86,589 | 45,471 | 16,731 | ||||||||||||||
Acquisition expenses | — | 16,744 | 14,778 | 14,893 | 10,897 | ||||||||||||||
Impairment loss | — | 965 | — | — | 1,750 | ||||||||||||||
Total expenses | 376,008 | 309,868 | 209,627 | 116,934 | 57,879 | ||||||||||||||
Income (loss) before equity in income of unconsolidated entities and net gain on sale of investment properties | 46,543 | 33,716 | 31,407 | 12,507 | (4,545 | ) | |||||||||||||
Equity in income of unconsolidated entities | 114 | 183 | 115 | 104 | 95 | ||||||||||||||
Gain on sale of investment properties, net | 11,664 | 5,874 | — | 130 | 32 | ||||||||||||||
Net income (loss) | 58,321 | 39,773 | 31,522 | 12,741 | (4,418 | ) | |||||||||||||
Net (income) loss attributable to noncontrolling interests: | |||||||||||||||||||
Partially owned properties (1) | (515 | ) | (491 | ) | (716 | ) | (377 | ) | (314 | ) | |||||||||
Net income (loss) attributable to controlling interest | 57,806 | 39,282 | 30,806 | 12,364 | (4,732 | ) | |||||||||||||
Preferred distributions | (1,340 | ) | (731 | ) | (1,857 | ) | (1,189 | ) | — | ||||||||||
Net income (loss) attributable to common unitholders | $ | 56,466 | $ | 38,551 | $ | 28,949 | $ | 11,175 | $ | (4,732 | ) | ||||||||
Net income (loss) per unit: | |||||||||||||||||||
Basic | $ | 0.30 | $ | 0.23 | $ | 0.22 | $ | 0.15 | $ | (0.12 | ) | ||||||||
Diluted | $ | 0.30 | $ | 0.23 | $ | 0.22 | $ | 0.15 | $ | (0.12 | ) | ||||||||
Dividends and distributions declared per common unit | $ | 0.920 | $ | 0.915 | $ | 0.900 | $ | 0.900 | $ | 0.900 | |||||||||
Balance Sheet Data (as of end of period): | |||||||||||||||||||
Assets: | |||||||||||||||||||
Net real estate investments | $ | 3,970,033 | $ | 4,045,388 | $ | 2,767,624 | $ | 1,579,483 | $ | 773,650 | |||||||||
Cash and cash equivalents | 19,161 | 2,727 | 15,491 | 3,143 | 15,923 | ||||||||||||||
Tenant receivables, net | 8,881 | 9,966 | 9,790 | 2,977 | 1,324 | ||||||||||||||
Other assets | 144,759 | 106,302 | 95,187 | 53,283 | 15,806 | ||||||||||||||
Total assets | $ | 4,142,834 | $ | 4,164,383 | $ | 2,888,092 | $ | 1,638,886 | $ | 806,703 | |||||||||
Liabilities and Capital: | |||||||||||||||||||
Credit facility | $ | 457,388 | $ | 324,394 | $ | 643,742 | $ | 389,375 | $ | 134,144 | |||||||||
Notes payable | 966,961 | 966,603 | 224,330 | — | — | ||||||||||||||
Mortgage debt | 108,504 | 186,471 | 123,083 | 94,240 | 77,091 | ||||||||||||||
Accounts payable | 3,886 | 11,023 | 4,423 | 644 | 700 | ||||||||||||||
Dividends and distributions payable | 43,821 | 43,804 | 32,179 | 20,783 | 16,548 | ||||||||||||||
Accrued expenses and other liabilities | 76,282 | 56,405 | 42,287 | 24,473 | 6,140 | ||||||||||||||
Acquired lease intangible, net | 13,585 | 15,702 | 9,253 | 5,950 | 2,871 | ||||||||||||||
Total liabilities | 1,670,427 | 1,604,402 | 1,079,297 | 535,465 | 237,494 | ||||||||||||||
Redeemable noncontrolling interest – Series A Preferred Units (2018, 2016, and 2015) and partially owned properties | 24,747 | 12,347 | 26,477 | 26,960 | — | ||||||||||||||
Total partners’ capital | 2,446,982 | 2,547,016 | 1,781,593 | 1,066,583 | 568,457 | ||||||||||||||
Noncontrolling interest - partially owned properties | 678 | 618 | 725 | 9,878 | 752 | ||||||||||||||
Total liabilities and capital | $ | 4,142,834 | $ | 4,164,383 | $ | 2,888,092 | $ | 1,638,886 | $ | 806,703 | |||||||||
(1) | Includes amounts attributable to redeemable noncontrolling interests for the years ended December 31, 2018, 2017, and 2016. No such adjustment was required for the years ended December 31, 2015 and 2014. |
43
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read in conjunction with our financial statements, including the notes to those statements, included in this report, and the Section entitled “Cautionary Statement Regarding Forward-Looking Statements” in this report. As discussed in more detail in the Section entitled “Cautionary Statement Regarding Forward-Looking Statements,” this discussion contains forward-looking statements which involve risks and uncertainties. Our actual results may differ materially from the results discussed in the forward-looking statements. Factors that might cause those differences include those discussed in Part I, Item 1. “Business” and Part I, Item 1A. “Risk Factors” and elsewhere in this report.
Overview
We are a self-managed healthcare real estate company organized in April 2013 to acquire, selectively develop, own, and manage healthcare properties that are leased to physicians, hospitals, and healthcare delivery systems. We invest in real estate that is integral to providing high quality healthcare services. Our properties are typically located on a campus with a hospital or other healthcare facilities or strategically affiliated with a hospital or other healthcare facilities. We believe the impact of government programs and continuing trends in the healthcare industry create attractive opportunities for us to invest in healthcare related real estate. In particular, we believe the demand for healthcare will continue to increase as a result of the aging population as older persons generally utilize healthcare services at a rate well in excess of younger people. Our management team has significant public healthcare REIT experience and has long-established relationships with physicians, hospitals, and healthcare delivery system decision makers that we believe will provide quality investment and growth opportunities. Our principal investments include medical office buildings, outpatient treatment facilities, as well as other real estate integral to healthcare providers. In recent years, we have seen increased competition for healthcare properties and we expect this trend to continue. We seek to generate attractive risk-adjusted returns for our shareholders through a combination of stable and increasing dividends and potential long-term appreciation in the value of our properties and our common shares.
We have grown our portfolio of gross real estate investments from approximately $124 million at the time of our IPO in July 2013 to approximately $4.4 billion as of December 31, 2018. During 2019, we look for a continuation of this strategy and execution with the potential for selective dispositions and investments, and a focus on operating performance. We intend to continue to be diligent in deploying capital in the market.
As of December 31, 2018, our portfolio consisted of 252 healthcare properties located in 30 states with approximately 13,624,598 net leasable square feet, which were approximately 96% leased with a weighted average remaining lease term of approximately 7.9 years. As of December 31, 2018, approximately 90% of the net leasable square footage of our portfolio was either on campus with a hospital or other healthcare facility or strategically affiliated with a hospital or other healthcare facility.
As of December 31, 2018, leases representing a percentage of our portfolio on the basis of leased square feet will expire as follows:
Year | Portfolio Lease Expirations | |
MTM (1) | 0.9% | |
2019 | 2.7% | |
2020 | 3.6% | |
2021 | 4.4% | |
2022 | 4.9% | |
2023 | 4.7% | |
2024 | 5.9% | |
2025 | 7.1% | |
2026 | 27.5% | |
2027 | 9.2% | |
2028 | 10.1% | |
Thereafter | 19.0% | |
Total | 100.0% | |
(1) | Includes 5 leases which expired on December 31, 2018, representing 0.2% of portfolio occupied leasable square feet. |
We receive a cash rental stream from these healthcare providers under our leases. Approximately 93% of the annualized base rent payments from our properties as of December 31, 2018 are from absolute and triple-net leases, pursuant to
44
which the tenants are responsible for all operating expenses relating to the property, including but not limited to real estate taxes, utilities, property insurance, routine maintenance and repairs, and property management. This structure helps insulate us from increases in certain operating expenses and provides more predictable cash flow.
Approximately 6% of the annualized base rent payments from our properties as of December 31, 2018 are from modified gross base stop leases which allow us to pass through certain increases in future operating expenses (e.g., property tax and insurance) to tenants for reimbursement, thus protecting us from increases in such operating expenses. We seek to structure our triple-net leases to generate attractive returns on a long-term basis. Our leases typically have initial terms of 5 to 15 years and include annual rent escalators of approximately 1.5% to 3.0%. Our operating results depend significantly upon the ability of our tenants to make required rental payments. We believe that our portfolio of medical office buildings and other healthcare facilities will enable us to generate stable cash flows over time because of the diversity of our tenants, staggered lease expiration schedule, long-term leases, and low historical occurrence of tenants defaulting under their leases.
We intend to grow our portfolio of high-quality healthcare properties leased to physicians, hospitals, healthcare delivery systems and other healthcare providers primarily through acquisitions of existing healthcare facilities that provide stable revenue growth and predictable long-term cash flows. We may also selectively finance the development of new healthcare facilities through joint venture or fee arrangements with healthcare real estate developers or health system development professionals. Generally, we only expect to make investments in new development properties when approximately 80% or more of the development property has been pre-leased before construction commences. We seek to invest in properties where we can develop strategic alliances with financially sound healthcare providers and healthcare delivery systems that offer need-based healthcare services in sustainable healthcare markets. We focus our investment activity on the following types of healthcare properties:
• | medical office buildings; |
• | outpatient treatment and diagnostic facilities; |
• | physician group practice clinics; |
• | ambulatory surgery centers; and |
• | specialty hospitals and treatment centers. |
We believe that shifting consumer preferences, limited space in hospitals, the desire of patients and healthcare providers to limit non-essential services provided in a hospital setting, and cost considerations, among other trends, continue to drive the industry trend of performing procedures in outpatient facilities that have traditionally been performed in hospitals, such as surgeries and other invasive medical procedures. As these trends continue, we believe that demand for medical office buildings and similar healthcare properties will continue to rise, and that our investment strategy accounts for these trends.
We may invest opportunistically in life science facilities, assisted living, and independent senior living facilities and in the longer term, senior housing properties, including skilled nursing. Consistent with our qualification as a REIT, we may also opportunistically invest in companies that provide healthcare services, and in joint venture entities with operating partners, structured to comply with RIDEA.
The Trust is a Maryland real estate investment trust and elected to be taxed as a REIT for U.S. federal income tax purposes. We conduct our business through an UPREIT structure in which our properties are owned by our Operating Partnership directly or through limited partnerships, limited liability companies, or other subsidiaries. The Trust is the sole general partner of our Operating Partnership and, as of December 31, 2018, owned approximately 97.2% of the OP Units. As of February 22, 2019, we have 182,417,778 common shares outstanding.
2018 Investment Activity
During 2018, we completed acquisitions of 4 operating healthcare properties and 1 land parcel located in 5 states for an aggregate purchase price of approximately $252.8 million. In addition, we funded $18.2 million of other investments, including the issuance of loans and buyouts of noncontrolling interests, resulting in total investments of $271.0 million. We also acquired 2 properties and an adjacent land parcel through the conversion and satisfaction of a previously outstanding construction loan, valued at an aggregate $18.8 million. Additionally, we acquired 2 parcels of land, which we had previously leased, as the result of a lease restructuring arrangement and equity recapitalization. Acquisitions are detailed in Note 3 to our consolidated financial statements included in Item 8 to this report.
During 2018, we sold 34 medical office buildings located in 9 states for approximately $220.4 million and recognized a net gain of approximately $11.7 million.
45
Recent Developments
On December 21, 2018, the Trust’s Board of Trustees authorized and we declared a cash distribution of $0.23 per common share and OP Unit for the quarterly period ended December 31, 2018. The distribution was paid on January 18, 2019 to common shareholders and OP Unit holders of record as of the close of business on January 4, 2019.
2019 Investment Activity
On January 18, 2019, the Company made a construction loan to finance the construction of a 27,000 square foot cancer center in Denton, Texas up to $15.5 million. The loan bears interest at a rate of 5.50% on the outstanding principal balance during construction and 6.25% following substantial completion. The loan is secured by a first deed of trust on the real estate and a completion guaranty, and includes a purchase option that is exercisable upon the first anniversary of substantial completion. The 100% pre-leased development is located across the street from the 208-bed Texas Health Presbyterian Hospital Denton campus, and is expected to include expanded radiation oncology services, CT, PET-CT, and a state of the art infusion center with direct access to a healing garden. As of February 22, 2019, $5.0 million has been funded under the construction loan facility.
On February 13, 2019, the Company funded a $15.0 million term loan that is secured by a first mortgage on real estate being developed in Columbus, Ohio and by a full recourse guaranty. The loan bears interest at a rate of 8.5% during its one-year term.
Assets Slated for Disposition
We consider 6 properties in 3 states, representing an aggregate of approximately 320,270 square feet of gross leasable area, to be slated for disposition as of December 31, 2018. These assets consist of 5 assets leased to entities who have succeeded to the interests of certain former Foundation Healthcare and 1 additional property which we believe no longer meet our core business strategy from a geography or line of business perspective. No assurance can be made, however, that any or all of the properties will be sold, that the Company will receive the anticipated consideration for the sale of any or all of the properties, or as to the timing of any such sale or sales.
46
Results of Operations
Year Ended December 31, 2018 compared to the Year Ended December 31, 2017.
The following table summarizes our results of operations for the years ended December 31, 2018 and 2017 (in thousands):
2018 | 2017 | Change | % | |||||||||||
Revenues: | ||||||||||||||
Rental revenues | $ | 313,006 | $ | 259,673 | $ | 53,333 | 20.5 | |||||||
Expense recoveries | 97,989 | 75,425 | 22,564 | 29.9 | ||||||||||
Interest income on real estate loans and other | 11,556 | 8,486 | 3,070 | 36.2 | ||||||||||
Total revenues | 422,551 | 343,584 | 78,967 | 23.0 | ||||||||||
Expenses: | ||||||||||||||
Interest expense | 66,183 | 47,008 | 19,175 | 40.8 | ||||||||||
General and administrative | 28,816 | 22,957 | 5,859 | 25.5 | ||||||||||
Operating expenses | 122,620 | 97,035 | 25,585 | 26.4 | ||||||||||
Depreciation and amortization | 158,389 | 125,159 | 33,230 | 26.6 | ||||||||||
Acquisition expenses | — | 16,744 | (16,744 | ) | (100.0 | ) | ||||||||
Impairment loss | — | 965 | (965 | ) | (100.0 | ) | ||||||||
Total expenses | 376,008 | 309,868 | 66,140 | 21.3 | ||||||||||
Income before equity in income of unconsolidated entities and gain on sale of investment properties, net: | 46,543 | 33,716 | 12,827 | 38.0 | ||||||||||
Equity in income of unconsolidated entities | 114 | 183 | (69 | ) | (37.7 | ) | ||||||||
Gain on sale of investment properties, net | 11,664 | 5,874 | 5,790 | 98.6 | ||||||||||
Net income | $ | 58,321 | $ | 39,773 | $ | 18,548 | 46.6 | |||||||
Revenues
Total revenues increased $79.0 million, or 23.0%, for the year ended December 31, 2018 as compared to the year ended December 31, 2017. An analysis of selected revenues follows.
Rental revenues. Rental revenues increased $53.3 million, or 20.5%, from $259.7 million for the year ended December 31, 2017 to $313.0 million for the year ended December 31, 2018. The increase in rental revenues primarily resulted from our 2018 and 2017 acquisitions which resulted in additional rental revenue of $11.7 million and $47.7 million, respectively. Revenues for the year ended December 31, 2018 also increased at the medical office building located in Kennewick, Washington (the “Kennewick MOB”) by $2.3 million and at certain of our buildings formerly occupied by Foundation Healthcare by $2.1 million. This was offset by a decrease in rental revenue of $10.3 million associated with our properties sold during 2018 and 2017.
Expense recoveries. Expense recoveries increased $22.6 million, or 29.9%, for the year ended December 31, 2018 as compared to the year ended December 31, 2017. The increase in expense recoveries primarily resulted from our 2018 and 2017 acquisitions which resulted in additional expense recoveries of $3.0 million and $19.4 million, respectively, and increases on our existing properties of $1.8 million. This was partially offset by a decrease of $1.7 million associated with our properties sold during 2018 and 2017.
Interest income on real estate loans and other. Interest income on real estate loans and other increased $3.1 million for the year ended December 31, 2018 as compared to the year ended December 31, 2017. The increase is attributable to a lease termination settlement of $2.2 million in 2018, and interest income from note receivables of $0.9 million in 2018 when compared to 2017.
Expenses
Total expenses increased by $66.1 million, or 21.3%, for the year ended December 31, 2018 as compared to the year ended December 31, 2017. An analysis of selected expenses follows.
47
Interest expense. Interest expense for the year ended December 31, 2018 was $66.2 million compared to $47.0 million for the year ended December 31, 2017, representing an increase of $19.2 million, or 40.8%. The increase is primarily attributable to the issuance of our public senior notes in March 2017 and December 2017 for an increase of $3.3 million and $12.9 million, respectively. Additionally, higher LIBOR rates increased interest expense on our credit facility by $3.2 million.
General and administrative. General and administrative expenses increased $5.9 million or 25.5%, from $23.0 million during the year ended December 31, 2017 to $28.8 million during the year ended December 31, 2018. The increase is primarily attributable to the adoption of ASU 2017-01, which resulted in the addition of approximately $3.9 million of internal acquisition pursuit costs that would have previously been classified as acquisition expenses. The increase is also attributable to an increase in stock compensation of $1.9 million, office expenditures of $0.4 million, bonus expense of $0.3 million, and other payroll and benefit increases of $0.4 million. These increases were partially offset by a decrease in professional fees of $1.1 million. Of the $5.9 million increase in general and administrative expenses, non-cash share compensation accounted for $3.6 million.
Operating expenses. Operating expenses increased $25.6 million or 26.4%, from $97.0 million during the year ended December 31, 2017 to $122.6 million during the year ended December 31, 2018. The increase is primarily due to our 2018 and 2017 property acquisitions which resulted in additional operating expenses of $3.4 million and $22.4 million, respectively. In addition, there was an increase of $1.9 million from additional operating expenses associated with the remainder of the portfolio, excluding Foundation Healthcare which had additional operating expenses of $1.0 million. This was offset by $3.2 million associated with our properties sold during 2018 and 2017.
Depreciation and amortization. Depreciation and amortization increased $33.2 million, or 26.6%, from $125.2 million during the year ended December 31, 2017 to $158.4 million during the year ended December 31, 2018. Our 2018 and 2017 property acquisitions resulted in additional depreciation and amortization of $5.9 million and $27.5 million, respectively. The termination of a lease located at the Kennewick MOB increased in-place lease intangible amortization by $6.6 million, and was partially offset by a reduction in depreciation and amortization of $6.5 million associated with our properties sold during 2018 and 2017.
Acquisition expenses. During the first quarter of 2018, the Company adopted ASU 2017-01 which clarifies the framework for determining whether an integrated set of assets and activities meets the definition of a business. The Company determined that none of our 2018 acquisitions met the revised definition of a business. As such, acquisition pursuit costs are capitalized in accordance with the new guidance and there is no acquisition expense for the year ended December 31, 2018. The Company recorded acquisition expenses totaling $16.7 million during the year ended December 31, 2017.
Impairment loss. The Company did not record an impairment loss for the year ended December 31, 2018. The Company recorded a $1.0 million impairment loss on one medical office building for the year ended December 31, 2017.
Equity in income of unconsolidated entity. The change in equity in income of unconsolidated entity for the year ended December 31, 2017 compared to the year ended December 31, 2018 is not significant.
Gain on sale of properties, net. During the year ended December 31, 2018 we sold 34 properties located in 9 states for approximately $220.4 million, realizing a net gain of $11.7 million. During the year ended December 31, 2017 we sold 5 properties in 2 states for approximately $20.7 million, realizing a net gain of $5.9 million.
48
Year Ended December 31, 2017 compared to the Year Ended December 31, 2016.
The following table summarizes our results of operations for the years ended December 31, 2017 and 2016 (in thousands):
2017 | 2016 | Change | % | |||||||||||
Revenues: | ||||||||||||||
Rental revenues | $ | 259,673 | $ | 186,301 | $ | 73,372 | 39.4 | |||||||
Expense recoveries | 75,425 | 45,875 | 29,550 | 64.4 | ||||||||||
Interest income on real estate loans and other | 8,486 | 8,858 | (372 | ) | (4.2 | ) | ||||||||
Total revenues | 343,584 | 241,034 | 102,550 | 42.5 | ||||||||||
Expenses: | ||||||||||||||
Interest expense | 47,008 | 23,864 | 23,144 | 97.0 | ||||||||||
General and administrative | 22,957 | 18,397 | 4,560 | 24.8 | ||||||||||
Operating expenses | 97,035 | 65,999 | 31,036 | 47.0 | ||||||||||
Depreciation and amortization | 125,159 | 86,589 | 38,570 | 44.5 | ||||||||||
Acquisition expenses | 16,744 | 14,778 | 1,966 | 13.3 | ||||||||||
Impairment loss | 965 | — | 965 | NM | ||||||||||
Total expenses | 309,868 | 209,627 | 100,241 | 47.8 | ||||||||||
Income before equity in income of unconsolidated entities and gain on sale of investment properties: | 33,716 | 31,407 | 2,309 | 7.4 | ||||||||||
Equity in income of unconsolidated entities | 183 | 115 | 68 | 59.1 | ||||||||||
Gain on sale of investment properties | 5,874 | — | 5,874 | NM | ||||||||||
Net income | $ | 39,773 | $ | 31,522 | $ | 8,251 | 26.2 | |||||||
NM = Not Meaningful
Revenues
Total revenues increased $102.6 million, or 42.5%, for the year ended December 31, 2017 as compared to the year ended December 31, 2016. An analysis of selected revenues follows.
Rental revenues. Rental revenues increased $73.4 million, or 39.4%, from $186.3 million for the year ended December 31, 2016 to $259.7 million for the year ended December 31, 2017. The increase in rental revenues primarily resulted from our 2017 and 2016 acquisitions which resulted in additional rental revenue of $35.4 million and $48.9 million, respectively. Revenues for the year ended December 31, 2017 were partially offset by declines in rental income recognized at the Kennewick MOB of $7.4 million and at certain of our buildings formerly occupied by Foundation Healthcare of $2.7 million.
Expense recoveries. Expense recoveries increased $29.6 million, or 64.4%, for the year ended December 31, 2017 as compared to the year ended December 31, 2016. The increase in expense recoveries primarily resulted from our 2017 and 2016 acquisitions which resulted in additional expense recoveries of $12.1 million and $16.7 million, respectively.
Interest income on real estate loans and other. Interest income on real estate loans and other decreased $0.4 million for the year ended December 31, 2017 as compared to the year ended December 31, 2016. Loan transactions completed during the prior year resulted in $2.0 million of increased interest revenue, while other income decreased $1.6 million relative to the prior year due to the payoff of a real estate loan, and interest income from note receivables decreased $0.8 million which relates to a note that was paid off during January 2017.
Expenses
Total expenses increased by $100.2 million, or 47.8%, for the year ended December 31, 2017 as compared to the year ended December 31, 2016. An analysis of selected expenses follows.
Interest expense. Interest expense for the year ended December 31, 2017 was $47.0 million compared to $23.9 million for the year ended December 31, 2016, representing an increase of $23.1 million, or 97.0%. An increase of $15.5 million
49
resulted from the issuance of our March 2017 and December 2017 public debt offerings, an increase of $3.8 million resulted from borrowings under the term loan provision of our unsecured credit facility, an increase of $2.2 million was the result of an increase in interest due to new mortgage debt, and an increase of $2.0 million resulted from the issuance of our 2016 senior notes.
General and administrative. General and administrative expenses increased $4.6 million or 24.8%, from $18.4 million during the year ended December 31, 2016 to $23.0 million during the year ended December 31, 2017. The increase is attributable to increased salaries and benefits, including non-cash share compensation of $1.1 million, increased office expenditures of $1.1 million, increased professional fees of $1.1 million, and increased travel expenditures of $0.5 million.
Operating expenses. Operating expenses increased $31.0 million or 47.0%, from $66.0 million during the year ended December 31, 2016 to $97.0 million during the year ended December 31, 2017. The increase is primarily due to our 2017 and 2016 property acquisitions which resulted in additional operating expenses of $13.5 million and $21.4 million, respectively, partially offset by a reduction in operating expenses associated with the previously existing portfolio.
Depreciation and amortization. Depreciation and amortization increased $38.6 million, or 44.5%, from $86.6 million during the year ended December 31, 2016 to $125.2 million during the year ended December 31, 2017. The increase is due to our 2017 and 2016 property acquisitions which resulted in additional depreciation and amortization of $18.8 million and $22.0 million, respectively, partially offset by a reduction in depreciation and amortization associated with the previously existing portfolio.
Acquisition expenses. Acquisition expenses increased $2.0 million, or 13.3%, from $14.8 million during the year ended December 31, 2016 to $16.7 million during the year ended December 31, 2017. During the twelve month periods ending December 31, 2017 and 2016, we acquired $1.2 billion and $735.8 million, respectively, of real estate that were considered business combinations and as such, the related acquisition costs were expensed.
Impairment loss. The Company recorded a $1.0 million impairment loss on one medical office building for the year ended December 31, 2017. No such impairment loss was recorded for the year ended December 31, 2016.
Equity in income of unconsolidated entity. The change in equity income from unconsolidated entity for the year ended December 31, 2016 compared to the year ended December 31, 2017 is not significant.
Gain on sale of properties. On April 7, 2017, the Company sold four properties with 80,292 net leasable square feet located in Georgia for approximately $18.2 million, recording a gain of $5.2 million. On December 18, 2017, the Company sold one property with 20,939 net leasable square feet located in Nebraska for approximately $2.5 million, recording a gain of $0.7 million. We did not dispose of any properties during the year ended December 31, 2016.
Cash Flows
Year Ended December 31, 2018 compared to the Year Ended December 31, 2017 (in thousands).
2018 | 2017 | ||||||
Cash provided by operating activities | $ | 208,694 | $ | 180,471 | |||
Cash used in investing activities | (77,183 | ) | (1,302,638 | ) | |||
Cash (used in) provided by financing activities | (115,077 | ) | 1,109,403 | ||||
Increase (decrease) in cash and cash equivalents | $ | 16,434 | $ | (12,764 | ) | ||
Cash flows from operating activities. Cash flows provided by operating activities was $208.7 million during the year ended December 31, 2018 compared to $180.5 million during the year ended December 31, 2017, representing an increase of $28.2 million. This change is primarily attributable to the increased operating cash flows resulting from our 2018 and 2017 acquisitions.
Cash flows from investing activities. Cash flows used in investing activities was $77.2 million during the year ended December 31, 2018 compared to cash flows used in investing activities of $1.3 billion during the year ended December 31, 2017, representing a change of $1.2 billion. The decrease in cash flows used in investing activities was primarily attributable to our $1.0 billion decrease in acquisition activity over the prior year, and an additional $0.2 billion in proceeds provided by the properties sold in 2018.
50
Cash flows from financing activities. Cash flows used in financing activities was $115.1 million during the year ended December 31, 2018 compared to cash flows provided by financing activities of $1.1 billion during the year ended December 31, 2017, representing a change of $1.2 billion. The 2018 activity was primarily attributable to sales of our common shares, resulting in net proceeds of $10.8 million and $422.0 million of proceeds from the credit facility. These were partially offset by the $287.0 million of payoffs on our credit facility and $168.1 million of dividends paid.
Year Ended December 31, 2017 compared to Year Ended December 31, 2016 (in thousands).
2017 | 2016 | ||||||
Net cash provided by operating activities | $ | 180,471 | $ | 127,197 | |||
Net cash used in investing activities | (1,302,638 | ) | (1,262,816 | ) | |||
Net cash provided by financing activities | 1,109,403 | 1,147,967 | |||||
(Decrease) increase in cash and cash equivalents | $ | (12,764 | ) | $ | 12,348 | ||
Cash flows from operating activities. Cash flows provided by operating activities was $180.5 million during the year ended December 31, 2017 compared to $127.2 million during the year ended December 31, 2016, representing an increase of $53.3 million. This change is primarily attributable to the increased operating cash flows resulting from our 2017 and 2016 acquisitions.
Cash flows from investing activities. Cash flows used in investing activities was $1.30 billion during the year ended December 31, 2017 compared to cash flows used in investing activities of $1.26 billion during the year ended December 31, 2016, representing a change of $39.8 million. The increase in cash flows used in investing activities was primarily attributable to our $31.8 million increase in acquisition activity over the prior year and cash used to fund real estate loans and notes totaling $28.9 million. These were partially offset by $20.4 million in proceeds on sale of investment property.
Cash flows from financing activities. Cash flows provided by financing activities was $1.11 billion during the year ended December 31, 2017 compared to cash flows provided by financing activities of $1.15 billion during the year ended December 31, 2016, representing a decrease of $38.6 million. The 2017 activity was primarily attributable to sales of our common shares, resulting in net proceeds of $844.7 million, $927.0 million of proceeds from the credit facility, and $743.1 million from our issuance of senior notes. These were partially offset by the $1.2 billion of payoffs on our credit facility and $143.1 million of dividends paid.
Non-GAAP Financial Measures
This report includes Funds From Operations (FFO), Normalized FFO, Normalized Funds Available For Distribution (FAD), Net Operating Income (NOI), Cash NOI, Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate (EBITDAre) and Adjusted EBITDAre, which are non-GAAP financial measures. For purposes of Item 10(e) of Regulation S-K promulgated under the Securities Act, a non-GAAP financial measure is a numerical measure of a company’s historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable financial measure calculated and presented in accordance with GAAP in the statement of operations, balance sheet or statement of cash flows (or equivalent statements) of the company, or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable financial measure so calculated and presented. As used in this report, GAAP refers to generally accepted accounting principles in the United States of America. Pursuant to the requirements of Item 10(e) of Regulation S-K promulgated under the Securities Act, we have provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.
51
FFO and Normalized FFO
We believe that information regarding FFO is helpful to shareholders and potential investors because it facilitates an understanding of the operating performance of our properties without giving effect to real estate depreciation and amortization, which assumes that the value of real estate assets diminishes ratably over time. We calculate FFO in accordance with standards established by the National Association of Real Estate Investment Trusts (“NAREIT”). NAREIT defines FFO as net income or loss (computed in accordance with GAAP) before noncontrolling interests of holders of OP units, excluding preferred distributions, gains (or losses) on sales of depreciable operating property, impairment write-downs on depreciable assets, plus real estate related depreciation and amortization (excluding amortization of deferred financing costs). Our FFO computation may not be comparable to FFO reported by other REITs that do not compute FFO in accordance with NAREIT definition or that interpret the NAREIT definition differently than we do. The GAAP measure that we believe to be most directly comparable to FFO, net income, includes depreciation and amortization expenses, gains or losses on property sales, impairments, and noncontrolling interests. In computing FFO, we eliminate these items because, in our view, they are not indicative of the results from the operations of our properties. To facilitate a clear understanding of our historical operating results, FFO should be examined in conjunction with net income (determined in accordance with GAAP) as presented in our financial statements. FFO does not represent cash generated from operating activities in accordance with GAAP, should not be considered to be an alternative to net income or loss (determined in accordance with GAAP) as a measure of our liquidity and is not indicative of funds available for our cash needs, including our ability to make cash distributions to shareholders.
We use Normalized FFO, which excludes from FFO net change in fair value of derivative financial instruments, acquisition expenses, acceleration of deferred financing costs, change in fair value of contingent consideration, and other normalizing items. However, our use of the term Normalized FFO may not be comparable to that of other real estate companies as they may have different methodologies for computing this amount. Normalized FFO should not be considered as an alternative to net income or loss (computed in accordance with GAAP), as an indicator of our financial performance or of cash flow from operating activities (computed in accordance with GAAP), or as an indicator of our liquidity, nor is it indicative of funds available to fund our cash needs, including our ability to make distributions. Normalized FFO should be reviewed in connection with other GAAP measurements.
The following is a reconciliation from net income, the most direct financial measure calculated and presented in accordance with GAAP, to FFO and Normalized FFO (in thousands, except per share data):
Year Ended December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Net income | $ | 58,321 | $ | 39,773 | $ | 31,522 | |||||
Earnings per share - diluted | $ | 0.30 | $ | 0.23 | $ | 0.22 | |||||
Net income | $ | 58,321 | $ | 39,773 | $ | 31,522 | |||||
Net income attributable to noncontrolling interests - partially owned properties | (515 | ) | (491 | ) | (716 | ) | |||||
Preferred distributions | (1,340 | ) | (731 | ) | (1,857 | ) | |||||
Depreciation and amortization expense | 158,163 | 125,022 | 86,501 | ||||||||
Depreciation and amortization expense - partially owned properties | (336 | ) | (531 | ) | (683 | ) | |||||
Gain on sale of investment properties, net | (11,664 | ) | (5,874 | ) | — | ||||||
Impairment loss | — | 965 | — | ||||||||
FFO applicable to common shares and OP Units | $ | 202,629 | $ | 158,133 | $ | 114,767 | |||||
FFO per common share and OP Unit | $ | 1.08 | $ | 0.94 | $ | 0.88 | |||||
Net change in fair value of derivative | (6 | ) | 150 | (240 | ) | ||||||
Acquisition expenses | — | 16,744 | 14,778 | ||||||||
Net change in fair value of contingent consideration | (50 | ) | (472 | ) | (840 | ) | |||||
Normalized FFO applicable to common shares and OP Units | $ | 202,573 | $ | 174,555 | $ | 128,465 | |||||
Normalized FFO per common share and OP Unit | $ | 1.08 | $ | 1.04 | $ | 0.98 | |||||
Weighted average number of common shares and OP Units outstanding | 187,526,762 | 168,231,299 | 130,446,893 | ||||||||
52
Normalized FAD
We define Normalized FAD, a non-GAAP measure, which excludes from Normalized FFO non-cash share compensation expense, straight-line rent adjustments, amortization of acquired above- or below-market leases and assumed debt, amortization of lease inducements, amortization of deferred financing costs, and recurring capital expenditures related to tenant improvements and leasing commissions, and includes cash payments from seller master leases and rent abatement payments. Other REITs or real estate companies may use different methodologies for calculating Normalized FAD, and accordingly, our computation may not be comparable to those reported by other REITs. Although our computation of Normalized FAD may not be comparable to that of other REITs, we believe Normalized FAD provides a meaningful supplemental measure of our performance due to its frequency of use by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. Normalized FAD should not be considered as an alternative to net income or loss attributable to controlling interest (computed in accordance with GAAP) or as an indicator of our financial performance. Normalized FAD should be reviewed in connection with other GAAP measurements.
The following is a reconciliation from net income, the most direct financial measure calculated and presented in accordance with GAAP, to Normalized FAD (in thousands):
Year Ended December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Net income | $ | 58,321 | $ | 39,773 | $ | 31,522 | |||||
Normalized FFO applicable to common shares and OP Units | $ | 202,573 | $ | 174,555 | $ | 128,465 | |||||
Normalized FFO applicable to common shares and OP Units | $ | 202,573 | $ | 174,555 | $ | 128,465 | |||||
Non-cash share compensation expense | 8,681 | 5,073 | 3,920 | ||||||||
Straight-line rent adjustments | (21,860 | ) | (16,202 | ) | (16,226 | ) | |||||
Amortization of acquired above/below-market leases/assumed debt | 3,287 | 3,596 | 2,778 | ||||||||
Amortization of lease inducements | 1,310 | 1,309 | 892 | ||||||||
Amortization of deferred financing costs | 2,428 | 2,299 | 2,325 | ||||||||
TI/LC and recurring capital expenditures | (19,779 | ) | (15,319 | ) | (8,087 | ) | |||||
Seller master lease and rent abatement payments | 229 | 973 | 1,032 | ||||||||
Normalized FAD applicable to common shares and OP Units | $ | 176,869 | $ | 156,284 | $ | 115,099 | |||||
NOI and Cash NOI
NOI is a non-GAAP financial measure that is defined as net income or loss, computed in accordance with GAAP, generated from our total portfolio of properties before general and administrative expenses, acquisition-related expenses, depreciation and amortization expense, interest expense, net change in the fair value of derivative financial instruments, gain or loss on the sale of investment properties, and impairment losses. We believe that NOI provides an accurate measure of operating performance of our operating assets because NOI excludes certain items that are not associated with management of the properties. Our use of the term NOI may not be comparable to that of other real estate companies as they may have different methodologies for computing this amount.
Cash NOI is a non-GAAP financial measure which excludes from NOI straight-line rent adjustments, amortization of acquired above and below market leases, and other non-cash and normalizing items. Other non-cash and normalizing items include items such as the amortization of lease inducements, payments received from seller master leases and rent abatements, and changes in fair value of contingent consideration. We believe that Cash NOI provides an accurate measure of the operating performance of our operating assets because it excludes certain items that are not associated with management of the properties. Additionally, we believe that Cash NOI is a widely accepted measure of comparative operating performance in the real estate community. Our use of the term Cash NOI may not be comparable to that of other real estate companies as such other companies may have different methodologies for computing this amount.
53
The following is a reconciliation from the Trust’s net income, the most direct financial measure calculated and presented in accordance with GAAP, to NOI, and Cash NOI (in thousands):
Year Ended December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Net income | $ | 58,321 | $ | 39,773 | $ | 31,522 | |||||
General and administrative | 28,816 | 22,957 | 18,397 | ||||||||
Acquisition expenses | — | 16,744 | 14,778 | ||||||||
Depreciation and amortization | 158,389 | 125,159 | 86,589 | ||||||||
Interest expense | 66,183 | 47,008 | 23,864 | ||||||||
Net change in the fair value of derivative | (6 | ) | 150 | (240 | ) | ||||||
Gain on sale of investment properties, net | (11,664 | ) | (5,874 | ) | — | ||||||
Impairment loss | — | 965 | — | ||||||||
NOI | $ | 300,039 | $ | 246,882 | $ | 174,910 | |||||
NOI | $ | 300,039 | $ | 246,882 | $ | 174,910 | |||||
Straight-line rent adjustments | (21,860 | ) | (16,202 | ) | (16,226 | ) | |||||
Amortization of acquired above/below-market leases/assumed debt | 3,287 | 3,596 | 2,778 | ||||||||
Amortization of lease inducements | 1,310 | 1,309 | 892 | ||||||||
Seller master lease and rent abatement payments | 229 | 973 | 1,032 | ||||||||
Change in fair value of contingent consideration | (50 | ) | (472 | ) | (840 | ) | |||||
Cash NOI | $ | 282,955 | $ | 236,086 | $ | 162,546 | |||||
EBITDAre and Adjusted EBITDAre
We define EBITDAre as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, loss (gain) on dispositions, and impairment loss on depreciated property. We define Adjusted EBITDAre as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, loss (gain) on dispositions, impairment loss on depreciated property, acquisition expenses, non-cash share compensation expense, non-cash changes in fair value, and other normalizing items. We consider EBITDAre and Adjusted EBITDAre important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.
The following is a reconciliation from the Trust’s net income, the most direct financial measure calculated and presented in accordance with GAAP, to EBITDAre and Adjusted EBITDAre (in thousands):
Year Ended December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Net income | $ | 58,321 | $ | 39,773 | $ | 31,522 | |||||
Depreciation and amortization | 158,389 | 125,159 | 86,589 | ||||||||
Interest expense | 66,183 | 47,008 | 23,864 | ||||||||
Gain on sale of investment properties, net | (11,664 | ) | (5,874 | ) | — | ||||||
Impairment loss on depreciated property | — | 965 | — | ||||||||
EBITDAre | $ | 271,229 | $ | 207,031 | $ | 141,975 | |||||
Acquisition expenses | — | 16,744 | 14,778 | ||||||||
Non-cash share compensation expense | 8,681 | 5,073 | 3,920 | ||||||||
Non-cash changes in fair value | (56 | ) | (322 | ) | (1,080 | ) | |||||
Adjusted EBITDAre | $ | 279,854 | $ | 228,526 | $ | 159,593 | |||||
54
Liquidity and Capital Resources
Our short-term liquidity requirements consist primarily of operating and interest expenses and other expenditures directly associated with our properties, including:
• | property expenses; |
• | interest expense and scheduled principal payments on outstanding indebtedness; |
• | general and administrative expenses; and |
• | capital expenditures for tenant improvements and leasing commissions. |
In addition, we will require funds for future distributions expected to be paid to our common shareholders and OP Unit holders in our Operating Partnership.
As of December 31, 2018, we had a total of $19.2 million of cash and cash equivalents and $618.0 million of near-term availability on our unsecured revolving credit facility. Our primary sources of cash include rent we collect from our tenants, borrowings under our unsecured credit facility, and financings of debt and equity securities. We believe that our existing cash and cash equivalents, cash flow from operating activities, and borrowings available under our unsecured revolving credit facility will be adequate to fund any existing contractual obligations to purchase properties and other obligations through the next year. However, because of the 90% distribution requirement under the REIT tax rules under the Code, we may not be able to fund all of our future capital needs from cash retained from operations, including capital needed to make investments and to satisfy or refinance maturing obligations. As a result, we expect to rely upon external sources of capital, including debt and equity financing, to fund future capital needs. If we are unable to obtain needed capital on satisfactory terms or at all, we may not be able to make the investments needed to expand our business or to meet our obligations and commitments as they mature. We will rely upon external sources of capital to fund future capital needs, and, if we encounter difficulty in obtaining such capital, we may not be able to make future acquisitions necessary to grow our business or meet maturing obligations.
Our long-term liquidity needs consist primarily of funds necessary to pay for acquisitions, recurring and non-recurring capital expenditures, and scheduled debt maturities. We expect to satisfy our long-term liquidity needs through cash flow from operations, unsecured borrowings, issuances of equity and debt securities, and, in connection with acquisitions of additional properties, the issuance of OP Units of our Operating Partnership, and proceeds from select property dispositions and joint venture transactions.
Our ability to access capital in a timely and cost-effective manner is essential to the success of our business strategy as it affects our ability to satisfy existing obligations, including repayment of maturing indebtedness, and to make future investments and acquisitions. Factors such as general market conditions, interest rates, credit ratings on our debt and equity securities, expectations of our potential future earnings and cash distributions, and the market price of our common shares, each of which are beyond our control and vary or fluctuate over time, all impact our access to and cost of capital. In particular, to the extent interest rates continue to rise, we may experience a decline in the trading price of our common shares, which may impact our decision to conduct equity offerings for capital raising purposes. We will likely also experience higher borrowing costs as interest rates rise, which may also impact our decisions to incur additional indebtedness, or to engage in transactions for which we may need to fund through borrowing. We expect to continue to utilize equity and debt financings to support our future growth and investment activity.
We also continuously evaluate opportunities to finance future investments. New investments are generally funded from temporary borrowings under our primary unsecured credit facility and the proceeds from financing transactions such as those discussed above. Our investments generate cash from net operating income and principal payments on loans receivable. Permanent financing for future investments, which generally replaces funds drawn under our primary unsecured credit facility, has historically been provided through a combination of the issuance of debt and equity securities and the incurrence or assumption of secured debt.
We intend to invest in additional properties as suitable opportunities arise and adequate sources of financing are available. We are currently evaluating additional potential investments consistent with the normal course of our business. There can be no assurance as to whether or when any portion of these investments will be completed. Our ability to complete investments is subject to a number of risks and variables, including our ability to negotiate mutually agreeable terms with sellers and our ability to finance the investment. We may not be successful in identifying and consummating suitable acquisitions or investment opportunities, which may impede our growth and negatively affect our results of operations and may result in the use of a significant amount of management’s resources. We expect that future investments in properties will
55
depend on and will be financed by, in whole or in part, our existing cash, borrowings, including under our unsecured revolving credit facility, or the proceeds from additional issuances of equity or debt securities.
While we intend to sell the six assets slated for disposition as of December 31, 2018 for other business reasons, we currently do not expect to sell any of our properties to meet our liquidity needs, although we may do so in the future.
We currently are in compliance with all debt covenants on our outstanding indebtedness.
Credit Facility
On August 7, 2018, the Operating Partnership, as borrower, and the Trust, as guarantor, executed a Second Amended and Restated Credit Agreement (the “Credit Agreement”) which extended the maturity date of the revolving credit facility under the Credit Agreement to September 18, 2022 and reduced the interest rate margin applicable to borrowings. The Credit Agreement includes an unsecured revolving credit facility of $850 million and contains a 7-year term loan feature of $250 million, bringing total borrowing capacity to $1.1 billion. The Credit Agreement also includes a swingline loan commitment for up to 10% of the maximum principal amount and provides an accordion feature allowing the Trust to increase borrowing capacity by up to an additional $500 million, subject to customary terms and conditions, resulting in a maximum borrowing capacity of $1.6 billion. The revolving credit facility under the Credit Agreement also includes a one-year extension option.
As of December 31, 2018, the Company had $215.0 million of borrowings outstanding under its unsecured revolving credit facility, and $250.0 million of borrowings outstanding under the term loan feature of the Credit Agreement. The Company has also issued a letter of credit for $17.0 million with no outstanding balance as of December 31, 2018. As defined by the Credit Agreement, $618.0 million is available to borrow without adding additional properties to the unencumbered borrowing base of assets. See Note 6 (Debt) to our accompanying consolidated financial statements for a further discussion of our credit facility.
Senior Notes
As of December 31, 2018, we had $975.0 million aggregate principal amount of senior notes issued and outstanding by the Operating Partnership, comprised of $15.0 million maturing in 2023, $25.0 million maturing in 2025, $70.0 million maturing in 2026, $425.0 million maturing in 2027, $395.0 million maturing in 2028, and $45.0 million maturing in 2031. See Note 6 (Debt) to our accompanying consolidated financial statements for a further discussion of our senior notes.
ATM Program
In August 2016, the Company entered into separate Sales Agreements to which the Trust may issue and sell, from time to time, its common shares having an aggregate offering price of up to $300.0 million. In accordance with the Sales Agreements, the Trust may offer and sell its common shares through any of the Agents, from time to time, by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended, which includes sales made directly on the New York Stock Exchange or other existing trading market, or sales made to or through a market maker. During the fiscal year-ended December 31, 2018, we issued and sold pursuant to the ATM Program 570,551 common shares at a weighted average price of $17.50 per share, resulting in net proceeds to us of approximately $9.9 million. As of February 22, 2019, we have $163.7 million remaining available under the ATM Program.
Dividend Reinvestment and Share Purchase Plan
On December 2, 2014, we adopted a Dividend Reinvestment and Share Purchase Plan (the “DRIP”). Under the DRIP:
• | existing shareholders may purchase additional common shares by reinvesting all or a portion of the dividends paid on their common shares and by making optional cash payments of not less than $50 and up to a maximum of $10,000 per month; |
• | new investors may join the DRIP by making an initial investment of not less than $1,000 and up to a maximum of $10,000; and |
• | once enrolled in the DRIP, participants may authorize electronic deductions from their bank account for optional cash payments to purchase additional shares. |
The DRIP is administered by our transfer agent, Computershare Trust Company, N.A. Our common shares sold under the DRIP will be newly issued or purchased in the open market, as further described in the DRIP. As of February 22, 2019, we have issued 79,765 common shares under the DRIP since its inception.
56
Critical Accounting Policies
Our consolidated financial statements are prepared in conformity with GAAP, which require us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates. Set forth below is a summary of our accounting policies that we believe are critical to the preparation of our consolidated financial statements.
Lease Accounting
We, as lessor, make a determination with respect to each of our leases whether they should be accounted for as operating leases or direct financing leases. The classification criteria is based on estimates regarding the fair value of the leased facilities, minimum lease payments, effective cost of funds, the economic life of the facilities, the existence of a bargain purchase option, and certain other terms in the lease agreements. We believe all of our leases should be accounted for as operating leases. Payments received under operating leases are accounted for in the consolidated statements of income as rental revenue for actual rent collected plus or minus a straight-line adjustment for estimated minimum lease escalators, adjustments relating to amortization of lease inducements and above/below-market leases, and rent abatements. Assets subject to operating leases are reported as real estate investments in the consolidated balance sheets.
Substantially all of our leases contain fixed or formula-based rent escalators. To the extent that escalator increases are tied to a fixed index or rate, lease payments are accounted for on a straight-line basis over the life of the lease.
Purchase of Investment Properties
With the adoption of ASU 2017-01 in January 2018, the majority of our future acquisitions will be accounted for as asset acquisitions, recording the purchase price for tangible and intangible assets and liabilities based on their relative fair values. Tangible assets primarily consist of land and buildings and improvements. Additionally, the purchase price includes acquisition related expenses, above- or below-market leases, in place leases, and above- or below-market debt assumed. Any future contingent consideration will be recorded when the contingency is resolved. The determination of the fair value requires us to make certain estimates and assumptions.
The determination of fair value involves the use of significant judgment and estimation. The Company makes estimates of the fair value of the tangible and intangible acquired assets and assumed liabilities using information obtained from multiple sources as a result of pre-acquisition due diligence and generally includes the assistance of a third party appraiser. The Company estimates the fair value of an acquired asset on an “as-if-vacant” basis and its value is depreciated in equal amounts over the course of its estimated remaining useful life. The Company determines the allocated value of other fixed assets, such as site improvements, based upon the replacement cost and depreciates such value over the assets’ estimated remaining useful lives as determined at the applicable acquisition date. The fair value of land is determined either by considering the sales prices of similar properties in recent transactions or based on an internal analysis of recently acquired and existing comparable properties within the Company’s portfolio.
The value of above- or below-market leases is estimated based on the present value (using a discount rate which reflected the risks associated with the leases acquired) of the difference between contractual amounts to be received pursuant to the leases and management’s estimate of market lease rates measured over a period equal to the estimated remaining term of the lease. The capitalized above-market or below-market lease intangibles are amortized as a reduction or addition to rental income over the estimated remaining term of the respective leases plus the term of any renewal options that the lessee would be economically compelled to exercise.
In determining the value of in-place leases, management considers current market conditions and costs to execute similar leases in arriving at an estimate of the carrying costs during the expected lease-up period from vacant to existing occupancy. In estimating carrying costs, management includes real estate taxes, insurance, other operating expenses, estimates of lost rental revenue during the expected lease-up periods, and costs to execute similar leases, including leasing commissions, tenant improvements, legal, and other related costs based on current market demand. The values assigned to in-place leases are amortized to amortization expense over the estimated remaining term of the lease. If a lease terminates prior to its scheduled expiration, all unamortized costs related to that lease are written off, net of any required lease termination payments.
The Company calculates the fair value of any long-term debt assumed by discounting the remaining contractual cash flows on each instrument at the current market rate for those borrowings, which the Company approximates based on the rate it
57
would expect to incur on a replacement instrument on the date of acquisition, and recognizes any fair value adjustments related to long-term debt as effective yield adjustments over the remaining term of the instrument.
Based on these estimates, the Company recognizes the acquired assets and assumed liabilities at their estimated relative fair values, which are generally determined using Level 3 inputs, such as market rental rates, capitalization rates, discount rates, or other available market data.
Real Estate Investment Properties and Identified Intangible Assets
We are required to make subjective assessments of the useful lives of our properties for purposes of determining the amount of depreciation to record on an annual basis with respect to our investments in real estate. These assessments have a direct impact on our net income because if we were to shorten the expected useful lives of our investments in real estate we would depreciate such investments over fewer years, resulting in more depreciation expense and lower net income on an annual basis. Real estate investment properties and identified intangible assets are carried at cost, net of accumulated depreciation and amortization. Medical office buildings are depreciated over their estimated useful lives, ranging up to 50 years, using the straight-line method. Tenant improvements and in-place leases are amortized over the lease life of the in-place leases or the tenant’s respective lease term. Cost of maintenance and repairs are charged to expense when incurred.
We periodically assess the carrying value of real estate investments and related intangible assets in accordance with ASC Topic 360, Property, Plant & Equipment (“ASC 360”), to determine if facts and circumstances exist that would suggest that the recorded amount of an asset might be impaired or that the estimated useful life should be modified. In the event impairment in value occurs and a portion of the carrying amount of the real estate investment will not be recovered in part or in whole, a provision will be recorded to reduce the carrying basis of the real estate investment and related intangibles to their estimated fair value. The estimated fair value of our real estate investments is determined by use of a number of customary industry standard methods that include discounted cash flow modeling using appropriate discount and capitalization rates and/or estimated cash proceeds received upon the anticipated disposition of the asset from market comparables. Estimates of future cash flows is based on a number of factors including the historical operating results, leases in place, known trends, and other market or economic factors affecting the real estate investment. The evaluation of anticipated cash flows is subjective and is based on assumptions regarding future occupancy, lease rates, and capital requirements that could differ materially from actual results. If our anticipated holding periods change or estimated cash flows decline based on market conditions or other unforeseen factors, impairment may be recorded. Long-lived assets to be disposed of are recorded at the lower of carrying value or fair value less estimated costs to sell.
Revenue
We recognize rental revenues in accordance with ASC 840, Leases (“ASC 840”). ASC 840 requires that rental revenue and adjustments relating to lease inducements and above- and below-market leases, be recognized on a straight-line basis over the term of the lease when collectability is reasonably assured. Recognizing rental revenue on a straight-line basis for leases may result in recognizing revenue for amounts more or less than amounts currently due from tenants. Amounts recognized in excess of amounts currently due are included in other assets on the consolidated balance sheets. If we determine the collectability of straight-line rents is not reasonably assured, we limit future recognition to amounts contractually owed and, where appropriate, establish an allowance for estimated losses.
Expense recoveries related to tenant reimbursement for real estate taxes, insurance, and other operating expenses are recognized as expense recoveries revenue in the period the applicable expenses are incurred. The reimbursements are recognized at gross, as we are generally the primary obligor with respect to real estate taxes and purchasing goods and services from third party suppliers, have discretion in selecting the supplier, and bear the credit risk.
We have certain tenants with absolute net leases. Under these lease agreements, the tenant is responsible for operating and building expenses. For absolute net leases, we do not recognize expense recoveries.
58
Use of Estimates
The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates are made for the valuation of real estate and related intangibles, valuation of financial instruments, impairment assessments, and fair value assessments with respect to purchase price allocations. Actual results could differ from those estimates.
REIT Qualification Requirements
We are subject to a number of operational and organizational requirements necessary to qualify and maintain our qualification as a REIT. If we fail to qualify as a REIT or fail to remain qualified as a REIT in any taxable year, our income would be subject to federal income tax at regular corporate rates and potentially increased state and local taxes and we could incur substantial tax liabilities which could have an adverse impact upon our results of operations, liquidity, and distributions to our shareholders.
Off-Balance Sheet Arrangements
As of December 31, 2018, we had no off-balance sheet debt arrangements.
Contractual Obligations
The following table summarizes our material contractual payment obligations and commitments as of December 31, 2018:
By Period (in thousands) | |||||||||||||||||||
Total | Less than 1 Year | 2020-2021 | 2022-2023 | 2024 and Thereafter | |||||||||||||||
Principal (1) | $ | 1,548,662 | $ | 25,205 | $ | 33,758 | $ | 501,818 | $ | 987,881 | |||||||||
Interest – fixed rate debt (1) | 405,169 | 50,588 | 98,278 | 93,243 | 163,060 | ||||||||||||||
Interest – variable rate debt (1) | 31,130 | 8,005 | 15,945 | 6,280 | 900 | ||||||||||||||
Tenant improvements | 47,024 | 25,703 | 11,771 | 6,518 | 3,032 | ||||||||||||||
Ground leases and other operating leases | 158,249 | 3,058 | 6,050 | 6,047 | 143,094 | ||||||||||||||
Total | $ | 2,190,234 | $ | 112,559 | $ | 165,802 | $ | 613,906 | $ | 1,297,967 | |||||||||
(1) | Obligations shown represent 100% of debt service and do not reflect joint venture interests. |
Inflation
Historically, inflation has not had a significant impact on the operating performance of our properties. Some of our lease agreements contain provisions designed to mitigate the adverse impact of inflation. These provisions include clauses that enable us to receive increased rent pursuant to escalation clauses which generally increase rental rates during the terms of the leases. These escalation clauses often provide for fixed rent increases or indexed escalations (based upon changes in the consumer price index or other measures). However, some of these contractual rent increases may be less than the actual rate of inflation. Most of our lease agreements also require the tenant to pay an allocable share of operating expenses, including common area maintenance costs, real estate taxes, and insurance. This requirement reduces our exposure to increases in these costs and operating expenses resulting from inflation.
59
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Our future income, cash flows, and fair values relevant to financial instruments are dependent upon prevailing market interest rates. Market risk refers to the risk of loss from adverse changes in market prices and interest rates. We use certain derivative financial instruments to manage, or hedge, interest rate risks related to our borrowings. We do not use derivatives for trading or speculative purposes and only enter into contracts with major financial institutions based upon their credit rating and other factors. Our derivative instruments consist of one embedded derivative, which is recognized as an asset on the consolidated balance sheets in other assets, and is measured at fair value and five interest rate swaps. See Note 2 (Summary of Significant Accounting Policies) and Note 7 (Derivatives) to our consolidated financial statements included in Item 8 to this report for further detail on our interest rate swaps.
Interest risk amounts are our management’s estimates and were determined by considering the effect of hypothetical interest rates on our consolidated financial instruments. These analyses do not consider the effect of any change in overall economic activity that could occur in that environment. Further, in the event of a change of that magnitude, we may take actions to further mitigate our exposure to the change. However, due to the uncertainty of the specific actions that would be taken and their possible effects, these analyses assume no changes in our financial structure.
Fixed Interest Rate Debt
As of December 31, 2018, our consolidated fixed interest rate debt totaled $1.1 billion, which represented 69.5% of our total consolidated debt, excluding the impact of interest rate swaps. On July 7, 2016, we entered into a pay-fixed receive-variable rate swap for the full $250.0 million borrowing amount of our term loan borrowings, fixing the LIBOR component of the borrowing rate to 1.07%, for an all-in fixed rate as of December 31, 2018 of 2.32%. Both the borrowing and pay-fixed receive-variable swap have a maturity date of June 10, 2023.
Assuming the effects of the interest rate swap agreement we entered into on July 7, 2016 relating to our unsecured debt, our fixed interest rate debt would represent 85.7% of our total consolidated debt. Interest rate fluctuations on our fixed interest rate debt will generally not affect our future earnings or cash flows unless such instruments mature or are otherwise terminated. However, interest rate changes could affect the fair value of our fixed interest rate debt.
As of December 31, 2018, the fair value and the carrying value of our consolidated fixed interest rate debt were approximately $1.0 billion and $1.1 billion, respectively. The fair value estimate of our fixed interest rate debt was estimated using a discounted cash flow analysis utilizing rates we would expect to pay for debt of a similar type and remaining maturity if the loans were originated on December 31, 2018. As we expect to hold our fixed interest rate debt instruments to maturity, based on the underlying structure of the debt instrument, and the amounts due under such instruments are limited to the outstanding principal balance and any accrued and unpaid interest, we do not expect that market fluctuations in interest rates, and the resulting change in fair value of our fixed interest rate debt instruments, would have a significant impact on our operating cash flows.
Variable Interest Rate Debt
As of December 31, 2018, our consolidated variable interest rate debt totaled $471.8 million, which represented 30.5% of our total consolidated debt. Assuming the effects of the interest rate swap agreement we entered into on July 7, 2016 relating to our unsecured debt, our variable interest rate debt would represent 14.3% of our total consolidated debt. Interest rate changes on our variable rate debt could impact our future earnings and cash flows but would not significantly affect the fair value of such debt. As of December 31, 2018, we were exposed to market risks related to fluctuations in interest rates on $221.8 million of consolidated borrowings. Assuming no increase in the amount of our variable rate debt, if LIBOR were to change by 100 basis points, interest expense on our variable rate debt as of December 31, 2018 would change by approximately $2.2 million annually.
Derivative Instruments
As of December 31, 2018, we had five outstanding interest rate swaps that were designated as cash flow hedges of interest rate risk, with a total notional amount of $250.0 million. See Note 7 (Derivatives) within our consolidated financial statements for further detail on our interest rate swaps. We are exposed to credit risk of the counterparty to our interest rate swap agreements in the event of non-performance under the terms of the agreements. If we were not able to replace these swaps in the event of non-performance by the counterparty, we would be subject to variability of the interest rate on the amount outstanding under our debt that is fixed through the use of the swaps.
60
Indebtedness
As of December 31, 2018, we had total consolidated indebtedness of approximately $1.5 billion. The weighted average interest rate on our consolidated indebtedness was 3.81% (based on the 30-day LIBOR rate as of December 31, 2018, of 2.46%). As of December 31, 2018, we had approximately $221.8 million, or approximately 14.3%, of our outstanding long-term debt exposed to fluctuations in short-term interest rates.
The following table sets forth certain information with respect to our consolidated indebtedness outstanding as of December 31, 2018 (in thousands):
Principal | Fixed/Floating Rate | Rate | Maturity | ||||||||
Senior Unsecured Revolving Credit Facility | $ | 215,000 | Floating | LIBOR + 1.10% | 9/18/2022 | ||||||
Senior Unsecured Term Loan (1) | 250,000 | Fixed | 2.32 | % | 6/10/2023 | ||||||
Senior Unsecured Notes | |||||||||||
January 2016 - Series A | 15,000 | Fixed | 4.03 | % | 1/7/2023 | ||||||
January 2016 - Series B | 45,000 | Fixed | 4.43 | % | 1/7/2026 | ||||||
January 2016 - Series C | 45,000 | Fixed | 4.57 | % | 1/7/2028 | ||||||
January 2016 - Series D | 45,000 | Fixed | 4.74 | % | 1/7/2031 | ||||||
August 2016 - Series A | 25,000 | Fixed | 4.09 | % | 8/11/2025 | ||||||
August 2016 - Series B | 25,000 | Fixed | 4.18 | % | 8/11/2026 | ||||||
August 2016 - Series C | 25,000 | Fixed | 4.24 | % | 8/11/2027 | ||||||
March 2017 Notes | 400,000 | Fixed | 4.30 | % | 3/15/2027 | ||||||
December 2017 Notes | 350,000 | Fixed | 3.95 | % | 1/15/2028 | ||||||
Peachtree Parking Deck | 17,000 | Fixed | 3.00 | % | 1/5/2020 | ||||||
Mid Coast Hospital Medical Office Building (2) | 6,830 | Floating | LIBOR + 2.75% | 11/13/2028 | |||||||
Oklahoma City, OK Medical Office Building | 6,901 | Fixed | 4.71 | % | 1/10/2021 | ||||||
Savage Medical Office Building | 5,284 | Fixed | 5.50 | % | 2/1/2022 | ||||||
St. Vincent Fishers Medical Center | 30,000 | Fixed | 4.00 | % | 1/10/2020 | ||||||
CareMount Medical - Lake Katrine | 25,618 | Fixed | 4.63 | % | 11/6/2024 | ||||||
Gwinnett Physicians Center | 17,029 | Fixed | 4.83 | % | 12/1/2022 | ||||||
Total principal | 1,548,662 | ||||||||||
Unamortized deferred financing costs | (9,920 | ) | |||||||||
Unamortized discounts | (6,086 | ) | |||||||||
Unamortized fair value adjustments | 197 | ||||||||||
Total | $ | 1,532,853 | |||||||||
(1) | Our borrowings under the term loan feature of our Credit Agreement bear interest at a rate which is determined by our credit rating, currently equal to LIBOR + 1.25%. We have entered into a pay-fixed receive-variable interest rate swap, fixing the LIBOR component of this rate at 1.07%, resulting in an effective interest rate of 2.32%. |
(2) | We own a 66.3% interest in the joint venture that owns this property. Debt shown in this schedule is the full amount of the mortgage indebtedness on this property. |
61
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Index to Consolidated Financial Statements
Page | ||
Reports of Independent Registered Public Accounting Firm | ||
Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting | ||
Financial Statements of Physicians Realty Trust | ||
Financial Statements of Physicians Realty L.P. | ||
Notes for Physicians Realty Trust and Physicians Realty L.P. | ||
62
Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Trustees of Physicians Realty Trust
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Physicians Realty Trust (the “Company”) as of December 31, 2018 and 2017, the related consolidated statements of income, comprehensive income, equity and cash flows for each of the three years in the period ended December 31, 2018, and the related notes and financial statement schedule included in the Index at Item 15 (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2018, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 28, 2019 expressed an unqualified opinion thereon.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2014.
Chicago, Illinois
February 28, 2019
63
Report of Independent Registered Public Accounting Firm
To the Partners of Physicians Realty L.P.
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of Physicians Realty L.P. (the “Company”) as of December 31, 2018 and 2017, the related consolidated statements of income, comprehensive income, changes in capital and cash flows for each of the three years in the period ended December 31, 2018, and the related notes and financial statement schedule included in the Index at Item 15 (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2018, in conformity with U.S. generally accepted accounting principles.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2017.
Chicago, Illinois
February 28, 2019
64
Report of Independent Registered Public Accounting Firm
To the Shareholders and the Board of Trustees of Physicians Realty Trust
Opinion on Internal Control over Financial Reporting
We have audited Physicians Realty Trust’s internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Physicians Realty Trust (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2018, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of Physicians Realty Trust at December 31, 2018 and 2017, the related consolidated statements of income, comprehensive income, equity and cash flows for each of the three years in the period ended December 31, 2018, and the related notes and financial statement schedule included in the Index at Item 15 and our report dated February 28, 2019 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting include in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of the financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
Chicago, Illinois
February 28, 2019
65
Physicians Realty Trust
Consolidated Balance Sheets
(in thousands, except share and per share data)
December 31, | |||||||
ASSETS | 2018 | 2017 | |||||
Investment properties: | |||||||
Land and improvements | $ | $ | |||||
Building and improvements | |||||||
Tenant improvements | |||||||
Acquired lease intangibles | |||||||
Accumulated depreciation | ( | ) | ( | ) | |||
Net real estate property | |||||||
Real estate loans receivable | |||||||
Investment in unconsolidated entities | |||||||
Net real estate investments | |||||||
Cash and cash equivalents | |||||||
Tenant receivables, net | |||||||
Other assets | |||||||
Total assets | $ | $ | |||||
LIABILITIES AND EQUITY | |||||||
Liabilities: | |||||||
Credit facility | $ | $ | |||||
Notes payable | |||||||
Mortgage debt | |||||||
Accounts payable | |||||||
Dividends and distributions payable | |||||||
Accrued expenses and other liabilities | |||||||
Acquired lease intangibles, net | |||||||
Total liabilities | |||||||
Redeemable noncontrolling interests - Series A Preferred Units (2018) and partially owned properties | |||||||
Equity: | |||||||
Common shares, $0.01 par value, 500,000,000 common shares authorized, 182,416,007 and 181,440,051 common shares issued and outstanding as of December 31, 2018 and December 31, 2017, respectively | |||||||
Additional paid-in capital | |||||||
Accumulated deficit | ( | ) | ( | ) | |||
Accumulated other comprehensive income | |||||||
Total shareholders’ equity | |||||||
Noncontrolling interests: | |||||||
Operating Partnership | |||||||
Partially owned properties | |||||||
Total noncontrolling interests | |||||||
Total equity | |||||||
Total liabilities and equity | $ | $ | |||||
The accompanying notes are an integral part of these consolidated financial statements.
66
Physicians Realty Trust
Consolidated Statements of Income
(in thousands, except share and per share data)
December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Revenues: | |||||||||||
Rental revenues | $ | $ | $ | ||||||||
Expense recoveries | |||||||||||
Interest income on real estate loans and other | |||||||||||
Total revenues | |||||||||||
Expenses: | |||||||||||
Interest expense | |||||||||||
General and administrative | |||||||||||
Operating expenses | |||||||||||
Depreciation and amortization | |||||||||||
Acquisition expenses | |||||||||||
Impairment loss | |||||||||||
Total expenses | |||||||||||
Income before equity in income of unconsolidated entities and gain on sale of investment properties, net: | |||||||||||
Equity in income of unconsolidated entities | |||||||||||
Gain on sale of investment properties, net | |||||||||||
Net income | |||||||||||
Net income attributable to noncontrolling interests: | |||||||||||
Operating Partnership | ( | ) | ( | ) | ( | ) | |||||
Partially owned properties (1) | ( | ) | ( | ) | ( | ) | |||||
Net income attributable to controlling interest | |||||||||||
Preferred distributions | ( | ) | ( | ) | ( | ) | |||||
Net income attributable to common shareholders | $ | $ | $ | ||||||||
Net income per share: | |||||||||||
Basic | $ | $ | $ | ||||||||
Diluted | $ | $ | $ | ||||||||
Weighted average common shares: | |||||||||||
Basic | |||||||||||
Diluted | |||||||||||
Dividends and distributions declared per common share and OP unit | $ | $ | $ | ||||||||
(1) |
The accompanying notes are an integral part of these consolidated financial statements.
67
Physicians Realty Trust
Consolidated Statements of Comprehensive Income
(in thousands)
December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Net income | $ | $ | $ | ||||||||
Other comprehensive income: | |||||||||||
Change in fair value of interest rate swap agreements, net | |||||||||||
Total other comprehensive income | |||||||||||
Comprehensive income | |||||||||||
Comprehensive income attributable to noncontrolling interests - Operating Partnership | ( | ) | ( | ) | ( | ) | |||||
Comprehensive income attributable to noncontrolling interests - partially owned properties | ( | ) | ( | ) | ( | ) | |||||
Comprehensive income attributable to common shareholders | $ | $ | $ | ||||||||
The accompanying notes are an integral part of these consolidated financial statements.
68
Physicians Realty Trust
Consolidated Statements of Equity
(in thousands)
Par Value | Additional Paid in Capital | Accumulated Deficit | Accumulated Other Comprehensive Income | Total Shareholders’ Equity | Operating Partnership Noncontrolling interest | Partially Owned Properties Noncontrolling Interest | Total Noncontrolling Interests | Total Equity | |||||||||||||||||||||||||||
Balance at January 1, 2016 | ( | ) | — | ||||||||||||||||||||||||||||||||
Net proceeds from sale of common shares | — | — | — | — | — | ||||||||||||||||||||||||||||||
Restricted share award grants, net | ( | ) | — | — | — | — | |||||||||||||||||||||||||||||
Purchase of OP Units | — | — | — | — | — | ( | ) | — | ( | ) | ( | ) | |||||||||||||||||||||||
Conversion of OP Units | — | — | ( | ) | — | ( | ) | ||||||||||||||||||||||||||||
Dividends/distributions declared | — | ( | ) | — | ( | ) | ( | ) | — | ( | ) | ( | ) | ||||||||||||||||||||||
Preferred distributions | — | — | ( | ) | — | ( | ) | — | ( | ) | |||||||||||||||||||||||||
Issuance of common shares and OP Units in connection with acquisitions | — | ( | ) | ||||||||||||||||||||||||||||||||
Contributions | — | — | — | — | — | ||||||||||||||||||||||||||||||
Distributions | — | — | — | — | — | — | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||
Change in market value of Redeemable Noncontrolling Interest in Operating Partnership | — | ( | ) | — | — | ( | ) | — | ( | ) | |||||||||||||||||||||||||
Reclassification of Noncontrolling Interest - partially owned properties | — | — | — | — | — | — | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||
Buyout of Noncontrolling Interests - partially owned property | — | — | — | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
Change in fair value of interest rate swap agreements | — | — | — | — | — | ||||||||||||||||||||||||||||||
Net income | — | — | — | ||||||||||||||||||||||||||||||||
Adjustment for Noncontrolling Interests ownership in Operating Partnership | — | ( | ) | — | — | ( | ) | — | |||||||||||||||||||||||||||
Balance at December 31, 2016 | ( | ) | |||||||||||||||||||||||||||||||||
Net proceeds from sale of common shares | — | — | — | — | — | ||||||||||||||||||||||||||||||
Restricted share award grants, net | ( | ) | — | — | — | — | |||||||||||||||||||||||||||||
Purchase of OP Units | — | — | — | — | — | ( | ) | — | ( | ) | ( | ) | |||||||||||||||||||||||
Conversion of OP Units | — | — | ( | ) | — | ( | ) | — | |||||||||||||||||||||||||||
Dividends/distributions declared | — | — | ( | ) | — | ( | ) | ( | ) | — | ( | ) | ( | ) | |||||||||||||||||||||
Preferred distributions | — | — | ( | ) | — | ( | ) | — | — | — | ( | ) | |||||||||||||||||||||||
Issuance of OP Units in connection with acquisitions | — | — | |||||||||||||||||||||||||||||||||
Contributions | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Distributions | — | — | — | — | — | — | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||
Buyout of Noncontrolling Interests - partially owned properties | — | ( | ) | — | — | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||
Change in fair value of interest rate swap agreements and redeemable equity - property | — | — | ( | ) | ( | ) | — | — | — | ( | ) | ||||||||||||||||||||||||
Net income | — | — | — | ||||||||||||||||||||||||||||||||
Adjustment for Noncontrolling Interests ownership in Operating Partnership | — | — | — | ( | ) | — | ( | ) | |||||||||||||||||||||||||||
Balance at December 31, 2017 | ( | ) | |||||||||||||||||||||||||||||||||
Net proceeds from sale of common shares | — | — | — | — | — | ||||||||||||||||||||||||||||||
Restricted share award grants, net | ( | ) | — | — | — | — | |||||||||||||||||||||||||||||
Purchase of OP Units | — | — | — | — | — | ( | ) | — | ( | ) | ( | ) | |||||||||||||||||||||||
Conversion of OP Units | — | — | ( | ) | — | ( | ) | — | |||||||||||||||||||||||||||
Dividends/distributions declared | — | — | ( | ) | — | ( | ) | ( | ) | — | ( | ) | ( | ) | |||||||||||||||||||||
Preferred distributions | — | — | ( | ) | — | ( | ) | — | — | — | ( | ) | |||||||||||||||||||||||
Distributions | — | — | — | — | — | — | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||||
Change in the market value of redeemable Noncontrolling interest in Operating Partnership | — | — | — | ||||||||||||||||||||||||||||||||
Change in fair value of interest rate swap agreements | — | — | — | — | — | — | |||||||||||||||||||||||||||||
Net income | — | — | — | ||||||||||||||||||||||||||||||||
Adjustment for Noncontrolling Interests ownership in Operating Partnership | — | ( | ) | — | — | ( | ) | — | |||||||||||||||||||||||||||
Balance at December 31, 2018 | $ | $ | $ | ( | ) | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
69
Physicians Realty Trust
Consolidated Statements of Cash Flows
(in thousands)
Year Ended December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Cash Flows from Operating Activities: | |||||||||||
Net income | $ | $ | $ | ||||||||
Adjustments to reconcile net income to net cash provided by operating activities | |||||||||||
Depreciation and amortization | |||||||||||
Amortization of deferred financing costs | |||||||||||
Amortization of lease inducements and above/below-market lease intangibles | |||||||||||
Straight-line rental revenue/expense | ( | ) | ( | ) | ( | ) | |||||
Amortization of discount on unsecured senior notes | |||||||||||
Amortization of above market assumed debt | ( | ) | ( | ) | ( | ) | |||||
Gain on sale of investment properties, net | ( | ) | ( | ) | |||||||
Equity in income of unconsolidated entities | ( | ) | ( | ) | ( | ) | |||||
Distributions from unconsolidated entities | |||||||||||
Change in fair value of derivatives | ( | ) | ( | ) | |||||||
Provision for bad debts | |||||||||||
Non-cash share compensation | |||||||||||
Net change in fair value of contingent consideration | ( | ) | ( | ) | ( | ) | |||||
Impairment on investment properties | |||||||||||
Change in operating assets and liabilities: | |||||||||||
Tenant receivables | ( | ) | ( | ) | |||||||
Other assets | ( | ) | ( | ) | ( | ) | |||||
Accounts payable | ( | ) | |||||||||
Accrued expenses and other liabilities | |||||||||||
Net cash provided by operating activities | |||||||||||
Cash Flows from Investing Activities: | |||||||||||
Proceeds on sale of investment properties | |||||||||||
Acquisition of investment properties, net | ( | ) | ( | ) | ( | ) | |||||
Acquisition of noncontrolling interests | ( | ) | ( | ) | |||||||
Escrowed cash - acquisition deposits/earnest deposits | ( | ) | ( | ) | |||||||
Capital expenditures on existing investment properties | ( | ) | ( | ) | ( | ) | |||||
Pay down of contingent consideration | ( | ) | ( | ) | |||||||
Issuances of real estate loans receivable | ( | ) | ( | ) | ( | ) | |||||
Repayments of real estate loan receivable | |||||||||||
Issuances of note receivable | ( | ) | |||||||||
Repayments of note receivable | |||||||||||
Leasing commissions | ( | ) | ( | ) | ( | ) | |||||
Lease inducements | ( | ) | ( | ) | ( | ) | |||||
Net cash used in investing activities | ( | ) | ( | ) | ( | ) | |||||
Cash Flows from Financing Activities: | |||||||||||
Net proceeds from sale of common shares | |||||||||||
Proceeds from credit facility borrowings | |||||||||||
Repayments on credit facility borrowings | ( | ) | ( | ) | ( | ) | |||||
Proceeds from issuance of mortgage debt | |||||||||||
Proceeds from issuance of senior unsecured notes | |||||||||||
Principal payments on mortgage debt | ( | ) | ( | ) | ( | ) | |||||
Debt issuance costs | ( | ) | ( | ) | ( | ) | |||||
Dividends paid - shareholders | ( | ) | ( | ) | ( | ) | |||||
Distributions to noncontrolling interest - Operating Partnership | ( | ) | ( | ) | ( | ) | |||||
Preferred distributions paid - OP Unit holders | ( | ) | ( | ) | ( | ) | |||||
Contributions to noncontrolling interests | |||||||||||
Distributions to noncontrolling interests - partially owned properties | ( | ) | ( | ) | ( | ) | |||||
Payments of employee taxes for withheld stock-based compensation shares | ( | ) | ( | ) | ( | ) | |||||
Purchases of Series A Preferred Units | ( | ) | ( | ) | |||||||
Purchases of OP Units | ( | ) | ( | ) | ( | ) | |||||
Net cash (used in) provided by financing activities | ( | ) | |||||||||
Net increase (decrease) in cash and cash equivalents | ( | ) | |||||||||
Cash and cash equivalents, beginning of year | |||||||||||
Cash and cash equivalents, end of year | $ | $ | $ | ||||||||
Supplemental disclosure of cash flow information - interest paid during the year | $ | $ | $ | ||||||||
Supplemental disclosure of noncash activity - change in fair value of interest rate swap agreements and redeemable equity - property | $ | $ | $ | ||||||||
Supplemental disclosure of noncash activity - assumed debt | $ | $ | $ | ||||||||
Supplemental disclosure of noncash activity - issuance of OP Units and Series A Preferred Units in connection with acquisitions | $ | $ | $ | ||||||||
Supplemental disclosure of noncash activity - contingent consideration | $ | $ | $ | ||||||||
The accompanying notes are an integral part of these consolidated financial statements.
70
Physicians Realty L.P.
Consolidated Balance Sheets
(in thousands, except unit and per unit data)
December 31, | |||||||
ASSETS | 2018 | 2017 | |||||
Investment properties: | |||||||
Land and improvements | $ | $ | |||||
Building and improvements | |||||||
Tenant improvements | |||||||
Acquired lease intangibles | |||||||
Accumulated depreciation | ( | ) | ( | ) | |||
Net real estate property | |||||||
Real estate loans receivable | |||||||
Investment in unconsolidated entities | |||||||
Net real estate investments | |||||||
Cash and cash equivalents | |||||||
Tenant receivables, net | |||||||
Other assets | |||||||
Total assets | $ | $ | |||||
LIABILITIES AND CAPITAL | |||||||
Liabilities: | |||||||
Credit facility | $ | $ | |||||
Notes payable | |||||||
Mortgage debt | |||||||
Accounts payable | |||||||
Dividends and distributions payable | |||||||
Accrued expenses and other liabilities | |||||||
Acquired lease intangibles, net | |||||||
Total liabilities | |||||||
Redeemable noncontrolling interests - Series A Preferred Units (2018) and partially owned properties | |||||||
Capital: | |||||||
Partners’ capital: | |||||||
General partners’ capital, 182,416,007 and 181,440,051 units issued and outstanding as of December 31, 2018 and 2017, respectively | |||||||
Limited partners’ capital, 5,182,784 and 5,364,632 units issued and outstanding as of December 31, 2018 and 2017, respectively | |||||||
Accumulated other comprehensive income | |||||||
Total partners’ capital | |||||||
Noncontrolling interest - partially owned properties | |||||||
Total capital | |||||||
Total liabilities and capital | $ | $ | |||||
The accompanying notes are an integral part of these consolidated financial statements.
71
Physicians Realty L.P.
Consolidated Statements of Income
(in thousands, except unit and per unit data)
December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Revenues: | |||||||||||
Rental revenues | $ | $ | $ | ||||||||
Expense recoveries | |||||||||||
Interest income on real estate loans and other | |||||||||||
Total revenues | |||||||||||
Expenses: | |||||||||||
Interest expense | |||||||||||
General and administrative | |||||||||||
Operating expenses | |||||||||||
Depreciation and amortization | |||||||||||
Acquisition expenses | |||||||||||
Impairment loss | |||||||||||
Total expenses | |||||||||||
Income before equity in income of unconsolidated entities and gain on sale of investment properties, net: | |||||||||||
Equity in income of unconsolidated entities | |||||||||||
Gain on sale of investment properties, net | |||||||||||
Net income | |||||||||||
Net income attributable to noncontrolling interests - partially owned properties (1) | ( | ) | ( | ) | ( | ) | |||||
Net income attributable to controlling interests | |||||||||||
Preferred distributions | ( | ) | ( | ) | ( | ) | |||||
Net income attributable to common unitholders | $ | $ | $ | ||||||||
Net income per common unit: | |||||||||||
Basic | $ | $ | $ | ||||||||
Diluted | $ | $ | $ | ||||||||
Weighted average common units: | |||||||||||
Basic | |||||||||||
Diluted | |||||||||||
Distributions declared per common unit | $ | $ | $ | ||||||||
(1) | Includes amounts attributable to redeemable noncontrolling interests. |
The accompanying notes are an integral part of these consolidated financial statements.
72
Physicians Realty L.P.
Consolidated Statements of Comprehensive Income
(in thousands)
December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Net income | $ | $ | $ | ||||||||
Other comprehensive income: | |||||||||||
Change in fair value of interest rate swap agreements, net | |||||||||||
Total other comprehensive income | |||||||||||
Comprehensive income | |||||||||||
Comprehensive income attributable to noncontrolling interests - partially owned properties | ( | ) | ( | ) | ( | ) | |||||
Comprehensive income attributable to common unitholders | $ | $ | $ | ||||||||
The accompanying notes are an integral part of these consolidated financial statements.
73
Physicians Realty L.P.
Consolidated Statements of Changes in Capital
(in thousands)
General Partner | Limited Partner | Accumulated Other Comprehensive Income | Total Partners’ Capital | Partially Owned Properties Noncontrolling Interest | Total Partners’ Capital | ||||||||||||||||||
Balance at January 1, 2016 | — | ||||||||||||||||||||||
Net proceeds from sale of Trust common shares and issuance of common units | — | — | — | ||||||||||||||||||||
Trust restricted share award grants, net | — | — | — | ||||||||||||||||||||
Purchase of OP Units | — | ( | ) | — | ( | ) | — | ( | ) | ||||||||||||||
Conversion of OP Units | ( | ) | — | — | — | ||||||||||||||||||
OP Units - distributions | ( | ) | ( | ) | — | ( | ) | — | ( | ) | |||||||||||||
Preferred distributions | ( | ) | — | — | ( | ) | — | ( | ) | ||||||||||||||
Issuance of OP Units in connection with acquisition | — | ( | ) | ||||||||||||||||||||
Contributions | — | — | — | — | |||||||||||||||||||
Distributions | — | — | — | — | ( | ) | ( | ) | |||||||||||||||
Change in market value of Redeemable Limited Partnership interests | ( | ) | — | — | ( | ) | — | ( | ) | ||||||||||||||
Reclassification of Noncontrolling Interest - partially owned properties | — | — | — | — | ( | ) | ( | ) | |||||||||||||||
Buyout of Noncontrolling Interest - partially owned properties | — | — | ( | ) | ( | ) | |||||||||||||||||
Change in fair value of interest rate swap agreements | — | — | — | ||||||||||||||||||||
Net income | — | ||||||||||||||||||||||
Adjustments for Limited Partners ownership in Operating Partnership | ( | ) | — | — | — | ||||||||||||||||||
Balance at December 31, 2016 | |||||||||||||||||||||||
Net proceeds from sale of Trust common shares and issuance of common units | — | — | — | ||||||||||||||||||||
Trust restricted share award grants, net | — | — | — | ||||||||||||||||||||
Purchase of OP Units | — | ( | ) | — | ( | ) | — | ( | ) | ||||||||||||||
Conversion of OP Units | ( | ) | — | — | — | ||||||||||||||||||
OP Units - distributions | ( | ) | ( | ) | — | ( | ) | — | ( | ) | |||||||||||||
Preferred distributions | ( | ) | — | — | ( | ) | — | ( | ) | ||||||||||||||
Issuance of OP Units in connection with acquisition | — | — | — | ||||||||||||||||||||
Contributions | — | — | — | — | |||||||||||||||||||
Distributions | — | — | — | — | ( | ) | ( | ) | |||||||||||||||
Buyout of Noncontrolling Interest - partially owned properties | ( | ) | — | ( | ) | ( | ) | ( | ) | ||||||||||||||
Change in fair value of interest rate swap agreements and redeemable equity - property | ( | ) | — | ( | ) | — | ( | ) | |||||||||||||||
Net income | — | ||||||||||||||||||||||
Adjustments for Limited Partners ownership in Operating Partnership | ( | ) | — | — | — | ||||||||||||||||||
Balance at December 31, 2017 | |||||||||||||||||||||||
Net proceeds from sale of Trust common shares and issuance of common units | — | — | — | ||||||||||||||||||||
Trust restricted share award grants, net | — | — | — | ||||||||||||||||||||
Purchase of OP Units | — | ( | ) | — | ( | ) | — | ( | ) | ||||||||||||||
Conversion of OP Units | ( | ) | — | — | — | ||||||||||||||||||
OP Units - distributions | ( | ) | ( | ) | — | ( | ) | — | ( | ) | |||||||||||||
Preferred distributions | ( | ) | — | — | ( | ) | — | ( | ) | ||||||||||||||
Distributions | — | — | — | — | ( | ) | ( | ) | |||||||||||||||
Change in market value of Redeemable Limited Partnership interest | — | — | — | ||||||||||||||||||||
Change in the market value of redeemable Noncontrolling interest in Operating Partnership | — | — | — | ||||||||||||||||||||
Change in fair value of interest rate swap agreements | — | — | — | ||||||||||||||||||||
Net income | — | ||||||||||||||||||||||
Adjustments for Limited Partners ownership in Operating Partnership | ( | ) | — | — | — | ||||||||||||||||||
Balance at December 31, 2018 | $ | $ | $ | $ | $ | $ | |||||||||||||||||
The accompanying notes are an integral part of these consolidated financial statements.
74
Physicians Realty L.P.
Consolidated Statements of Cash Flows
(in thousands)
Year Ended December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Cash Flows from Operating Activities: | |||||||||||
Net income | $ | $ | $ | ||||||||
Adjustments to reconcile net income to net cash provided by operating activities | |||||||||||
Depreciation and amortization | |||||||||||
Amortization of deferred financing costs | |||||||||||
Amortization of lease inducements and above/below-market lease intangibles | |||||||||||
Straight-line rental revenue/expense | ( | ) | ( | ) | ( | ) | |||||
Amortization of discount on unsecured senior notes | |||||||||||
Amortization of above market assumed debt | ( | ) | ( | ) | ( | ) | |||||
Gain on sale of investment properties | ( | ) | ( | ) | |||||||
Equity in income of unconsolidated entities | ( | ) | ( | ) | ( | ) | |||||
Distribution from unconsolidated entities | |||||||||||
Change in fair value of derivatives | ( | ) | ( | ) | |||||||
Provision for bad debts | |||||||||||
Non-cash share compensation | |||||||||||
Net change in fair value of contingent consideration | ( | ) | ( | ) | ( | ) | |||||
Impairment on investment properties | |||||||||||
Change in operating assets and liabilities: | |||||||||||
Tenant receivables | ( | ) | ( | ) | |||||||
Other assets | ( | ) | ( | ) | ( | ) | |||||
Accounts payable | ( | ) | |||||||||
Accrued expenses and other liabilities | |||||||||||
Net cash provided by operating activities | |||||||||||
Cash Flows from Investing Activities: | |||||||||||
Proceeds on sale of investment properties | |||||||||||
Acquisition of investment properties, net | ( | ) | ( | ) | ( | ) | |||||
Acquisition of non-controlling interests | ( | ) | ( | ) | |||||||
Escrowed cash - acquisition deposits/earnest deposits | ( | ) | ( | ) | |||||||
Capital expenditures on existing investment properties | ( | ) | ( | ) | ( | ) | |||||
Pay down of contingent consideration | ( | ) | ( | ) | |||||||
Issuance of real estate loans receivable | ( | ) | ( | ) | ( | ) | |||||
Repayment of real estate loan receivable | |||||||||||
Issuance of note receivable | ( | ) | |||||||||
Repayment of note receivable | |||||||||||
Leasing commissions | ( | ) | ( | ) | ( | ) | |||||
Lease Inducements | ( | ) | ( | ) | ( | ) | |||||
Net cash used in investing activities | ( | ) | ( | ) | ( | ) | |||||
Cash Flows from Financing Activities: | |||||||||||
Net proceeds from sale of Trust common shares and issuance of common units | |||||||||||
Proceeds from credit facility borrowings | |||||||||||
Payment on credit facility borrowings | ( | ) | ( | ) | ( | ) | |||||
Proceeds from issuance of senior unsecured notes | |||||||||||
Proceeds from issuance of mortgage debt | |||||||||||
Principal payments on mortgage debt | ( | ) | ( | ) | ( | ) | |||||
Debt issuance costs | ( | ) | ( | ) | ( | ) | |||||
OP Units distributions - General Partner | ( | ) | ( | ) | ( | ) | |||||
OP Units distributions - Limited Partner | ( | ) | ( | ) | ( | ) | |||||
Preferred OP Units distributions - Limited Partner | ( | ) | ( | ) | ( | ) | |||||
Contributions to noncontrolling interest | |||||||||||
Distributions to noncontrolling interest - partially owned properties | ( | ) | ( | ) | ( | ) | |||||
Payments of employee taxes for withheld stock based compensation shares | ( | ) | ( | ) | ( | ) | |||||
Purchase of Preferred Limited Partner Units | ( | ) | ( | ) | |||||||
Purchase of Limited Partner Units | ( | ) | ( | ) | ( | ) | |||||
Net cash (used in) provided by financing activities | ( | ) | |||||||||
Net increase (decrease) in cash and cash equivalents | ( | ) | |||||||||
Cash and cash equivalents, beginning of year | |||||||||||
Cash and cash equivalents, end of year | $ | $ | $ | ||||||||
Supplemental disclosure of cash flow information - interest paid during the year | $ | $ | $ | ||||||||
Supplemental disclosure of noncash activity - change in fair value of interest rate swap agreements and redeemable equity - property | $ | $ | $ | ||||||||
Supplemental disclosure of noncash activity - assumed debt | $ | $ | $ | ||||||||
Supplemental disclosure of noncash activity - issuance of OP Units and Series A Preferred Units in connection with acquisitions | $ | $ | $ | ||||||||
Supplemental disclosure of noncash activity - contingent consideration | $ | $ | $ | ||||||||
The accompanying notes are an integral part of these consolidated financial statements.
75
Physicians Realty Trust and Physicians Realty L.P.
Notes to Consolidated Financial Statements
Unless otherwise indicated or unless the context requires otherwise the use of the words “we,” “us,” “our,” and the “Company,” refer to Physicians Realty Trust, together with its consolidated subsidiaries, including Physicians Realty L.P.
Note 1. Organization and Business
The Trust was organized in the state of Maryland on April 9, 2013. As of December 31, 2018, the Trust was authorized to issue up to 500,000,000 common shares of beneficial interest, par value $0.01 per share (“common shares”). The Trust filed a Registration Statement on Form S-11 with the Commission with respect to a proposed underwritten IPO and completed the IPO of its common shares and commenced operations on July 24, 2013.
The Trust contributed the net proceeds from the IPO to the Operating Partnership. The Trust and the Operating Partnership are managed and operated as one entity. The Trust has no significant assets other than its investment in the Operating Partnership. The Trust’s operations are conducted through the Operating Partnership and wholly-owned and majority-owned subsidiaries of the Operating Partnership. The Trust, as the general partner of the Operating Partnership, controls the Operating Partnership and consolidates the assets, liabilities, and results of operations of the Operating Partnership. Therefore, the assets and liabilities of the Trust and the Operating Partnership are the same.
The Trust is a self-managed REIT formed primarily to acquire, selectively develop, own, and manage healthcare properties that are leased to physicians, hospitals, and healthcare delivery systems.
ATM Program
On August 5, 2016, the Trust and the Operating Partnership entered into separate Sales Agreements with each of KeyBanc Capital Markets Inc., Credit Agricole Securities (USA) Inc., JMP Securities LLC, Raymond James & Associates, Inc., and Stifel Nicolaus & Company, Incorporated (the “Agents”), pursuant to which the Trust may issue and sell, from time to time, its common shares having an aggregate offering price of up to $300.0 million, through the Agents (the “ATM Program”). In accordance with the Sales Agreements, the Trust may offer and sell its common shares through any of the Agents, from time to time, by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended, which includes sales made directly on the New York Stock Exchange or other existing market, or sales made to or through a market maker. With the Trust’s express written consent, sales may also be made in negotiated transactions or any other method permitted by law.
2018 | 2017 | ||||||||||||||||||||
Common shares sold | Weighted average price | Net proceeds | Common shares sold | Weighted average price | Net proceeds | ||||||||||||||||
Quarterly period ended March 31 | $ | $ | $ | $ | |||||||||||||||||
Quarterly period ended June 30 | |||||||||||||||||||||
Quarterly period ended September 30 | |||||||||||||||||||||
Quarterly period ended December 31 | |||||||||||||||||||||
Year ended December 31 | $ | $ | $ | $ | |||||||||||||||||
Note 2. Summary of Significant Accounting Policies
GAAP requires us to identify entities for which control is achieved through means other than voting rights and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). ASC 810 broadly defines a VIE as an entity in which either (i) the equity investors as a group, if any, lack the power through voting or similar rights to direct the activities of such entity that most significantly impact such entity’s economic performance or (ii) the equity investment at risk is insufficient to finance that entity’s activities without additional subordinated financial support. We identify
76
the primary beneficiary of a VIE as the enterprise that has both of the following characteristics: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or receive benefits of the VIE that could potentially be significant to the entity. We consolidate our investment in a VIE when we determine that we are the VIE’s primary beneficiary. We may change our original assessment of a VIE upon subsequent events such as the modification of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposition of all or a portion of an interest held by the primary beneficiary. We perform this analysis on an ongoing basis.
For property holding entities not determined to be VIEs, we consolidate such entities in which the Operating Partnership owns 100 % of the equity or has a controlling financial interest evidenced by ownership of a majority voting interest. All intercompany balances and transactions are eliminated in consolidation. For entities in which the Operating Partnership owns less than 100% of the equity interest, the Operating Partnership consolidates the property if it has the direct or indirect ability to control the entities’ activities based upon the terms of the respective entities’ ownership agreements. For these entities, the Operating Partnership records a noncontrolling interest representing equity held by noncontrolling interests.
The Company presents the portion of any equity it does not own in entities that it controls (and thus consolidates) as noncontrolling interests and classifies such interests as a component of consolidated equity, separate from the Company’s total shareholders’ equity, on the consolidated balance sheets.
Operating Partnership: Net income or loss is allocated to noncontrolling interests (limited partners) based on their respective ownership percentage of the Operating Partnership. The ownership percentage is calculated by dividing the number of OP Units held by the noncontrolling interests by the total OP Units held by the noncontrolling interests and the Trust. Issuance of additional common shares and OP Units changes the ownership interests of both the noncontrolling interests and the Trust. Such transactions and the related proceeds are treated as capital transactions.
During the year ended December 31, 2017, the Operating Partnership partially funded one property acquisition by issuing an aggregate of 2,247,817 OP Units valued at approximately $44.3 million on the date of issuance. The acquisition had a total purchase price of approximately $78.6 million. In addition, during the year ended December 31, 2017, the Operating Partnership funded the acquisition of the remaining non-controlling interest on a property by issuing an aggregate of 38,641 OP Units valued at approximately $0.7 million.
Noncontrolling interests in the Company include OP Units held by other investors. As of December 31, 2018 and 2017, the Trust held a 97.2 % and 97.1 % interest in the Operating Partnership, respectively. As the sole general partner and the majority interest holder, the Trust consolidates the financial position and results of operations of the Operating Partnership.
Holders of OP Units may not transfer their units without the Trust’s prior written consent, as general partner of the Operating Partnership. Beginning on the first anniversary of the issuance of OP Units, OP Unit holders may tender their units for redemption by the Operating Partnership in exchange for cash equal to the market price of the Trust’s common shares at the time of redemption or for unregistered common shares on a one -for-one basis. Such selection to pay cash or issue common shares to satisfy an OP Unit holder’s redemption request is solely within the control of the Trust. Accordingly, the Trust presents the OP Units of the Operating Partnership held by investors other than the Trust as noncontrolling interests within equity in the consolidated balance sheets.
Partially Owned Properties: The Trust and Operating Partnership reflect noncontrolling interests in partially owned properties on the balance sheet for the portion of consolidated properties that are not wholly owned by the Company. The earnings or losses from those properties attributable to the noncontrolling interests are reflected as noncontrolling interests in partially owned properties in the consolidated statements of income.
Redeemable Noncontrolling Interests-Series A Preferred Units and Partially Owned Properties
On February 5, 2015, the Trust entered into a Second Amended and Restated Agreement of Limited Partnership (the “Partnership Agreement”) which provides for the designation and issuance of the newly designated Series A Participating Redeemable Preferred Units of the Operating Partnership (“Series A Preferred Units”). Series A Preferred Units have priority over all other partnership interests of the Operating Partnership with respect to distributions and liquidation. Holders of Series A Preferred Units are entitled to a 5 % cumulative return and upon redemption, the receipt of one common share and $200 . The holders of the Series A Preferred Units have agreed not to cause the Operating Partnership to redeem their Series A Preferred Units prior to one year from the issuance date. In addition, Series A Preferred Units are redeemable at the option of the holders
77
which redemption obligation may be satisfied, at the Trust’s option, in cash or registered common shares. Instruments that require settlement in registered common shares may not be classified in permanent equity as it is not always completely within an issuer’s control to deliver registered common shares. Due to the redemption rights associated with the Series A Preferred Units, the Company classifies the Series A Preferred Units in the mezzanine section of its consolidated balance sheets.
The Series A Preferred Units were evaluated for embedded features that should be bifurcated and separately accounted for as a freestanding derivative. The Company determined that the Series A Preferred Units contained features that require bifurcation. The Company records the carrying amount of the redeemable noncontrolling interests, less the value of the embedded derivative, at the greater of the carrying value or redemption value in the consolidated balance sheets.
On January 9, 2018, the acquisition of the HealthEast Clinic & Specialty Center (“Hazelwood Medical Commons”) was partially funded with the issuance of 104,172 Series A Preferred Units, with a value of $22.7 million. As of December 31, 2018, the value of the embedded derivative is $3.7 million and is classified in accrued expenses and other liabilities on the consolidated balance sheets.
As of December 31, 2018, there were 104,172 Series A Preferred Units outstanding. No Series A Preferred Units were outstanding as of December 31, 2017.
In connection with the December 29, 2015 acquisition of a medical office building located on the campus of the Great Falls Clinic and Hospital in Great Falls, Montana, physicians affiliated with the seller retained a noncontrolling interest which may, at the holders’ option, be redeemed at any time. Due to the redemption provision, which is outside of the control of the Trust, the Trust classifies the investment in the mezzanine section of its consolidated balance sheets. The Trust records the carrying amount of the redeemable noncontrolling interests at the greater of the carrying value or redemption value.
Declaration Date | Record Date | Payment Date | Cash Dividend per Share/Unit | |||||
December 21, 2018 | January 4, 2019 | January 18, 2019 | $ | |||||
September 19, 2018 | October 3, 2018 | October 18, 2018 | $ | |||||
June 21, 2018 | July 3, 2018 | July 18, 2018 | $ | |||||
March 23, 2018 | April 3, 2018 | April 18, 2018 | $ | |||||
December 21, 2017 | January 3, 2018 | January 18, 2018 | $ | |||||
September 21, 2017 | October 3, 2017 | October 18, 2017 | $ | |||||
June 12, 2017 | July 3, 2017 | July 18, 2017 | $ | |||||
March 17, 2017 | April 5, 2017 | April 18, 2017 | $ | |||||
December 22, 2016 | January 5, 2017 | January 18, 2017 | $ | |||||
September 26, 2016 | October 6, 2016 | October 18, 2016 | $ | |||||
June 23, 2016 | July 5, 2016 | July 18, 2016 | $ | |||||
March 18, 2016 | April 1, 2016 | April 18, 2016 | $ | |||||
78
Our distributions of current and accumulated earnings and profits for U.S. federal income tax purposes generally are taxable to shareholders as ordinary income. Distributions in excess of these earnings and profits generally are treated as a non-taxable reduction of the shareholders’ basis in the shares to the extent thereof (non-dividend distributions) and thereafter as taxable gain.
Year Ended December 31, | ||||||||||||
2018 | 2017 | 2016 | ||||||||||
Per common share and OP Unit: | ||||||||||||
Ordinary dividends | $ | $ | $ | |||||||||
Section 199A Qualified REIT Dividend | ||||||||||||
Qualified dividends | ||||||||||||
Capital gain distributions | ||||||||||||
Non-dividend distributions | ||||||||||||
Total | $ | $ | $ | |||||||||
With the adoption of ASU 2017-01 in January 2018, our 2018 acquisitions of investment properties and the majority of our future investments will be accounted for as asset acquisitions, resulting in the purchase price inclusive of acquisition costs, for tangible and intangible assets and liabilities to be based on their relative fair values. Tangible assets primarily consist of land and buildings and improvements. Additionally, the purchase price includes acquisition related expenses, above- or below-market leases, in place leases, and above- or below-market debt assumed. Any future contingent consideration will be recorded when the contingency is resolved. The determination of the fair value requires us to make certain estimates and assumptions.
The determination of fair value involves the use of significant judgment and estimation. The Company makes estimates of the fair value of the tangible and intangible acquired assets and assumed liabilities using information obtained from multiple sources as a result of pre-acquisition due diligence and generally includes the assistance of a third party appraiser. The Company estimates the fair value of an acquired asset on an “as-if-vacant” basis and its value is depreciated in equal amounts over the course of its estimated remaining useful life. The Company determines the allocated value of other fixed assets, such as site improvements, based upon the replacement cost and depreciates such value over the assets’ estimated remaining useful lives as determined at the applicable acquisition date. The fair value of land is determined either by considering the sales prices of similar properties in recent transactions or based on an internal analysis of recently acquired and existing comparable properties within the Company’s portfolio.
The value of above- or below-market leases is estimated based on the present value (using a discount rate which reflected the risks associated with the leases acquired) of the difference between contractual amounts to be received pursuant to the leases and management’s estimate of market lease rates measured over a period equal to the estimated remaining term of the lease. The capitalized above-market or below-market lease intangibles are amortized as a reduction or addition to rental income over the estimated remaining term of the respective leases plus the term of any renewal options that the lessee would be economically compelled to exercise.
In determining the value of in-place leases, management considers current market conditions and costs to execute similar leases in arriving at an estimate of the carrying costs during the expected lease-up period from vacant to existing occupancy. In estimating carrying costs, management includes real estate taxes, insurance, other operating expenses, estimates
79
of lost rental revenue during the expected lease-up periods, and costs to execute similar leases, including leasing commissions, tenant improvements, legal, and other related costs based on current market demand. The values assigned to in-place leases are amortized to amortization expense over the estimated remaining term of the lease. If a lease terminates prior to its scheduled expiration, all unamortized costs related to that lease are written off, net of any required lease termination payments.
The Company calculates the fair value of any long-term debt assumed by discounting the remaining contractual cash flows on each instrument at the current market rate for those borrowings, which the Company approximates based on the rate it would expect to incur on a replacement instrument on the date of acquisition, and recognizes any fair value adjustments related to long-term debt as effective yield adjustments over the remaining term of the instrument.
The Company periodically evaluates its long-lived assets, primarily consisting of investments in real estate, for impairment indicators or whenever events or changes in circumstances indicate that the recorded amount of an asset may not be fully recoverable. If indicators of impairment are present, the Company evaluates the carrying value of the related real estate properties in relation to the undiscounted expected future cash flows of the underlying operations. In performing this evaluation, management considers market conditions and current intentions with respect to holding or disposing of the real estate property. The Company adjusts the net book value of real estate properties to fair value if the sum of the expected future undiscounted cash flows, including sales proceeds, is less than book value. The Company recognizes an impairment loss at the time it makes any such determination. If the Company determines that an asset is impaired, the impairment to be recognized is measured as the amount by which the recorded amount of the asset exceeds its fair value. Fair value is typically determined using a discounted future cash flow analysis or other acceptable valuation techniques which are based, in turn, upon Level 3 inputs, such as revenue and expense growth rates, capitalization rates, discount rates, or other available market data.
The Company did not record impairment charges in the years ended December 31, 2018 and 2016. During the year ended December 31, 2017, the Company recorded an impairment charge of $1.0 million on a vacant medical office building in Port Charlotte, Florida.
80
Expense recoveries relate to tenant reimbursement of real estate taxes, insurance, and other operating expenses that are recognized as expense recovery revenue in the period the applicable expenses are incurred. The reimbursements are recorded gross, as the Company is generally the primary obligor with respect to real estate taxes and purchasing goods and services from third-party suppliers, has discretion in selecting the supplier, and bears the credit risk of tenant reimbursement.
When the Company has derivative instruments embedded in other contracts, it records them either as an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sale exception. When specific hedge accounting criteria are not met or if the Company does not elect to apply for hedge accounting, changes in the Company’s derivative instruments’ fair value are recognized currently in earnings. If hedge accounting is applied to a derivative instrument, such changes are reported in accumulated other comprehensive income within the consolidated statement of equity or capital, exclusive of ineffectiveness amounts, which are recognized as adjustments to net income.
To manage interest rate risk for certain of its variable-rate debt, the Company uses interest rate swaps as part of its risk management strategy. These derivatives are designed to mitigate the risk of future interest rate increases by providing a fixed interest rate for a limited, pre-determined period of time. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of December 31, 2018, the Company had five outstanding interest rate swap contracts that are designated as cash flow hedges of interest rate risk. For presentational purposes, they are shown as one derivative due to the identical nature of their economic terms. Further detail is provided in Note 7 (Derivatives).
The effective portion of the change in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income (“AOCI”) on the consolidated balance sheets and is subsequently reclassified into earnings as interest expense for the period that the hedged forecasted transaction affects earnings. The
81
The Trust elected to be taxed as a REIT for federal tax purposes commencing with the filing of its tax return for the short taxable year ending December 31, 2013. The Trust had no taxable income prior to electing REIT status. To qualify as a REIT, the Trust must meet certain organizational and operational requirements, including a requirement to distribute at least 90% of its annual REIT taxable income to its shareholders (which is computed without regard to the dividends paid deduction or net capital gain and which does not necessarily equal net income as calculated in accordance with GAAP). As a REIT, the Trust generally will not be subject to federal income tax to the extent it distributes qualifying dividends to its shareholders. If the Trust fails to qualify as a REIT in any taxable year, it will be subject to federal income tax (including any applicable alternative minimum tax) on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost, unless the Internal Revenue Service grants the Trust relief under certain statutory provisions. Such an event could materially adversely affect the Trust’s net income and net cash available for distribution to shareholders. However, the Trust intends to continue to operate in such a manner as to continue qualifying for treatment as a REIT. Although the Trust continues to qualify for taxation as a REIT, in various instances, the Trust is subject to state and local taxes on its income and property, and federal income and excise taxes on its undistributed income.
On December 22, 2017, the U.S. President signed a tax reform bill commonly referred to as the Tax Cuts and Jobs Act into law. The tax reform legislation is a far-reaching and complex revision to the U.S. federal income tax laws with disparate and, in some cases, countervailing effects on different categories of taxpayers and industries. The legislation is unclear in many respects and will require clarification and interpretation by the U.S. Treasury Department and the IRS in the form of amendments, technical corrections, regulations, or other forms of guidance, any of which could either lessen or increase the effect of the legislation on us or our stockholders. The outcome of this legislation on state and local tax authorities, and the response by such authorities, is also unclear. We continue to monitor changes made to, or as a result of, the federal tax law and its potential effect on us.
Certain of our acquisitions provide for additional consideration to the seller in the form of an earn-out associated with lease-up contingencies. The Company recognizes the contingent liabilities only if certain parameters or other substanti
82
ve contingencies are met, at which time the consideration becomes payable. Resolved contingent liabilities increase our acquired assets and reduce our liabilities.
In January 2017, the FASB issued ASU No. 2017-01, Clarifying the Definition of a Business, which changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. The Company adopted ASU 2017-01 on January 1, 2018. As such, the Company recorded all 2018 real estate investments and will record the majority of future real estate investments as asset acquisitions and any future contingent consideration will be recorded when the contingency is resolved. Prior to January 1, 2018, the Company recorded certain contingent liabilities which are included in accrued expenses and other liabilities on its consolidated balance sheets. These were recorded at fair value as of the acquisition date and until they expire, the Company reassesses the fair value at the end of each reporting period, with any changes being recognized in earnings.
Based on existing leases as of December 31, 2018, committed but unspent tenant related obligations were $47.0 million.
Related Parties
In 2018, the Company recognized rental revenues totaling $1.1 million and $8.0 million from Advocate Aurora Health and Baylor Scott and White Health, respectively. Both are healthcare systems affiliated with certain members of the Trust’s Board of Trustees.
In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which creates a new Topic, Accounting Standards Codification Topic 606. The standard is principle-based and provides a five-step model to determine when and how revenue is recognized. The core principle is that a company should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. We adopted ASU 2014-09 as of January 1, 2018 under the modified retrospective approach. Based on our assessment, we have identified all of our revenue streams and concluded rental income from leasing arrangements represents a substantial portion of our revenue. Income from leasing arrangements is specifically excluded from Topic 606 and will be evaluated with the anticipated adoption of ASU 2016-02, Leases. Therefore, the impact of adopting ASU 2014-09 was minimal on our current recognition and presentation of non-lease revenue.
In February 2016, the FASB issued ASU 2016-02, Leases. The update amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets and making targeted changes to lessor accounting. The standard provides the option of a modified retrospective transition approach or a cumulative effect for all leases existing at, or entered into after, the date of initial application, with an option to use certain transition relief. In July 2018, the FASB issued ASU 2018-11, Leases, Targeted Improvements ("ASU 2018-11"). ASU 2018-11 provides entities with a transition method option to not restate comparative periods presented, but to recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. In addition, ASU 2018-11 provides entities with a practical expedient allowing lessors to not separate non-lease components from the associated lease components when certain criteria are met. ASU 2016-02 and ASU 2018-11 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, and early adoption is permitted. We expect to elect these practical expedients and adopt ASC 842 on January 1, 2019. As a result of adopting ASU 2016-02, the Company will recognize all of its operating leases for which it is the lessee, including ground, office, and equipment leases, on its consolidated balance sheets as a lease liability and corresponding right-of-use asset. We have detailed our future minimum lease obligations under non-cancelable leases in Note 12 (Rent Expense).
The Company currently expects that the adoption of ASU 2016-02 will result in recognition of lease liabilities of approximately $64 million and a corresponding right-of-use asset based on the remaining minimum rental payments as of January 1, 2019. The right-of-use asset will be recognized based upon the amount of recognized lease liabilities, adjusted for prepaid lease payments, intangible assets, and right of use impairment charges. The Company has concluded that the initially recognized right of use asset will be approximately $9 million more than the lease liabilities recognized as of January 1, 2019.
83
The Company is finalizing the impact of the adoption of ASU 2016-02 and 2018-11 but has substantially completed the process of estimating the operating lease liabilities based on the remaining rental payments and the Company’s estimate of its incremental borrowing rate. The Company continues to monitor recent accounting pronouncements of the FASB and complete its final evaluation of the impact of the adoption of ASU 2016-02 and ASU 2018-11 on its disclosures.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses, which changes the impairment model for most financial instruments by requiring companies to recognize an allowance for expected losses, rather than incur losses as required currently by the other-than-temporary impairment model. ASU 2016-13 will apply to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables, loans, held-to-maturity debt securities, net investments in leases, and off-balance-sheet credit exposures (e.g., loan commitments). ASU 2016-13 is effective for reporting periods beginning after December 15, 2019, with early adoption permitted, and will be applied as a cumulative adjustment to retained earnings as of the effective date. We are currently assessing the potential effect the adoption of ASU 2016-13 will have on our consolidated financial statements.
In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payment. ASU 2016-15 clarifies the guidance on the classification of certain cash receipts and payments in the statement of cash flows to reduce diversity in practice with respect to: (i) debt prepayment or debt extinguishment costs; (ii) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (iii) contingent consideration payments made after a business combination; (iv) proceeds from the settlement of insurance claims; (v) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (vi) distributions received from equity method investees; (vii) beneficial interests in securitization transactions; and (viii) separately identifiable cash flows and application of the predominance principle. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 with early adoption permitted. The Company adopted ASU 2016-15 on January 1, 2018, with no material effect on its consolidated financial statements and no adjustments made to prior periods.
In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Restricted Cash, which will require companies to include restricted cash with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the statement of cash flows. ASU 2016-18 will require disclosure of a reconciliation between the balance sheet and the statement of cash flows when the balance sheet includes more than one line item for cash, cash equivalents, restricted cash, and restricted cash equivalents. An entity with material restricted cash and restricted cash equivalents balances will be required to disclose the nature of the restrictions. ASU 2016-18 is effective for reporting periods beginning after December 15, 2017 and is required to be applied retrospectively to all periods presented. The Company adopted ASU 2016-18 on January 1, 2018, with no material effect on its consolidated financial statements and no adjustments made to prior periods.
In January 2017, the FASB issued ASU No. 2017-01, Clarifying the Definition of a Business, which changes the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. ASU 2017-01 states that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or group of similar identifiable assets, the set is not a business. If this initial test is not met, a set cannot be considered a business unless it includes an acquired input and a substantive process that together significantly contribute to the ability to create outputs. In addition, ASU 2017-01 clarifies the requirements for a set of activities to be considered a business and narrows the definition of an output. This ASU is to be applied prospectively and is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company adopted ASU 2017-01 on January 1, 2018 and as a result, have classified our real estate acquisitions completed during the year ended December 31, 2018 as asset acquisitions rather than business combinations due to the fact that substantially all of the fair value of the gross assets acquired were concentrated in a single asset or group of similar identifiable assets. The Company has recorded identifiable assets acquired, liabilities assumed, and any noncontrolling interests associated with any asset acquisitions at cost on a relative fair value basis and has capitalized transaction costs incurred.
In May 2017, the FASB issued ASU No. 2017-09, Scope of Modification Accounting, which clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. The standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early adoption permitted. The Company adopted ASU 2017-09 as of January 1, 2018 and there have not been, nor do we anticipate, any reclassification or material impacts on our consolidated financial statements as a result of this adoption.
In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging: Targeted Improvements to Accounting for Hedging Activities, which expands and refines hedge accounting for both nonfinancial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. It also
84
Note 3. Acquisitions and Dispositions
Effective January 1, 2018, with our adoption of ASU 2017-01, transaction costs incurred for asset acquisitions are capitalized as a component of purchase price and all other non-capitalizable costs are reflected in “General and Administrative Expenses” on our consolidated statements of income. Certain acquisitions that occurred prior to January 1, 2018 were accounted for as business combinations.
During 2018, the Company completed the acquisition of 4 operating healthcare properties and 1 land parcel located in 5 states, for an aggregate purchase price of approximately $252.8 million. In addition, the Company completed $11.8 million of loan investments, and a $6.4 million noncontrolling interest buyout, resulting in total investment activity of approximately $271.0 million. The Company also acquired 2 properties and an adjacent land parcel through the conversion and satisfaction of a previously outstanding construction loan, valued at an aggregate $18.8 million. Additionally, the Company acquired 2 parcels of land, which it had previously leased, as the result of a lease restructuring arrangement and equity recapitalization.
Property | Location | Acquisition Date | Purchase Price (in thousands) | |||||||
Hazelwood Medical Commons | (1) | Maplewood, MN | January 9, 2018 | $ | ||||||
Lee's Hill Medical Plaza | Fredericksburg, VA | January 23, 2018 | ||||||||
Scottsdale, Arizona Land | (2) | Scottsdale, AZ | February 16, 2018 | |||||||
Noncontrolling Interest Buyout - Minnesota portfolio | (3) | March 1, 2018 | ||||||||
HMG Medical Plaza | Kingsport, TN | April 3, 2018 | ||||||||
Northside Medical Midtown MOB | Atlanta, GA | September 14, 2018 | ||||||||
Loan Investments | (4) | Various | Various | |||||||
$ | ||||||||||
(1) | The Company partially funded the purchase price of this acquisition by issuing a total of |
(2) | The Company acquired the land beneath a previously acquired facility. |
(3) | The Company acquired an additional |
(4) |
During 2018, the Company recorded revenues and net income of $14.7 million and $5.4 million, respectively, from its 2018 acquisitions.
During 2017, the Company completed acquisitions of 40 properties, 2 condominium units, and 1 parking deck located in 15 states, for an aggregate purchase price of approximately $1.37 billion. In addition, the Company completed $39.1 million of loan investments, $1.1 million of redeemable noncontrolling interest buyouts, and $2.8 million of noncontrolling interest buyouts, resulting in total investment activity of approximately $1.41 billion.
85
Investment activity for the year ending December 31, 2017 is summarized below:
Property (1) | Location | Acquisition Date | Purchase Price (in thousands) | |||||||
Orthopedic Associates | (2) | Flower Mound, TX | January 5, 2017 | $ | ||||||
Medical Arts Center at Hartford | (2) | Plainville, CT | January 11, 2017 | |||||||
Noncontrolling Interest Buyout - New Albany | (3) | New Albany, OH | January 31, 2017 | |||||||
CareMount - Lake Katrine MOB | (2) | (4) | Lake Katrine, NY | February 14, 2017 | ||||||
CareMount - Rhinebeck MOB | (2) | Rhinebeck, NY | February 14, 2017 | |||||||
Syracuse Condos | (2) | Fayetteville & Liverpool, NY | February 27, 2017 | |||||||
Monterey Medical Center - MOB | (2) | Stuart, FL | March 7, 2017 | |||||||
Creighton University Medical Center | (5) | Omaha, NE | March 28, 2017 | |||||||
Strictly Pediatrics Specialty Center | (2) | (6) | Austin, TX | March 31, 2017 | ||||||
MedStar Stephen's Crossing | (2) | Brandywine, MD | June 16, 2017 | |||||||
2017 CHI Portfolio - Tranche 1 (8 MOBs) | (5) | AR, MN, ND, NE, TN, TX | June 29, 2017 | |||||||
St. Vincent Portfolio (2 MOBs) | (2) | Carmel & Fishers, IN | June 29, 2017 | |||||||
Baylor Charles A. Sammons Cancer Center | (2) | Dallas, TX | June 30, 2017 | |||||||
Orthopedic & Sports Institute of the Fox Valley | (7) | Appleton, WI | June 30, 2017 | |||||||
Peachtree Dunwoody Medical Center - Parking Deck | (7) | Atlanta, GA | June 30, 2017 | |||||||
Clearview Cancer Institute | (2) | Huntsville, AL | August 4, 2017 | |||||||
Northside Cherokee/Town Lake MOB | (2) | Atlanta, GA | August 15, 2017 | |||||||
HonorHealth Mesa MOB | (2) | Mesa, AZ | August 15, 2017 | |||||||
2017 CHI Portfolio - Tranche 2 (5 MOBs) | (5) | AR, MN, NE, TX | August 24, 2017 & August 31, 2017 | |||||||
Noncontrolling Interest Buyout - Great Falls Clinic | (8) | Great Falls, MT | September 21, 2017 | |||||||
Legends Park MOB & ASC | (2) | Midland, TX | September 27, 2017 | |||||||
Franklin MOB & ASC | (2) | Franklin, TN | October 12, 2017 | |||||||
Eagle Point MOB | (2) | Lake Elmo, MN | October 31, 2017 | |||||||
Edina East MOB | (2) | Edina, MN | October 31, 2017 | |||||||
Northside MOB - Center Pointe | (2) | Atlanta, GA | November 10, 2017 | |||||||
Gwinnett 500 Building | (2) | Lawrenceville, GA | November 17, 2017 | |||||||
Hudgens Professional Building | (2) | Duluth, GA | November 17, 2017 | |||||||
St. Vincent Building | (2) | Indianapolis, IN | November 17, 2017 | |||||||
Gwinnett Physicians Center | (2) | (9) | Lawrenceville, GA | December 1, 2017 | ||||||
Apple Valley Medical Center | (2) | Apple Valley, MN | December 18, 2017 | |||||||
Desert Cove MOB | (2) | (10) | Scottsdale, AZ | December 18, 2017 | ||||||
Westgate MOB | (2) | Glendale, AZ | December 21, 2017 | |||||||
Loan Investments | (11) | Various | Various | |||||||
$ | ||||||||||
(1) | “MOB” means medical office building. “ASC” means ambulatory surgical center. |
(2) | The Company accounted for these acquisitions as business combinations pursuant to the acquisition method and expensed total acquisition costs of $ |
(3) | The Company acquired the previously outstanding interest in the New Albany MOB from the predecessor owner. As consideration, the Operating Partnership paid approximately $ |
(4) | The Company partially funded this acquisition through the assumption of an existing mortgage valued at approximately $ |
86
(5) | These acquisitions are part of the CHI portfolio. The Company accounted for nine of these facilities, consisting of an aggregate purchase price of $ |
(6) | The Company partially funded the purchase price of this acquisition by issuing a total of |
(7) | The Company accounted for these acquisitions as asset acquisitions and capitalized total acquisition costs of $ |
(8) | The Company acquired an additional |
(9) | As part of this acquisition, the Company assumed a $ |
(10) | The Company acquired an additional |
(11) |
For 2017, the Company recorded revenues and net income of $49.6 million and $8.6 million, respectively, from its 2017 acquisitions.
December 31, 2018 | December 31, 2017 | ||||||
Land | $ | $ | |||||
Building and improvements | |||||||
In-place lease intangible | |||||||
Above market in-place lease intangible | |||||||
Below market in-place lease intangible | ( | ) | ( | ) | |||
Above market in-place ground lease | ( | ) | |||||
Below market in-place ground lease | |||||||
Contingent consideration | ( | ) | |||||
Receivable | |||||||
Debt assumed | ( | ) | |||||
Issuance of OP Units | ( | ) | |||||
Investment in unconsolidated entity | ( | ) | |||||
Mortgage escrow | |||||||
Prepaid expenses | ( | ) | |||||
Issuance of Series A Preferred Units | ( | ) | |||||
Net assets acquired | $ | $ | |||||
Dispositions
On February 16, 2018, the Company sold 1 medical office building located in Florida for approximately $1.4 million and recognized a net loss on the sale of approximately $0.1 million. On March 30, 2018, the Company sold 1 medical office building located in Michigan for approximately $1.1 million and recognized a net gain on the sale of approximately $0.1 million. On June 28, 2018, the Company sold 15 medical office buildings located in 3 states for approximately $90.7 million and recognized a net loss on the sale of approximately $2.6 million. On July 27, 2018, the Company sold 17 medical office buildings located in 7 states for approximately $127.2 million and recognized a net gain on the sale of approximately $14.2 million.
87
Year Ended December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Revenue | $ | $ | $ | ||||||||
Income before gain on sale of investment properties, net | $ | $ | $ | ||||||||
Gain on sale of investment properties, net | |||||||||||
Net income | $ | $ | $ | ||||||||
The following table summarizes revenues and net income related to the 2017 disposition properties for the periods presented (in thousands):
Year Ended December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Revenue | $ | $ | $ | ||||||||
Income before gain on sale of investment properties, net | $ | $ | $ | ||||||||
Gain on sale of investment properties, net | |||||||||||
Net income | $ | $ | $ | ||||||||
Note 4. Intangibles
December 31, 2018 | December 31, 2017 | ||||||||||||||||||||||
Cost | Accumulated Amortization | Net | Cost | Accumulated Amortization | Net | ||||||||||||||||||
Assets | |||||||||||||||||||||||
In-place leases | $ | $ | ( | ) | $ | $ | $ | ( | ) | $ | |||||||||||||
Above-market leases | ( | ) | ( | ) | |||||||||||||||||||
Leasehold interest | ( | ) | ( | ) | |||||||||||||||||||
Below-market ground lease | ( | ) | ( | ) | |||||||||||||||||||
Total | $ | $ | ( | ) | $ | $ | $ | ( | ) | $ | |||||||||||||
Liabilities | |||||||||||||||||||||||
Below-market lease | $ | $ | ( | ) | $ | $ | $ | ( | ) | $ | |||||||||||||
Above-market ground lease | ( | ) | ( | ) | |||||||||||||||||||
Total | $ | $ | ( | ) | $ | $ | $ | ( | ) | $ | |||||||||||||
December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Amortization expense related to in-place leases | $ | $ | $ | ||||||||
Decrease of rental income related to above-market leases | |||||||||||
Decrease of rental income related to leasehold interests | |||||||||||
Increase of rental income related to below-market leases | |||||||||||
Decrease of operating expense related to above-market ground leases | |||||||||||
Increase in operating expense related to below-market ground leases | |||||||||||
88
For the year ended December 31, 2018, the Company wrote off in-place lease intangibles of $9.6 million, net of previously recognized accumulated amortization, which included $6.6 million related to a lease termination. In addition, the Company had amortization of $11.9 million related to assets sold during the twelve months ended December 31, 2018.
Net Decrease in Revenue | Net Increase in Expenses | ||||||
2019 | $ | ( | ) | $ | |||
2020 | ( | ) | |||||
2021 | ( | ) | |||||
2022 | ( | ) | |||||
2023 | ( | ) | |||||
Thereafter | ( | ) | |||||
Total | $ | ( | ) | $ | |||
Note 5. Other Assets
December 31, | |||||||
2018 | 2017 | ||||||
Straight-line rent receivable, net | $ | $ | |||||
Notes receivable | |||||||
Prepaid expenses | |||||||
Interest rate swap | |||||||
Lease inducements, net | |||||||
Leasing commissions, net | |||||||
Escrows | |||||||
Earnest deposits | |||||||
Other | |||||||
Total | $ | $ | |||||
89
Note 6. Debt
December 31, | ||||||||
2018 | 2017 | |||||||
Fixed interest mortgage notes | $ | (1) | $ | (2) | ||||
Variable interest mortgage notes | (3) | (4) | ||||||
Total mortgage debt | ||||||||
$850 million unsecured revolving credit facility bearing variable interest of LIBOR plus 1.10% at December 31, 2018 and LIBOR plus 1.20% at December 30, 2017, due September 2022 | ||||||||
$400 million senior unsecured notes bearing fixed interest of 4.30%, due March 2027 | ||||||||
$350 million senior unsecured notes bearing fixed interest of 3.95%, due January 2028 | ||||||||
$250 million unsecured term borrowing bearing fixed interest of 2.32% at December 31, 2018 and 2.87% at December 31, 2017, due June 2023 | (5) | (6) | ||||||
$150 million senior unsecured notes bearing fixed interest of 4.03% to 4.74%, due January 2023 to 2031 | ||||||||
$75 million senior unsecured notes bearing fixed interest of 4.09% to 4.24%, due August 2025 to 2027 | ||||||||
Total principal | ||||||||
Unamortized deferred financing costs | ( | ) | ( | ) | ||||
Unamortized discounts | ( | ) | ( | ) | ||||
Unamortized fair value adjustments | ||||||||
Total debt | $ | $ | ||||||
(1) | Fixed interest mortgage notes, bearing interest from |
(2) | Fixed interest mortgage notes, bearing interest from |
(3) | Variable interest mortgage note, bearing variable interest of LIBOR plus |
(4) | Variable interest mortgage notes bearing variable interest of LIBOR plus |
(5) | The Trust’s borrowings under the term loan feature of the Credit Agreement bear interest at a rate which is determined by the Trust’s credit rating, currently equal to LIBOR + 1.25%. The Trust has entered into a pay-fixed receive-variable interest rate swap, fixing the LIBOR component of this rate at |
(6) |
On August 7, 2018, the Operating Partnership, as borrower, and the Trust, as guarantor, executed a Second Amended and Restated Credit Agreement (the “Credit Agreement”) which extended the maturity date of the revolving credit facility under the Credit Agreement to September 18, 2022 and reduced the interest rate margin applicable to borrowings. The Credit Agreement includes unsecured revolving credit facility of $850 million and contains a term loan feature of $250 million, bringing total borrowing capacity to $1.1 billion. The Credit Agreement also includes a swingline loan commitment for up to 10 % of the maximum principal amount and provides an accordion feature allowing the Trust to increase borrowing capacity by up to an additional $500 million, subject to customary terms and conditions, resulting in a maximum borrowing capacity of $1.6 billion. The revolving credit facility under the Credit Agreement also includes a one-year extension option.
Borrowings under the Credit Agreement bear interest on the outstanding principal amount at an adjusted LIBOR rate, which is based on the Trust’s investment grade rating under the Credit Agreement. As of December 31, 2018, the Trust had an investment grade rating of Baa3 from Moody’s and BBB- from S&P. As such, borrowings under the revolving credit facility of
90
the Credit Agreement accrue interest on the outstanding principal at a rate of LIBOR + 1.10 %. The Credit Agreement includes a facility fee equal to 0.25 % per annum, which is also determined by the Trust’s investment grade rating.
On July 7, 2016, the Operating Partnership borrowed $250.0 million under the 7 -year term loan feature of the Credit Agreement. Pursuant to the credit agreement, borrowings under the term loan feature of the Credit Agreement bear interest on the outstanding principal amount at a rate which is determined by the Trust’s credit rating, currently equal to LIBOR + 1.25 %. The Trust simultaneously entered into a pay-fixed receive-variable rate swap for the full borrowing amount, fixing the LIBOR component of the borrowing rate to 1.07 %, for a current all-in fixed rate of 2.32 %. As of December 31, 2018, both the borrowing and pay-fixed receive-variable swap have a maturity date of June 10, 2023.
Credit Rating | Margin for Revolving Loans: Adjusted LIBOR Rate Loans and Letter of Credit Fee | Margin for Revolving Loans: Base Rate Loans | Margin for Term Loans: Adjusted LIBOR Rate Loans and Letter of Credit Fee | Margin for Term Loans: Base Rate Loans | ||||||
At Least A- or A3 | LIBOR + 0.775% | % | LIBOR + 0.85% | % | ||||||
At Least BBB+ or Baa1 | LIBOR + 0.825% | % | LIBOR + 0.90% | % | ||||||
At Least BBB or Baa2 | LIBOR + 0.90% | % | LIBOR + 1.00% | % | ||||||
At Least BBB- or Baa3 | LIBOR + 1.10% | % | LIBOR + 1.25% | % | ||||||
Below BBB- or Baa3 | LIBOR + 1.45% | % | LIBOR + 1.65% | % | ||||||
The Credit Agreement contains financial covenants that, among other things, require compliance with leverage and coverage ratios and maintenance of minimum tangible net worth, as well as covenants that may limit the Trust’s and the Operating Partnership’s ability to incur additional debt, grant liens, or make distributions. The Company may, at any time, voluntarily prepay any revolving or term loan under the Credit Agreement in whole or in part without premium or penalty. As of December 31, 2018, the Company was in compliance with all financial covenants related to the Credit Agreement.
The Credit Agreement includes customary representations and warranties by the Trust and the Operating Partnership and imposes customary covenants on the Operating Partnership and the Trust. The Credit Agreement also contains customary events of default, and if an event of default occurs and continues, the Operating Partnership is subject to certain actions by the administrative agent, including without limitation, the acceleration of repayment of all amounts outstanding under the Credit Agreement.
As of December 31, 2018, the Company had $215.0 million of borrowings outstanding under its unsecured revolving credit facility, and $250.0 million of borrowings outstanding under the term loan feature of the Credit Agreement. The Company has also issued a letter of credit for $17.0 million with no outstanding balance as of December 31, 2018. As defined by the Credit Agreement, $618.0 million is available to borrow without adding additional properties to the unencumbered borrowing base of assets.
Notes Payable
On January 7, 2016, the Operating Partnership issued and sold $150.0 million aggregate principal amount of senior notes, comprised of (i) $15.0 million aggregate principal amount of 4.03 % Senior Notes, Series A, due January 7, 2023, (ii) $45.0 million aggregate principal amount of 4.43 % Senior Notes, Series B, due January 7, 2026, (iii) $45.0 million aggregate principal amount of 4.57 % Senior Notes, Series C, due January 7, 2028, and (iv) $45.0 million aggregate principal amount of 4.74 % Senior Notes, Series D, due January 7, 2031. On August 11, 2016, the note agreement for these notes was amended to make certain changes to its terms, including certain changes to affirmative covenants, negative covenants, and definitions contained therein. Interest on each respective series of the January 2016 Senior Notes is payable semi-annually.
On August 11, 2016, the Operating Partnership issued and sold $75.0 million aggregate principal amount of senior notes, comprised of (i) $25.0 million aggregate principal amount of 4.09 % Senior Notes, Series A, due August 11, 2025, (ii) $25.0 million aggregate principal amount of 4.18 % Senior Notes, Series B, due August 11, 2026, and (iii) $25.0 million aggregate principal amount of 4.24 % Senior Notes, Series C, due August 11, 2027. Interest on each respective series of the August 2016 Senior Notes is payable semi-annually.
On March 7, 2017, the Operating Partnership issued and sold $400.0 million aggregate principal amount of 4.30 % Senior Notes which will mature on March 15, 2027. The Senior Notes began accruing interest on March 7, 2017 and began paying interest semi-annually beginning September 15, 2017. The Senior Notes were sold at an issue price of 99.68 % of their
91
face value, before the underwriters’ discount. Our net proceeds from the offering, after deducting underwriting discounts and expenses, were approximately $396.1 million.
On December 1, 2017, the Operating Partnership issued and sold $350.0 million aggregate principal amount of 3.95 % Senior Notes which will mature on January 15, 2028. The Senior Notes began accruing interest on December 1, 2017 and began paying interest semi-annually beginning July 15, 2018. The Senior Notes were sold at an issue price of 99.78 % of their face value, before the underwriters’ discount. Our net proceeds from the offering, after deducting underwriting discounts and expenses, were approximately $347.0 million.
Certain properties have mortgage debt that contains financial covenants. As of December 31, 2018, the Trust was in compliance with all senior notes and mortgage debt financial covenants.
2019 | $ | ||
2020 | |||
2021 | |||
2022 | |||
2023 | |||
Thereafter | |||
Total Payments | $ | ||
Note 7. Derivatives
In the normal course of business, a variety of financial instruments are used to manage or hedge interest rate risk. The Company has implemented ASC 815, Derivatives and Hedging (“ASC 815”), which establishes accounting and reporting standards requiring that all derivatives, including certain derivative instruments embedded in other contracts, be recorded as either an asset or a liability measured at their fair value unless they qualify for a normal purchase or normal sales exception.
When specific hedge accounting criteria are not met, ASC 815 requires that changes in a derivative’s fair value be recognized currently in earnings. Changes in the fair market values of the Company’s derivative instruments are recorded in the consolidated statements of income if such derivatives do not qualify for, or the Company does not elect to apply for, hedge accounting. If hedge accounting is applied to a derivative instrument, such changes are reported in accumulated other comprehensive income within the consolidated statements of equity, exclusive of ineffectiveness amounts, which are recognized as adjustments to net income.
To manage interest rate risk for certain of its variable-rate debt, the Company uses interest rate swaps as part of its risk management strategy. These derivatives are designed to mitigate the risk of future interest rate increases by providing a fixed interest rate for a limited, pre-determined period of time. Interest rate swaps designated as cash flow hedges involve the receipt of variable-rate amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. As of December 31, 2018, the Company had five outstanding interest rate swap contracts that are designated as cash flow hedges of interest rate risk. For presentational purposes, they are shown as one derivative due to the identical nature of their economic terms.
The effective portion of the change in the fair value of derivatives designated and that qualify as cash flow hedges is recorded in accumulated other comprehensive income on the consolidated balance sheets and is subsequently reclassified into earnings as interest expense for the period that the hedged forecasted transaction affects earnings. The ineffective portion of the change in fair value of the derivatives is recognized directly in earnings. For the year ended December 31, 2018 hedge ineffectiveness was insignificant. The Company expects hedge ineffectiveness to be insignificant in the next 12 months.
92
Total notional amount | $ | |||
Effective fixed interest rate | (1) | % | ||
Effective date | ||||
Maturity date | ||||
Asset balance at December 31, 2018 (included in Other assets) | $ | |||
Asset balance at December 31, 2017 (included in Other assets) | $ | |||
(1) |
Note 8. Accrued Expenses and Other Liabilities
December 31, | |||||||
2018 | 2017 | ||||||
Real estate taxes payable | $ | $ | |||||
Prepaid rent | |||||||
Accrued interest | |||||||
Accrued expenses | |||||||
Embedded derivative | |||||||
Security deposits | |||||||
Tenant improvement allowance | |||||||
Accrued incentive compensation | |||||||
Contingent consideration | |||||||
Other | |||||||
Total | $ | $ | |||||
Note 9. Stock-based Compensation
The Company follows ASC 718, Compensation - Stock Compensation (“ASC 718”), in accounting for its share-based payments. This guidance requires measurement of the cost of employee services received in exchange for stock compensation based on the grant-date fair value of the employee stock awards. This cost is recognized as compensation expense ratably over the employee’s requisite service period. Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized when incurred. Share-based payments classified as liability awards are marked to fair value at each reporting period. Any common shares issued pursuant to the Company's incentive equity compensation and employee stock purchase plans will result in the Operating Partnership issuing OP Units to the Trust on a one-for-one basis, with the Operating Partnership receiving the net cash proceeds of such issuances.
Certain of the Company’s employee stock awards vest only upon the achievement of performance targets. ASC 718 requires recognition of compensation cost only when achievement of performance conditions is considered probable. Consequently, the Company’s determination of the amount of stock compensation expense requires a significant level of judgment in estimating the probability of achievement of these performance targets. Subsequent changes in actual experience are monitored and estimates are updated as information is available.
In connection with the IPO, the Trust adopted the 2013 Equity Incentive Plan (“2013 Plan”), which made available 600,000 common shares to be administered by the Compensation Committee of the Board of Trustees. On August 7, 2014, at the Annual Meeting of Shareholders of Physicians Realty Trust, the Trust’s shareholders approved an amendment to the 2013 Plan to increase the number of common shares authorized for issuance under the 2013 Plan by 1,850,000 common shares, for a total of 2,450,000 common shares authorized for issuance.
93
Restricted Common Shares:
Restricted common shares granted under the 2013 Plan are eligible for dividends as well as the right to vote. During 2016, a total of 155,306 restricted common shares with a total value of $2.8 million were granted to Company employees with vesting periods ranging from one to three years. During 2017, the Trust granted a total of 143,593 restricted common shares with a total value of $2.8 million to the Company’s officers and certain of its employees, which have a one-year vesting period for senior management award-recipients and a three-year vesting period for employee award-recipients. During 2018, the Trust granted a total of 206,446 restricted common shares with a total value of $3.1 million to the Company’s officers and certain of its employees, which have a one-year vesting period for senior management award-recipients and a three-year vesting period for employee award-recipients.
Common Shares | Weighted Average Grant Date Fair Value | |||||
Non-vested at December 31, 2015 | $ | |||||
Granted | ||||||
Vested | ( | ) | ||||
Forfeited | ( | ) | ||||
Non-vested at December 31, 2016 | ||||||
Granted | ||||||
Vested | ( | ) | ||||
Forfeited | ( | ) | ||||
Non-vested at December 31, 2017 | ||||||
Granted | ||||||
Vested | ( | ) | ||||
Forfeited | ( | ) | ||||
Non-vested at December 31, 2018 | $ | |||||
For all service awards, the Company records compensation expense for the entire award on a straight-line basis over the requisite service period. For the years ended December 31, 2018, 2017, and 2016 the Company recognized non-cash share compensation of $3.1 million, $3.1 million, and $3.6 million, respectively. Unrecognized compensation expense at December 31, 2018, 2017, and 2016 was $1.0 million, $1.0 million, and $1.2 million, respectively.
Restricted Share Units:
In March 2018, March 2017, and March 2016 under the Trust’s 2013 Plan, the Trust granted (i) restricted share units at a target level of 254,282 , 174,320 , and 104,553 respectively, to the Trust’s senior management, which are subject to certain performance and market conditions and a three-year service period and (ii) 50,745 , 32,831 , and 36,784 restricted share units, respectively, to the members of the Board of Trustees, which are subject to a two-year vesting period. Each restricted share unit contains one dividend equivalent. The recipient will accrue dividend equivalents on awarded share units equal to the cash dividend that would have been paid on the awarded share unit had the awarded share unit been an issued and outstanding common share on the record date for the dividend.
94
Approximately 40 % of the restricted share units issued to officers in 2018, 70 % issued to officers in 2017, and 80 % issued to officers in 2016, vest based on certain market conditions. The market conditions were valued with the assistance of independent valuation specialists. The Company utilized a Monte Carlo simulation to calculate the weighted average grant date fair values in 2018, 2017, and 2016 of $19.28 , $33.43 , and $28.50 per unit, respectively, using the following assumptions:
2018 | 2017 | 2016 | |||||||||
Volatility | % | % | % | ||||||||
Dividend assumption | reinvested | reinvested | reinvested | ||||||||
Expected term in years | |||||||||||
Risk-free rate | % | % | % | ||||||||
Stock price (per share) | $ | $ | $ | ||||||||
The remaining 60 % of the restricted share units issued to officers in 2018, 30 % issued to officers in 2017, and 20 % issued to officers in 2016, vest based upon certain performance conditions. With respect to the performance conditions of the March 2018 grant, the grant date fair value of $14.78 per unit was based on the share price at the date of grant. The combined weighted average grant date fair value of the March 2018 restricted share units issued to officers is $16.58 per unit. With respect to the performance conditions of the March 2017 grant, the grant date fair value of $19.80 per unit was based on the share price at the date of grant. The combined weighted average grant date fair value of the March 2017 restricted share units issued to officers is $29.34 per unit. With respect to the performance conditions of the March 2016 grant, the grant date fair value of $17.67 per unit was based on the share price at the date of grant. The combined weighted average grant date fair value of the March 2016 restricted share units issued to officers is $26.33 per unit.
Executive Awards | Trustee Awards | ||||||||||||
Restricted Share Units | Weighted Average Grant Date Fair Value | Restricted Share Units | Weighted Average Grant Date Fair Value | ||||||||||
Non-vested at December 31, 2015 | $ | $ | |||||||||||
Granted | |||||||||||||
Vested | ( | ) | |||||||||||
Non-vested at December 31, 2016 | |||||||||||||
Granted | |||||||||||||
Vested | ( | ) | (1) | ( | ) | ||||||||
Non-vested at December 31, 2017 | |||||||||||||
Granted | |||||||||||||
Vested | ( | ) | (2) | ( | ) | ||||||||
Non-vested at December 31, 2018 | $ | $ | |||||||||||
(1) | Restricted units vested by Company executives in 2017 resulted in the issuance of |
(2) |
Note 10. Fair Value Measurements
ASC Topic 820, Fair Value Measurement (“ASC 820”), requires certain assets and liabilities be reported and/or disclosed at fair value in the financial statements and provides a framework for establishing that fair value. The framework for determining fair value is based on a hierarchy that prioritizes the valuation techniques and inputs used to measure fair value.
In general, fair values determined by Level 1 inputs use quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Fair values determined by Level 2 inputs use other inputs that are
95
observable, either directly or indirectly. These Level 2 inputs include quoted prices for similar assets and liabilities in active markets, and other inputs such as interest rates and yield curves that are observable at commonly quoted intervals.
Level 3 inputs are unobservable inputs, including inputs that are available in situations where there is little, if any, market activity for the related asset. These Level 3 fair value measurements are based primarily on management’s own estimates using pricing models, discounted cash flow methodologies, or similar techniques taking into account the characteristics of the asset or liability. In instances where inputs used to measure fair value fall into different levels of the fair value hierarchy, fair value measurements in their entirety are categorized based on the lowest level input that is significant to the valuation. The assessment of the significance of particular inputs to these fair value measurements requires judgment and considers factors specific to each asset or liability. As part of the Company’s acquisition process, Level 3 inputs are used to measure the fair value of the assets acquired and liabilities assumed.
The Company’s derivative instruments as of December 31, 2018, consist of one embedded derivative as detailed in the Redeemable Noncontrolling Interests - Series A Preferred Units and Partially Owned Properties section of Note 2 (Summary of Significant Accounting Policies) and five interest rate swaps. For presentational purposes, the Company’s interest rate swaps are shown as a single derivative due to the identical nature of their economic terms, as detailed in the Derivative Instruments section of Note 2 (Summary of Significant Accounting Policies) and Note 7 (Derivatives).
Neither the embedded derivative nor the interest rate swaps are traded on an exchange. The Company’s derivative assets and liabilities are recorded at fair value based on a variety of observable inputs including contractual terms, interest rate curves, yield curves, measure of volatility, and correlations of such inputs. The Company measures its derivatives at fair value on a recurring basis. The fair values are based on Level 2 inputs described above. The Company considers its own credit risk, as well as the credit risk of its counterparties, when evaluating the fair value of its derivatives.
The Company also has assets that under certain conditions are subject to measurement at fair value on a non-recurring basis. This generally includes assets subject to impairment. There were no assets measured at fair value as of December 31, 2018.
The carrying amounts of cash and cash equivalents, tenant receivables, payables, and accrued interest are reasonable estimates of fair value because of the short term maturities of these instruments. Fair values for real estate loans receivable and mortgage debt are estimated based on rates currently prevailing for similar instruments of similar maturities and are based primarily on Level 2 inputs.
December 31, | |||||||||||||||
2018 | 2017 | ||||||||||||||
Carrying Amount | Fair Value | Carrying Amount | Fair Value | ||||||||||||
Assets: | |||||||||||||||
Real estate loans receivable | $ | $ | $ | $ | |||||||||||
Note receivable | $ | $ | $ | $ | |||||||||||
Derivative assets | $ | $ | $ | $ | |||||||||||
Liabilities: | |||||||||||||||
Credit facility | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Notes payable | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
Mortgage debt | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
96
Note 11. Tenant Operating Leases
The Company is lessor of medical office buildings and other healthcare facilities. Leases have expirations from 2019 through 2039. As of December 31, 2018, the future minimum rental payments on non-cancelable leases, exclusive of expense recoveries, were as follows (in thousands):
2019 | $ | ||
2020 | |||
2021 | |||
2022 | |||
2023 | |||
Thereafter | |||
Total | $ | ||
Note 12. Rent Expense
The Company leases the rights to parking structures at 3 of its properties, the air space above 1 property, and the land upon which 76 of its properties are located from third party land owners pursuant to separate leases. In addition, the Company leases 5 individual office spaces. The leases require fixed rental payments and may also include escalation clauses and renewal options. These leases have terms of up to 87 years remaining, excluding extension options. As of December 31, 2018, the future minimum lease obligations under non-cancelable parking, air, ground, and office leases were as follows (in thousands):
2019 | $ | ||
2020 | |||
2021 | |||
2022 | |||
2023 | |||
Thereafter | |||
Total | $ | ||
Note 13. Credit Concentration
The Company uses annualized base rent (“ABR”) as its credit concentration metric. Annualized base rent is calculated by multiplying contractual base rent for the month ended December 31, 2018 by 12, excluding the impact of concessions and straight-line rent. The following table summarizes certain information about the Company’s top five tenant credit concentrations as of December 31, 2018 (in thousands):
Tenant | Total ABR | Percent of ABR | |||||
CHI - Nebraska | $ | % | |||||
CHI - KentuckyOne Health | % | ||||||
Northside Hospital | % | ||||||
Baylor Scott and White Health | % | ||||||
Ascension - St. Vincent's - Indianapolis | % | ||||||
Remaining portfolio | % | ||||||
Total | $ | % | |||||
97
Annualized base rent collected from the Company’s top five tenant relationships comprises 19.2 % of its total annualized base rent for the period ending December 31, 2018. Total annualized base rent from CHI affiliated tenants totals 19.2 %, including the affiliates disclosed above. Although CHI is not a party to nor a guarantor of the related lease agreements, it controls each of the subsidiaries and the affiliates that are parties to the master lease agreements, which were entered into in connection with the closing of the transactions. Consolidated financial statements of CHI, the parent of the subsidiaries and affiliates of the entities party to master lease agreements, are publicly available on the Catholic Health Initiatives website (http://www.catholichealthinitiatives.org/). Information included on the CHI website is not incorporated by reference within this Annual Report on Form 10-K.
State | Total ABR | Percent of ABR | |||||
Texas | $ | % | |||||
Georgia | % | ||||||
Indiana | % | ||||||
Nebraska | % | ||||||
Minnesota | % | ||||||
Other | % | ||||||
Total | $ | % | |||||
Note 14. Earnings Per Share and Earnings Per Unit
Year Ended December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Numerator for earnings per share - basic: | |||||||||||
Net income | $ | $ | $ | ||||||||
Net income attributable to noncontrolling interests: | |||||||||||
Operating Partnership | ( | ) | ( | ) | ( | ) | |||||
Partially owned properties | ( | ) | ( | ) | ( | ) | |||||
Preferred distributions | ( | ) | ( | ) | ( | ) | |||||
Numerator for earnings per share - basic: | $ | $ | $ | ||||||||
Numerator for earnings per share - diluted: | |||||||||||
Numerator for earnings per share - basic: | |||||||||||
Operating Partnership net income | |||||||||||
Numerator for earnings per share - diluted | $ | $ | $ | ||||||||
Denominator for earnings per share - basic and diluted: | |||||||||||
Weighted average number of shares outstanding - basic | |||||||||||
Effect of dilutive securities: | |||||||||||
Noncontrolling interest - Operating Partnership units | |||||||||||
Restricted common shares | |||||||||||
Restricted share units | |||||||||||
Denominator for earnings per share - diluted | |||||||||||
Earnings per share - basic | $ | $ | $ | ||||||||
Earnings per share - diluted | $ | $ | $ | ||||||||
98
Year Ended December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Numerator for earnings per unit - basic and diluted: | |||||||||||
Net income | $ | $ | $ | ||||||||
Net income attributable to noncontrolling interests - partially owned properties | ( | ) | ( | ) | ( | ) | |||||
Preferred distributions | ( | ) | ( | ) | ( | ) | |||||
Numerator for earnings per unit - basic and diluted | $ | $ | $ | ||||||||
Denominator for earnings per unit - basic and diluted: | |||||||||||
Weighted average number of units outstanding - basic | |||||||||||
Effect of dilutive securities: | |||||||||||
Restricted common shares | |||||||||||
Restricted share units | |||||||||||
Denominator for earnings per unit - diluted | |||||||||||
Earnings per unit - basic | $ | $ | $ | ||||||||
Earnings per unit - diluted | $ | $ | $ | ||||||||
Note 15. Subsequent Events
On January 18, 2019, the Company made a construction loan to finance the construction of a 27,000 square foot cancer center in Denton, Texas up to $15.5 million. The loan bears interest at a rate of 5.50 % on the outstanding principal balance during construction and 6.25 % following substantial completion. The 100 % pre-leased development is located across the street from the 208 -bed Texas Health Presbyterian Hospital Denton campus. As of February 22, 2019, $5.0 million has been funded under the construction loan facility.
On February 13, 2019, the Company funded a $15.0 million term loan that is secured by a first mortgage on real estate being developed in Columbus, Ohio and by a full recourse guaranty. The loan bears interest at a rate of 8.5 % during its one-year term.
99
Note 16. Quarterly Data (Unaudited)
Physicians Realty Trust
The following unaudited quarterly data has been prepared on the basis of a December 31 year-end. Amounts are in thousands, except for common share and per share amounts.
Quarter Ended | ||||||||||||||||
2018 | March 31 | June 30 | September 30 | December 31 | ||||||||||||
Total revenues | $ | $ | $ | $ | ||||||||||||
Net income | ||||||||||||||||
Net income attributable to common shareholders | ||||||||||||||||
Earnings per share – basic: | ||||||||||||||||
Net income available to common shareholders | $ | $ | $ | $ | ||||||||||||
Weighted average number of shares outstanding | ||||||||||||||||
Earnings per share – diluted: | ||||||||||||||||
Net income available to common shareholders | $ | $ | $ | $ | ||||||||||||
Weighted average number of shares outstanding | ||||||||||||||||
Quarter Ended | ||||||||||||||||
2017 | March 31 | June 30 | September 30 | December 31 | ||||||||||||
Total revenues | $ | $ | $ | $ | ||||||||||||
Net income | ||||||||||||||||
Net income available to common shareholders | ||||||||||||||||
Earnings per share – basic: | ||||||||||||||||
Net income available to common shareholders | $ | $ | $ | $ | ||||||||||||
Weighted average number of shares outstanding | ||||||||||||||||
Earnings per share – diluted: | ||||||||||||||||
Net income available to common shareholders | $ | $ | $ | $ | ||||||||||||
Weighted average number of shares outstanding | ||||||||||||||||
100
Physicians Realty L.P.
As a result of the acquisition activity and equity offerings throughout 2018 and 2017, the quarterly periods are not comparable quarter over quarter.
Quarter Ended | ||||||||||||||||
2018 | March 31 | June 30 | September 30 | December 31 | ||||||||||||
Total revenues | $ | $ | $ | $ | ||||||||||||
Net income | ||||||||||||||||
Net income attributable to common unitholders | ||||||||||||||||
Earnings per unit – basic: | ||||||||||||||||
Net income available to common unitholders | $ | $ | $ | $ | ||||||||||||
Weighted average number of units outstanding | ||||||||||||||||
Earnings per unit – diluted: | ||||||||||||||||
Net income available to common unitholders | $ | $ | $ | $ | ||||||||||||
Weighted average number of units outstanding | ||||||||||||||||
Quarter Ended | ||||||||||||||||
2017 | March 31 | June 30 | September 30 | December 31 | ||||||||||||
Total revenues | $ | $ | $ | $ | ||||||||||||
Net income | ||||||||||||||||
Net income attributable to common unitholders | ||||||||||||||||
Earnings per unit – basic: | ||||||||||||||||
Net income available to common unitholders | $ | $ | $ | $ | ||||||||||||
Weighted average number of units outstanding | ||||||||||||||||
Earnings per unit – diluted: | ||||||||||||||||
Net income available to common unitholders | $ | $ | $ | $ | ||||||||||||
Weighted average number of units outstanding | ||||||||||||||||
101
Physicians Realty Trust and Physicians Realty L.P.
Schedule III – Real Estate and Accumulated Depreciation
December 31, 2018
(dollars in thousands)
102
Physicians Realty Trust and Physicians Realty L.P.
Schedule III – Real Estate and Accumulated Depreciation
December 31, 2018
(dollars in thousands)
103
Physicians Realty Trust and Physicians Realty L.P.
Schedule III – Real Estate and Accumulated Depreciation
December 31, 2018
(dollars in thousands)
104
Physicians Realty Trust and Physicians Realty L.P.
Schedule III – Real Estate and Accumulated Depreciation
December 31, 2018
(dollars in thousands)
105
Physicians Realty Trust and Physicians Realty L.P.
Schedule III – Real Estate and Accumulated Depreciation
December 31, 2018
(dollars in thousands)
Initial Cost to Company | Gross Amount at Which Carried as of Close of Period | |||||||||||||||||||||||||||||||||||||||
Description | Location | Encumbrances | Land | Buildings and Improvements | Cost Capitalized Subsequent to Acquisitions | Land | Buildings and Improvements | Total | Accumulated Depreciation | Year Built | Date Acquired | Life on Which Building Depreciation in Income Statement is Computed | ||||||||||||||||||||||||||||
Arrowhead Commons | Phoenix, AZ | $ | $ | $ | $ | $ | $ | $ | $ | ( | ) | 2004 | 5/31/2008 | |||||||||||||||||||||||||||
Aurora Medical Office Building | Green Bay, WI | ( | ) | 2010 | 4/15/2010 | |||||||||||||||||||||||||||||||||||
El Paso Medical Office Building | El Paso, TX | ( | ) | 1987 | 8/24/2006 | |||||||||||||||||||||||||||||||||||
Firehouse Square | Milwaukee, WI | ( | ) | 2002 | 8/15/2007 | |||||||||||||||||||||||||||||||||||
Hackley Medical Center | Grand Rapids, MI | ( | ) | 1968 | 12/22/2006 | |||||||||||||||||||||||||||||||||||
MeadowView Professional Center | Kingsport, TN | ( | ) | 2005 | 5/10/2007 | |||||||||||||||||||||||||||||||||||
Mid Coast Hospital Medical Office Building | Portland, ME | ( | ) | 2008 | 5/1/2008 | |||||||||||||||||||||||||||||||||||
New Albany Professional Building | Columbus, OH | ( | ) | 2000 | 1/4/2008 | |||||||||||||||||||||||||||||||||||
Remington Medical Commons | Chicago, IL | ( | ) | 2008 | 6/1/2008 | |||||||||||||||||||||||||||||||||||
Valley West Hospital Medical Office Building | Chicago, IL | ( | ) | 2007 | 11/1/2007 | |||||||||||||||||||||||||||||||||||
East El Paso Medical Office Building | El Paso, TX | ( | ) | 2004 | 8/30/2013 | |||||||||||||||||||||||||||||||||||
East El Paso Surgical Hospital | El Paso, TX | ( | ) | 2004 | 8/30/2013 | |||||||||||||||||||||||||||||||||||
LifeCare Plano LTACH | Plano, TX | ( | ) | 1987 | 9/18/2013 | |||||||||||||||||||||||||||||||||||
Crescent City Surgical Centre | New Orleans, LA | ( | ) | 2010 | 9/30/2013 | |||||||||||||||||||||||||||||||||||
Foundation Surgical Affiliates Medical Office Building | Oklahoma City, OK | ( | ) | 2004 | 9/30/2013 | |||||||||||||||||||||||||||||||||||
Central Ohio Neurosurgical Surgeons Medical Office | Columbus, OH | ( | ) | 2007 | 11/27/2013 | |||||||||||||||||||||||||||||||||||
Great Falls Ambulatory Surgery Center | Great Falls, MT | ( | ) | 1999 | 12/11/2013 | |||||||||||||||||||||||||||||||||||
Foundation San Antonio Surgical Hospital | San Antonio, TX | ( | ) | 2007 | 2/19/2014 | |||||||||||||||||||||||||||||||||||
21st Century Radiation Oncology Centers — Sarasota | Sarasota, FL | ( | ) | 1975 | 2/26/2014 | |||||||||||||||||||||||||||||||||||
21st Century Radiation Oncology Centers - Venice | Venice, FL | ( | ) | 1987 | 2/26/2014 | |||||||||||||||||||||||||||||||||||
21st Century Radiation Oncology Centers - Englewood | Englewood, FL | ( | ) | 1992 | 2/26/2014 | |||||||||||||||||||||||||||||||||||
Foundation San Antonio Healthplex | San Antonio, TX | ( | ) | 2007 | 2/28/2014 | |||||||||||||||||||||||||||||||||||
Peachtree Dunwoody Medical Center | Atlanta, GA | ( | ) | 1987 | 2/28/2014 | |||||||||||||||||||||||||||||||||||
LifeCare LTACH — Fort Worth | Fort Worth, TX | ( | ) | 1985 | 3/28/2014 | |||||||||||||||||||||||||||||||||||
LifeCare LTACH — Pittsburgh | Pittsburgh, PA | ( | ) | 1987 | 3/28/2014 | |||||||||||||||||||||||||||||||||||
PinnacleHealth Medical Office Building | Harrisburg, PA | ( | ) | 1990 | 4/22/2014 | |||||||||||||||||||||||||||||||||||
Pinnacle Health Medical Office Building | Carlisle, PA | ( | ) | 2002 | 4/22/2014 | |||||||||||||||||||||||||||||||||||
South Bend Orthopaedics Medical Office Building | Mishawaka, IN | ( | ) | 2007 | 4/30/2014 | |||||||||||||||||||||||||||||||||||
Grenada Medical Complex | Grenada, MS | ( | ) | 1975 | 4/30/2014 | |||||||||||||||||||||||||||||||||||
Mississippi Ortho Medical Office Building | Jackson, MS | ( | ) | 1987 | 5/23/2014 | |||||||||||||||||||||||||||||||||||
Carmel Medical Pavilion | Carmel, IN | ( | ) | 1993 | 5/28/2014 | |||||||||||||||||||||||||||||||||||
Renaissance Ambulatory Surgery Center | Oshkosh, WI | ( | ) | 2007 | 6/30/2014 | |||||||||||||||||||||||||||||||||||
Summit Urology | Bloomington, IN | ( | ) | 1996 | 6/30/2014 | |||||||||||||||||||||||||||||||||||
500 Landmark | Bloomington, IN | ( | ) | 2000 | 7/1/2014 | |||||||||||||||||||||||||||||||||||
550 Landmark | Bloomington, IN | ( | ) | 2000 | 7/1/2014 | |||||||||||||||||||||||||||||||||||
574 Landmark | Bloomington, IN | ( | ) | 2004 | 7/1/2014 | |||||||||||||||||||||||||||||||||||
Carlisle II MOB | Carlisle, PA | ( | ) | 1996 | 7/25/2014 | |||||||||||||||||||||||||||||||||||
Surgical Institute of Monroe | Monroe, MI | ( | ) | 2010 | 7/28/2014 | |||||||||||||||||||||||||||||||||||
The Oaks @ Lady Lake | Lady Lake, FL | ( | ) | 2011 | 7/31/2014 | |||||||||||||||||||||||||||||||||||
Mansfield ASC | Mansfield, TX | ( | ) | 2010 | 9/2/2014 | |||||||||||||||||||||||||||||||||||
Eye Center of Southern Indiana | Bloomington, IN | ( | ) | 1995 | 9/5/2014 | |||||||||||||||||||||||||||||||||||
Zangmeister | Columbus, OH | ( | ) | 2007 | 9/30/2014 | |||||||||||||||||||||||||||||||||||
Ortho One - Columbus | Columbus, OH | ( | ) | 2009 | 9/30/2014 | |||||||||||||||||||||||||||||||||||
Ortho One - Westerville | Columbus, OH | ( | ) | 2007 | 9/30/2014 | |||||||||||||||||||||||||||||||||||
Berger Medical Center | Columbus, OH | ( | ) | 2007 | 9/30/2014 | |||||||||||||||||||||||||||||||||||
El Paso - Lee Trevino | El Paso, TX | ( | ) | 1983 | 9/30/2014 | |||||||||||||||||||||||||||||||||||
El Paso - Murchison | El Paso, TX | ( | ) | 1970 | 9/30/2014 | |||||||||||||||||||||||||||||||||||
El Paso - Kenworthy | El Paso, TX | ( | ) | 1983 | 9/30/2014 | |||||||||||||||||||||||||||||||||||
Pinnacle - 32 Northeast | Harrisburg, PA | ( | ) | 1994 | 10/29/2014 | |||||||||||||||||||||||||||||||||||
Pinnacle - 4518 Union Deposit | Harrisburg, PA | ( | ) | 2000 | 10/29/2014 | |||||||||||||||||||||||||||||||||||
Pinnacle - 4520 Union Deposit | Harrisburg, PA | ( | ) | 1997 | 10/29/2014 | |||||||||||||||||||||||||||||||||||
Pinnacle - 240 Grandview | Harrisburg, PA | ( | ) | 1980 | 10/29/2014 | |||||||||||||||||||||||||||||||||||
Pinnacle - Market Place Way | Harrisburg, PA | ( | ) | 2004 | 10/29/2014 | |||||||||||||||||||||||||||||||||||
Middletown Medical - 111 Maltese | Middletown, NY | ( | ) | 1988 | 11/28/2014 | |||||||||||||||||||||||||||||||||||
Middletown Medical - 2 Edgewater | Middletown, NY | ( | ) | 1992 | 11/28/2014 | |||||||||||||||||||||||||||||||||||
Initial Cost to Company | Gross Amount at Which Carried as of Close of Period | |||||||||||||||||||||||||||||||||||||||
Description | Location | Encumbrances | Land | Buildings and Improvements | Cost Capitalized Subsequent to Acquisitions | Land | Buildings and Improvements | Total | Accumulated Depreciation | Year Built | Date Acquired | Life on Which Building Depreciation in Income Statement is Computed | ||||||||||||||||||||||||||||
Napoleon Medical Office Building | New Orleans, LA | ( | ) | 1974 | 12/19/2014 | |||||||||||||||||||||||||||||||||||
West TN Bone & Joint - Physicians Drive | Jackson, TN | ( | ) | 1991 | 12/30/2014 | |||||||||||||||||||||||||||||||||||
Edina MOB | Edina MN | ( | ) | 1979 | 1/22/2015 | |||||||||||||||||||||||||||||||||||
Crystal MOB | Crystal, MN | ( | ) | 2012 | 1/22/2015 | |||||||||||||||||||||||||||||||||||
Savage MOB | Savage, MN | ( | ) | 2011 | 1/22/2015 | |||||||||||||||||||||||||||||||||||
Dell Road MOB | Chanhassen, MN | ( | ) | 2008 | 1/22/2015 | |||||||||||||||||||||||||||||||||||
Methodist Sports MOB | Greenwood, IN | ( | ) | 2008 | 1/28/2015 | |||||||||||||||||||||||||||||||||||
Vadnais Heights MOB | Vadnais Heights, MN | ( | ) | 2013 | 1/29/2015 | |||||||||||||||||||||||||||||||||||
Minnetonka MOB | Minnetonka, MN | ( | ) | 2014 | 2/5/2015 | |||||||||||||||||||||||||||||||||||
Jamestown MOB | Jamestown, ND | ( | ) | 2013 | 2/5/2015 | |||||||||||||||||||||||||||||||||||
Indiana American II | Greenwood, IN | ( | ) | 2008 | 2/13/2015 | |||||||||||||||||||||||||||||||||||
Indiana American III | Greenwood, IN | ( | ) | 2001 | 2/13/2015 | |||||||||||||||||||||||||||||||||||
Indiana American IV | Greenwood, IN | ( | ) | 2001 | 2/13/2015 | |||||||||||||||||||||||||||||||||||
Southpointe | Indianapolis, IN | ( | ) | 1993 | 2/13/2015 | |||||||||||||||||||||||||||||||||||
Minnesota Eye MOB | Minnetonka, MN | ( | ) | 2014 | 2/17/2015 | |||||||||||||||||||||||||||||||||||
Baylor Cancer Center | Dallas, TX | ( | ) | 2001 | 2/27/2015 | |||||||||||||||||||||||||||||||||||
Bridgeport Medical Center | Lakewood, WA | ( | ) | 2004 | 2/27/2015 | |||||||||||||||||||||||||||||||||||
Renaissance Office Building | Milwaukee, WI | ( | ) | 1896 | 3/27/2015 | |||||||||||||||||||||||||||||||||||
Calkins 125 | Rochester, NY | ( | ) | 1997 | 3/31/2015 | |||||||||||||||||||||||||||||||||||
Calkins 200 | Rochester, NY | ( | ) | 2000 | 3/31/2015 | |||||||||||||||||||||||||||||||||||
Calkins 300 | Rochester, NY | ( | ) | 2002 | 3/31/2015 | |||||||||||||||||||||||||||||||||||
Calkins 400 | Rochester, NY | ( | ) | 2007 | 3/31/2015 | |||||||||||||||||||||||||||||||||||
Calkins 500 | Rochester, NY | ( | ) | 2008 | 3/31/2015 | |||||||||||||||||||||||||||||||||||
Premier Surgery Center of Louisville | Louisville, KY | ( | ) | 2013 | 4/10/2015 | |||||||||||||||||||||||||||||||||||
Baton Rouge MOB | Baton Rouge, LA | ( | ) | 2003 | 4/15/2015 | |||||||||||||||||||||||||||||||||||
Healthpark Medical Center | Grand Blanc, MI | ( | ) | 2006 | 4/30/2015 | |||||||||||||||||||||||||||||||||||
Northern Ohio Medical Center | Sheffield, OH | ( | ) | 1999 | 5/28/2015 | |||||||||||||||||||||||||||||||||||
University of Michigan - Northville MOB | Livonia, MI | ( | ) | 1988 | 5/29/2015 | |||||||||||||||||||||||||||||||||||
Coon Rapids Medical Center MOB | Coon Rapids, MN | ( | ) | 2007 | 6/1/2015 | |||||||||||||||||||||||||||||||||||
Premier Landmark MOB | Bloomington, IN | ( | ) | 2008 | 6/5/2015 | |||||||||||||||||||||||||||||||||||
Palm Beach ASC | Palm Beach, FL | ( | ) | 2003 | 6/26/2015 | |||||||||||||||||||||||||||||||||||
Brookstone Physician Center MOB | Jacksonville, AL | ( | ) | 2007 | 6/30/2015 | |||||||||||||||||||||||||||||||||||
Hillside Medical Center MOB | Hanover, PA | ( | ) | 2003 | 6/30/2015 | |||||||||||||||||||||||||||||||||||
Randall Road MOB | Elgin, IL | ( | ) | 2006 | 6/30/2015 | |||||||||||||||||||||||||||||||||||
Medical Specialists of Palm Beach MOB | Atlantis, FL | ( | ) | 2002 | 7/24/2015 | |||||||||||||||||||||||||||||||||||
OhioHealth - SW Health Center MOB | Grove City, OH | ( | ) | 2001 | 7/31/2015 | |||||||||||||||||||||||||||||||||||
Trios Health MOB | Kennewick, WA | ( | ) | 2015 | 7/31/2015 | |||||||||||||||||||||||||||||||||||
IMS - Paradise Valley MOB | Phoenix, AZ | ( | ) | 2004 | 8/14/2015 | |||||||||||||||||||||||||||||||||||
IMS - Avondale MOB | Avondale, AZ | ( | ) | 2006 | 8/19/2015 | |||||||||||||||||||||||||||||||||||
IMS - Palm Valley MOB | Goodyear, AZ | ( | ) | 2006 | 8/19/2015 | |||||||||||||||||||||||||||||||||||
IMS - North Mountain MOB | Phoenix, AZ | ( | ) | 2008 | 8/31/2015 | |||||||||||||||||||||||||||||||||||
Memorial Hermann - Phase I | Katy, TX | ( | ) | 2005 | 9/1/2015 | |||||||||||||||||||||||||||||||||||
Memorial Hermann - Phase II | Katy, TX | ( | ) | 2006 | 9/1/2015 | |||||||||||||||||||||||||||||||||||
New Albany Medical Center MOB | New Albany, OH | ( | ) | 2005 | 9/9/2015 | |||||||||||||||||||||||||||||||||||
Fountain Hills Medical Campus MOB | Fountain Hills, AZ | ( | ) | 1995 | 9/30/2015 | |||||||||||||||||||||||||||||||||||
Fairhope MOB | Fairhope, AL | ( | ) | 2005 | 10/13/2015 | |||||||||||||||||||||||||||||||||||
Foley MOB | Foley, AL | ( | ) | 1997 | 10/13/2015 | |||||||||||||||||||||||||||||||||||
Foley Venture | Foley, AL | ( | ) | 2002 | 10/13/2015 | |||||||||||||||||||||||||||||||||||
North Okaloosa MOB | Crestview, FL | ( | ) | 2005 | 10/13/2015 | |||||||||||||||||||||||||||||||||||
Commons on North Davis | Pensacola, FL | ( | ) | 2009 | 10/13/2015 | |||||||||||||||||||||||||||||||||||
Sorrento Road | Pensacola, FL | ( | ) | 2010 | 10/13/2015 | |||||||||||||||||||||||||||||||||||
Breakfast Point Medical Park | Panama City, FL | ( | ) | 2012 | 10/13/2015 | |||||||||||||||||||||||||||||||||||
Panama City Beach | Panama City, FL | ( | ) | 2012 | 10/13/2015 | |||||||||||||||||||||||||||||||||||
Perdido Medical Park | Pensacola, FL | ( | ) | 2010 | 10/13/2015 | |||||||||||||||||||||||||||||||||||
Ft. Walton Beach | Ft. Walton Beach, FL | ( | ) | 1979 | 10/13/2015 | |||||||||||||||||||||||||||||||||||
Panama City | Panama City, FL | ( | ) | 2003 | 10/13/2015 | |||||||||||||||||||||||||||||||||||
Pensacola - Catalyst | Pensacola, FL | ( | ) | 2001 | 10/13/2015 | |||||||||||||||||||||||||||||||||||
Arete Surgical Center | Johnstown, CO | ( | ) | 2013 | 10/19/2015 | |||||||||||||||||||||||||||||||||||
Cambridge Professional Center MOB | Waldorf, MD | ( | ) | 1999 | 10/30/2015 | |||||||||||||||||||||||||||||||||||
HonorHealth 44th Street MOB | Phoenix, AZ | ( | ) | 1988 | 11/13/2015 | |||||||||||||||||||||||||||||||||||
Initial Cost to Company | Gross Amount at Which Carried as of Close of Period | |||||||||||||||||||||||||||||||||||||||
Description | Location | Encumbrances | Land | Buildings and Improvements | Cost Capitalized Subsequent to Acquisitions | Land | Buildings and Improvements | Total | Accumulated Depreciation | Year Built | Date Acquired | Life on Which Building Depreciation in Income Statement is Computed | ||||||||||||||||||||||||||||
Mercy Medical Center MOB | Fenton, MO | ( | ) | 1999 | 12/1/2015 | |||||||||||||||||||||||||||||||||||
Nashville MOB | Nashville, TN | ( | ) | 2015 | 12/17/2015 | |||||||||||||||||||||||||||||||||||
Great Falls Clinic MOB | Great Falls, MT | ( | ) | 2004 | 12/29/2015 | |||||||||||||||||||||||||||||||||||
Great Falls Hospital | Great Falls, MT | ( | ) | 2015 | 1/25/2016 | |||||||||||||||||||||||||||||||||||
Monterey Medical Center ASC | Stuart, FL | ( | ) | 2013 | 2/1/2016 | |||||||||||||||||||||||||||||||||||
Park Nicollet Clinic | Chanhassen, MN | ( | ) | 2005 | 2/8/2016 | |||||||||||||||||||||||||||||||||||
HEB Cancer Center | Bedford, TX | ( | ) | 2014 | 2/12/2016 | |||||||||||||||||||||||||||||||||||
Riverview Medical Center | Lancaster, OH | ( | ) | 1997 | 2/26/2016 | |||||||||||||||||||||||||||||||||||
St. Luke's Cornwall MOB | Cornwall, NY | ( | ) | 2006 | 2/26/2016 | |||||||||||||||||||||||||||||||||||
HonorHealth Glendale | Glendale, AZ | ( | ) | 2015 | 3/15/2016 | |||||||||||||||||||||||||||||||||||
Columbia MOB | Hudson, NY | ( | ) | 2006 | 3/21/2016 | |||||||||||||||||||||||||||||||||||
St Vincent POB 1 | Birmingham, AL | ( | ) | 1975 | 3/23/2016 | |||||||||||||||||||||||||||||||||||
St Vincent POB 2 | Birmingham, AL | ( | ) | 1988 | 3/23/2016 | |||||||||||||||||||||||||||||||||||
St Vincent POB 3 | Birmingham, AL | ( | ) | 1992 | 3/23/2016 | |||||||||||||||||||||||||||||||||||
Emerson Medical Building | Creve Coeur, MO | ( | ) | 1989 | 3/24/2016 | |||||||||||||||||||||||||||||||||||
Eye Associates of NM - Santa Fe | Santa Fe, NM | ( | ) | 2002 | 3/31/2016 | |||||||||||||||||||||||||||||||||||
Eye Associates of NM - Albuquerque | Albuquerque, NM | ( | ) | 2007 | 3/31/2016 | |||||||||||||||||||||||||||||||||||
Gardendale Surgery Center | Gardendale, AL | ( | ) | 2011 | 4/11/2016 | |||||||||||||||||||||||||||||||||||
HealthEast - Curve Crest | Stillwater, MN | ( | ) | 2011 | 4/14/2016 | |||||||||||||||||||||||||||||||||||
HealthEast - Victor Gardens | Hugo, MN | ( | ) | 2008 | 4/14/2016 | |||||||||||||||||||||||||||||||||||
NOMS - Clyde | Clyde, OH | ( | ) | 2015 | 5/10/2016 | |||||||||||||||||||||||||||||||||||
Blandford MOB | Little Rock, AR | ( | ) | 1983 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Cardwell MOB | Lufkin, TX | ( | ) | 1999 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Dacono Neighborhood Health | Dacono, CO | ( | ) | 2014 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Franciscan Health | Tacoma, WA | ( | ) | 1951 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Grand Island Specialty Clinic | Grand Island, NE | ( | ) | 1978 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Hot Springs MOB | Hot Springs Village, AR | ( | ) | 1988 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Jewish Medical Center East | Louisville, KY | ( | ) | 2003 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Jewish Medical Center South MOB - 1 | Shepherdsville, KY | ( | ) | 2005 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Jewish Medical Plaza I | Louisville, KY | ( | ) | 1970 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Jewish Medical Plaza II | Louisville, KY | ( | ) | 1964 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Jewish OCC | Louisville, KY | ( | ) | 1985 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Lexington Surgery Center | Lexington, KY | ( | ) | 2000 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Medical Arts Pavilion | Lufkin, TX | ( | ) | 2004 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Memorial Outpatient Center | Lufkin, TX | ( | ) | 1990 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Midlands Two Professional Center | Papillion, NE | ( | ) | 1976 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Parkview MOB | Little Rock, AR | ( | ) | 1988 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Peak One ASC | Frisco, CO | ( | ) | 2006 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Physicians Medical Center | Tacoma, WA | ( | ) | 1977 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
St. Alexius - Minot Medical Plaza | Minot, ND | ( | ) | 2015 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
St. Clare Medical Pavilion | Lakewood, WA | ( | ) | 1989 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
St. Joseph Medical Pavilion | Tacoma, WA | ( | ) | 1989 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
St. Joseph Office Park | Lexington, KY | ( | ) | 1992 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
St. Mary - Caritas Medical II | Louisville, KY | ( | ) | 1979 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
St. Mary - Caritas Medical III | Louisville, KY | ( | ) | 1974 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
Thornton Neighborhood Health | Thornton, CO | ( | ) | 2014 | 5/11/2016 | |||||||||||||||||||||||||||||||||||
St. Francis MOB | Federal Way, WA | ( | ) | 1987 | 6/2/2016 | |||||||||||||||||||||||||||||||||||
Children's Hospital MOB | Milwaukee, WI | ( | ) | 2016 | 6/3/2016 | |||||||||||||||||||||||||||||||||||
Jewish Medical Center South MOB - 2 | Shepherdsville, KY | ( | ) | 2006 | 6/8/2016 | |||||||||||||||||||||||||||||||||||
Good Samaritan North Annex Building | Kearney, NE | ( | ) | 1984 | 6/28/2016 | |||||||||||||||||||||||||||||||||||
NE Heart Institute Medical Building | Lincoln, NE | ( | ) | 2004 | 6/28/2016 | |||||||||||||||||||||||||||||||||||
St. Vincent West MOB | Little Rock, AR | ( | ) | 2012 | 6/29/2016 | |||||||||||||||||||||||||||||||||||
Meridan MOB | Englewood, CO | ( | ) | 2002 | 6/29/2016 | |||||||||||||||||||||||||||||||||||
St. Mary - Caritas Medical I | Louisville, KY | ( | ) | 1991 | 6/29/2016 | |||||||||||||||||||||||||||||||||||
St. Alexius - Medical Arts Pavilion | Bismarck, ND | ( | ) | 1974 | 6/29/2016 | |||||||||||||||||||||||||||||||||||
St. Alexius - Mandan Clinic | Mandan, ND | ( | ) | 2014 | 6/29/2016 | |||||||||||||||||||||||||||||||||||
St. Alexius - Orthopaedic Center | Bismarck, ND | ( | ) | 1997 | 6/29/2016 | |||||||||||||||||||||||||||||||||||
St. Alexius - Rehab Center | Bismarck, ND | ( | ) | 1997 | 6/29/2016 | |||||||||||||||||||||||||||||||||||
St. Alexius - Tech & Ed | Bismarck, ND | ( | ) | 2011 | 6/29/2016 | |||||||||||||||||||||||||||||||||||
Good Samaritan MOB | Kearney, NE | ( | ) | 1999 | 6/29/2016 | |||||||||||||||||||||||||||||||||||
Lakeside Two Professional Building | Omaha, NE | ( | ) | 2000 | 6/29/2016 | |||||||||||||||||||||||||||||||||||
Initial Cost to Company | Gross Amount at Which Carried as of Close of Period | |||||||||||||||||||||||||||||||||||||||
Description | Location | Encumbrances | Land | Buildings and Improvements | Cost Capitalized Subsequent to Acquisitions | Land | Buildings and Improvements | Total | Accumulated Depreciation | Year Built | Date Acquired | Life on Which Building Depreciation in Income Statement is Computed | ||||||||||||||||||||||||||||
Lakeside Wellness Center | Omaha, NE | ( | ) | 2000 | 6/29/2016 | |||||||||||||||||||||||||||||||||||
McAuley Center | Omaha, NE | ( | ) | 1988 | 6/29/2016 | |||||||||||||||||||||||||||||||||||
Memorial Health Center | Grand Island, NE | ( | ) | 1955 | 6/29/2016 | |||||||||||||||||||||||||||||||||||
Missionary Ridge MOB | Chattanooga, TN | ( | ) | 1976 | 6/29/2016 | |||||||||||||||||||||||||||||||||||
Pilot Medical Center | Birmingham, AL | ( | ) | 2005 | 6/29/2016 | |||||||||||||||||||||||||||||||||||
St. Joseph Medical Clinic | Tacoma, WA | ( | ) | 1991 | 6/30/2016 | |||||||||||||||||||||||||||||||||||
Woodlands Medical Arts Center | The Woodlands, TX | ( | ) | 2001 | 6/30/2016 | |||||||||||||||||||||||||||||||||||
FESC MOB | Tacoma, WA | ( | ) | 1980 | 6/30/2016 | |||||||||||||||||||||||||||||||||||
Prairie Care MOB | Maplewood, MN | ( | ) | 2016 | 7/6/2016 | |||||||||||||||||||||||||||||||||||
Springwoods MOB | Spring, TX | ( | ) | 2015 | 7/21/2016 | |||||||||||||||||||||||||||||||||||
Unity - ASC, Imaging & MOB | West Lafayette, IN | ( | ) | 2001 | 8/8/2016 | |||||||||||||||||||||||||||||||||||
Unity - Medical Pavilion | West Lafayette, IN | ( | ) | 2001 | 8/8/2016 | |||||||||||||||||||||||||||||||||||
Unity - Faith, Hope & Love | West Lafayette, IN | ( | ) | 2001 | 8/8/2016 | |||||||||||||||||||||||||||||||||||
Unity - Immediate Care & OCC | West Lafayette, IN | ( | ) | 2004 | 8/8/2016 | |||||||||||||||||||||||||||||||||||
Medical Village at Maitland | Orlando, FL | ( | ) | 2006 | 8/23/2016 | |||||||||||||||||||||||||||||||||||
Tri-State Orthopaedics MOB | Evansville, IN | ( | ) | 2004 | 8/30/2016 | |||||||||||||||||||||||||||||||||||
Maury Regional Healthcare MOB | Spring Hill, TN | ( | ) | 2012 | 9/30/2016 | |||||||||||||||||||||||||||||||||||
Spring Ridge Medical Center | Wyomissing, PA | ( | ) | 2002 | 9/30/2016 | |||||||||||||||||||||||||||||||||||
Doctors Community Hospital POB | Lanham, MD | ( | ) | 2009 | 9/30/2016 | |||||||||||||||||||||||||||||||||||
Gig Harbor Medical Pavilion | Gig Harbor, WA | ( | ) | 1991 | 9/30/2016 | |||||||||||||||||||||||||||||||||||
Midlands One Professional Center | Papillion, NE | ( | ) | 2010 | 9/30/2016 | |||||||||||||||||||||||||||||||||||
N.W. Michigan Surgery Center Units #1, #2, & #4 | Traverse City, MI | ( | ) | 2004 | 10/28/2016 | |||||||||||||||||||||||||||||||||||
Northeast Medical Center | Fayetteville, NY | ( | ) | 1998 | 11/23/2016 | |||||||||||||||||||||||||||||||||||
North Medical Center | Liverpool, NY | ( | ) | 1989 | 11/23/2016 | |||||||||||||||||||||||||||||||||||
Cincinnati Eye Institute | Cincinnati, OH | ( | ) | 1985 | 11/23/2016 | |||||||||||||||||||||||||||||||||||
HonorHealth - Scottsdale MOB | Scottsdale, AZ | ( | ) | 2000 | 12/2/2016 | |||||||||||||||||||||||||||||||||||
Fox Valley Hematology & Oncology | Appleton, WI | ( | ) | 2015 | 12/8/2016 | |||||||||||||||||||||||||||||||||||
Northern Vision Eye Center | Traverse City, MI | ( | ) | 2006 | 12/15/2016 | |||||||||||||||||||||||||||||||||||
Flower Mound MOB | Flower Mound, TX | ( | ) | 2011 | 12/16/2016 | |||||||||||||||||||||||||||||||||||
Carrollton MOB | Flower Mound, TX | ( | ) | 2002 | 12/16/2016 | |||||||||||||||||||||||||||||||||||
HonorHealth IRF | Scottsdale, AZ | ( | ) | 2000 | 12/22/2016 | |||||||||||||||||||||||||||||||||||
Orthopedic Associates | Flower Mound, TX | ( | ) | 2011 | 1/5/2017 | |||||||||||||||||||||||||||||||||||
Medical Arts Center at Hartford | Plainville, CT | ( | ) | 2015 | 1/11/2017 | |||||||||||||||||||||||||||||||||||
CareMount - Lake Katrine MOB | Lake Katrine, NY | ( | ) | 2013 | 2/14/2017 | |||||||||||||||||||||||||||||||||||
CareMount - Rhinebeck MOB | Rhinebeck, NY | ( | ) | 1965 | 2/14/2017 | |||||||||||||||||||||||||||||||||||
Monterey Medical Center - MOB | Stuart, FL | ( | ) | 2003 | 3/7/2017 | |||||||||||||||||||||||||||||||||||
Creighton University Medical Center | Omaha, NE | ( | ) | 2017 | 3/28/2017 | |||||||||||||||||||||||||||||||||||
Strictly Pediatrics Specialty Center | Austin, TX | ( | ) | 2006 | 3/31/2017 | |||||||||||||||||||||||||||||||||||
MedStar Stephen's Crossing | Brandywine, MD | ( | ) | 2015 | 6/16/2017 | |||||||||||||||||||||||||||||||||||
CHI Health Clinic Building | Omaha, NE | ( | ) | 2017 | 6/29/2017 | |||||||||||||||||||||||||||||||||||
St Gabriel's Centracare | Little Falls, MN | ( | ) | 1990 | 6/29/2017 | |||||||||||||||||||||||||||||||||||
Craven-Hagan Clinic | Williston, ND | ( | ) | 1984 | 6/29/2017 | |||||||||||||||||||||||||||||||||||
Chattanooga Heart Institute | Chattanooga, TN | ( | ) | 1993 | 6/29/2017 | |||||||||||||||||||||||||||||||||||
CHI St. Vincent Mercy Heart & Vascular Center | Hot Springs, AR | ( | ) | 1998 | 6/29/2017 | |||||||||||||||||||||||||||||||||||
South Campus MOB | Hot Springs, AR | ( | ) | 2009 | 6/29/2017 | |||||||||||||||||||||||||||||||||||
CHI St. Vincent Mercy Cancer Center | Hot Springs, AR | ( | ) | 2001 | 6/29/2017 | |||||||||||||||||||||||||||||||||||
St. Joseph Professional Office Building | Bryan, TX | ( | ) | 1996 | 6/29/2017 | |||||||||||||||||||||||||||||||||||
St. Vincent Carmel Women's Center | Carmel, IN | ( | ) | 2014 | 6/29/2017 | |||||||||||||||||||||||||||||||||||
St. Vincent Fishers Medical Center | Fishers, IN | ( | ) | 2008 | 6/29/2017 | |||||||||||||||||||||||||||||||||||
Baylor Charles A. Sammons Cancer Center | Dallas, TX | ( | ) | 2011 | 6/30/2017 | |||||||||||||||||||||||||||||||||||
Orthopedic & Sports Institute of the Fox Valley | Appleton, WI | ( | ) | 2005 | 6/30/2017 | |||||||||||||||||||||||||||||||||||
Clearview Cancer Institute | Huntsville, AL | ( | ) | 2006 | 8/4/2017 | |||||||||||||||||||||||||||||||||||
Northside Cherokee/Town Lake MOB | Atlanta, GA | ( | ) | 2013 | 8/15/2017 | |||||||||||||||||||||||||||||||||||
HonorHealth Mesa MOB | Mesa, AZ | ( | ) | 2013 | 8/15/2017 | |||||||||||||||||||||||||||||||||||
Little Falls Orthopedics | Little Falls, MN | ( | ) | 1999 | 8/24/2017 | |||||||||||||||||||||||||||||||||||
Little Falls Dialysis Center | Little Falls, MN | ( | ) | 1959 | 8/24/2017 | |||||||||||||||||||||||||||||||||||
Immanuel One Professional Center | Omaha, NE | ( | ) | 1993 | 8/24/2017 | |||||||||||||||||||||||||||||||||||
SJRHC Cancer Center | Bryan, TX | ( | ) | 1997 | 8/24/2017 | |||||||||||||||||||||||||||||||||||
St. Vincent Women's Center | Hot Springs, AR | ( | ) | 2001 | 8/31/2017 | |||||||||||||||||||||||||||||||||||
Legends Park MOB & ASC | Midland, TX | ( | ) | 2003 | 9/27/2017 | |||||||||||||||||||||||||||||||||||
Initial Cost to Company | Gross Amount at Which Carried as of Close of Period | |||||||||||||||||||||||||||||||||||||||
Description | Location | Encumbrances | Land | Buildings and Improvements | Cost Capitalized Subsequent to Acquisitions | Land | Buildings and Improvements | Total | Accumulated Depreciation | Year Built | Date Acquired | Life on Which Building Depreciation in Income Statement is Computed | ||||||||||||||||||||||||||||
Franklin MOB & ASC | Franklin, TN | ( | ) | 2014 | 10/12/2017 | |||||||||||||||||||||||||||||||||||
Eagle Point MOB | Lake Elmo, MN | ( | ) | 2015 | 10/31/2017 | |||||||||||||||||||||||||||||||||||
Edina East MOB | Edina, MN | ( | ) | 1962 | 10/31/2017 | |||||||||||||||||||||||||||||||||||
Northside MOB - Center Pointe | Atlanta, GA | ( | ) | 2009 | 11/10/2017 | |||||||||||||||||||||||||||||||||||
Gwinnett 500 Building | Lawrenceville, GA | ( | ) | 1995 | 11/17/2017 | |||||||||||||||||||||||||||||||||||
Hudgens Professional Building | Duluth, GA | ( | ) | 1994 | 11/17/2017 | |||||||||||||||||||||||||||||||||||
St. Vincent Building | Indianapolis, IN | ( | ) | 2007 | 11/17/2017 | |||||||||||||||||||||||||||||||||||
Gwinnett Physicians Center | Lawrenceville, GA | ( | ) | ( | ) | 2010 | 12/1/2017 | |||||||||||||||||||||||||||||||||
Apple Valley Medical Center | Apple Valley, MN | ( | ) | 1974 | 12/18/2017 | |||||||||||||||||||||||||||||||||||
Desert Cove MOB | Scottsdale, AZ | ( | ) | 1991 | 12/18/2017 | |||||||||||||||||||||||||||||||||||
Westgate MOB | Glendale, AZ | ( | ) | 2016 | 12/21/2017 | |||||||||||||||||||||||||||||||||||
Hazelwood Medical Commons | Maplewood, MN | ( | ) | 2017 | 1/9/2018 | |||||||||||||||||||||||||||||||||||
Lee's Hill Medical Plaza | Fredericksburg, VA | ( | ) | 2006 | 1/23/2018 | |||||||||||||||||||||||||||||||||||
HMG Medical Plaza | Kingsport, TN | ( | ) | 2010 | 4/3/2018 | |||||||||||||||||||||||||||||||||||
Jacksonville MedPlex (Building B) | Jacksonville, FL | ( | ) | 2010 | 7/26/2018 | |||||||||||||||||||||||||||||||||||
Jacksonville MedPlex (Building C) | Jacksonville, FL | ( | ) | 2010 | 7/26/2018 | |||||||||||||||||||||||||||||||||||
Northside Medical Midtown MOB | Atlanta, GA | ( | ) | 2018 | 9/14/2018 | |||||||||||||||||||||||||||||||||||
$ | $ | $ | $ | $ | $ | $ | $ | ( | ) | |||||||||||||||||||||||||||||||
The cost capitalized subsequent to acquisitions is net of dispositions.
The changes in total real estate for the years ended December 31, 2018, 2017, and 2016 are as follows (in thousands):
Year Ended December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Balance as of the beginning of the year | $ | $ | $ | ||||||||
Acquisitions | |||||||||||
Additions | |||||||||||
Impairment | ( | ) | |||||||||
Dispositions | ( | ) | ( | ) | |||||||
Balance as of the end of the year | $ | $ | $ | ||||||||
The changes in accumulated depreciation for the years ended December 31, 2018, 2017, and 2016 are as follows (in thousands):
Year Ended December 31, | |||||||||||
2018 | 2017 | 2016 | |||||||||
Balance as of the beginning of the year | $ | $ | $ | ||||||||
Depreciation | |||||||||||
Dispositions | ( | ) | ( | ) | |||||||
Balance as of the end of the year | $ | $ | $ | ||||||||
106
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
ITEM 9A. CONTROLS AND PROCEDURES
Physicians Realty Trust
Evaluation of Disclosure Controls and Procedures.
The Trust’s management, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Trust’s disclosure controls and procedures (as defined in Rules 13a- 15(e) and 15d- 15(e) under the Exchange Act), as of the end of the period covered by this report. Based on such evaluation, the Trust’s Chief Executive Officer and Chief Financial Officer concluded that as of December 31, 2018, the Trust’s disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information it is required to disclose in reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Trust’s management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting.
There have been no changes in the Trust’s system of internal control over financial reporting during the quarter ended December 31, 2018, that have materially affected, or are reasonably likely to materially affect, the Trust’s internal control over financial reporting.
Management’s Report on Internal Control over Financial Reporting.
The Trust’s management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an assessment of the effectiveness of the Trust’s internal control over financial reporting based on the criteria set forth in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on the assessment, management has concluded that the Trust’s internal control over financial reporting was effective as of December 31, 2018 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP.
The effectiveness of the Trust’s internal control over financial reporting as of December 31, 2018 has been audited by Ernst & Young LLP (“EY”), an independent registered public accounting firm, as stated in their report included in Part II, Item 8 of this Annual Report on Form 10-K.
Limitations on Effectiveness of Controls and Procedures.
In designing and evaluating the disclosure controls and procedures and the Trust’s internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and the Trust’s internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Physicians Realty L.P.
Evaluation of Disclosure Controls and Procedures.
The Operating Partnership’s management, with the participation of the Chief Executive Officer and Chief Financial Officer of the Operating Partnership’s general partner, has evaluated the effectiveness of the Operating Partnership’s disclosure controls and procedures (as defined in Rules 13a- 15(e) and 15d- 15(e) under the Exchange Act), as of the end of the period covered by this report. Based on such evaluation, the Chief Executive Officer and Chief Financial Officer of the Operating Partnership’s general partner concluded that as of December 31, 2018, the Operating Partnership’s disclosure controls and
107
procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information it is required to disclose in reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer of the Operating Partnership’s general partner, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting.
There have been no changes in the Operating Partnership’s system of internal control over financial reporting during the quarter ended December 31, 2018, that have materially affected, or are reasonably likely to materially affect, the Operating Partnership’s internal control over financial reporting.
Management’s Report on Internal Control over Financial Reporting.
The Operating Partnership’s management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an assessment of the effectiveness of the Operating Partnership’s internal control over financial reporting based on the criteria set forth in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on the assessment, management has concluded that the Operating Partnership’s internal control over financial reporting was effective as of December 31, 2018 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP.
Limitations on Effectiveness of Controls and Procedures.
In designing and evaluating the disclosure controls and procedures and the Operating Partnership’s internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and the Operating Partnership’s internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
ITEM 9B. OTHER INFORMATION
None.
108
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Incorporated herein by reference are “Proposal 1 - Election of Trustees”, “Section 16(a) Beneficial Ownership Reporting Compliance”, “Corporate Governance Matters - Trustee Nomination Procedure”, “Corporate Governance Matters - Audit Committee” and, “Executive Officers” to be included in the Trust’s 2019 Proxy Statement, which will be filed with the SEC within 120 days after the end of its fiscal year ended December 31, 2018.
Code of Business Conduct and Ethics
Information regarding our Code of Business Conduct and Ethics is provided in Part I., Item 1. “Business - Available Information” and is incorporated herein by reference.
ITEM 11. EXECUTIVE COMPENSATION
Incorporated herein by reference are “Executive Compensation”, “2018 Non-Employee Trustee Compensation”, “Compensation Committee Interlocks and Insider Participation”, and “Compensation Committee Report” to be included in the Trust’s 2019 Proxy Statement, which will be filed with the SEC within 120 days after the end of its fiscal year ended December 31, 2018.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
Incorporated herein by reference are “Security Ownership of Certain Beneficial Owners and Management” and “Equity Compensation Plan Information” to be included in the Trust’s 2019 Proxy Statement, which will be filed with the SEC within 120 days after the end of its fiscal year ended December 31, 2018.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE
Incorporated herein by reference are “Certain Relationships and Related Transactions” and “Trustee Independence” to be included in the Trust’s 2019 Proxy Statement, which will be filed with the SEC within 120 days after the end of its fiscal year ended December 31, 2018.
ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Incorporated herein by reference is “Proposal 2 - Ratification of Independent Registered Public Accounting Firm” to be included in the Trust’s 2019 Proxy Statement, which will be filed with the SEC within 120 days after the end of its fiscal year ended December 31, 2018.
109
PART IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
(a)The following documents are filed as part of this report:
(1)Financial Statements:
Page | ||
Reports of Independent Registered Public Accounting Firm | ||
Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting | ||
Financial Statements of Physicians Realty Trust | ||
Financial Statements of Physicians Realty L.P. | ||
Notes for Physicians Realty Trust and Physicians Realty L.P. | ||
(2)Financial Statement Schedules:
All other schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission are omitted because they are not required under the related instructions or are not applicable, or because the required information is shown in the consolidated financial statements or notes thereto.
(3)Exhibits:
See the Exhibit Index immediately following the signature page of this report on Form 10-K.
110
ITEM 16. FORM 10-K SUMMARY
None.
111
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PHYSICIANS REALTY TRUST | ||
Dated: | February 28, 2019 | /s/ John T. Thomas |
John T. Thomas | ||
Chief Executive Officer and President | ||
(Principal Executive Officer) | ||
Power of Attorney
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John T. Thomas and Jeffrey N. Theiler and each of them severally, his or her true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his or her name, place and stead, in any and all capacities, to do any and all things and execute any and all instruments that such attorney may deem necessary or advisable under the Securities Exchange Act of 1934 and any rules, regulations and requirements of the Securities and Exchange Commission in connection with this Annual Report on Form 10-K and any and all amendments hereto, as fully and for all intents and purposes as he or she might do or could do in person, and hereby ratifies and confirms all said attorneys-in-fact and agents, each acting alone, and his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
112
Signature | Title | Date | ||
/s/ JOHN T. THOMAS | Chief Executive Officer and | February 28, 2019 | ||
John T. Thomas | President and Trustee (Principal Executive Officer) | |||
/s/ JEFFREY N. THEILER | Executive Vice President and | February 28, 2019 | ||
Jeffrey N. Theiler | Chief Financial Officer (Principal Financial Officer) | |||
/s/ JOHN W. LUCEY | Senior Vice President - Chief Accounting and | February 28, 2019 | ||
John W. Lucey | Administrative Officer (Principal Accounting Officer) | |||
/s/ STANTON D. ANDERSON | Trustee | February 28, 2019 | ||
Stanton D. Anderson | ||||
/s/ MARK A. BAUMGARTNER | Trustee | February 28, 2019 | ||
Mark A. Baumgartner | ||||
/s/ ALBERT C. BLACK, JR. | Trustee | February 28, 2019 | ||
Albert C. Black, Jr. | ||||
/s/ WILLIAM A. EBINGER, M.D. | Trustee | February 28, 2019 | ||
William A. Ebinger, M.D. | ||||
/s/ PAMELA J. KESSLER | Trustee | February 28, 2019 | ||
Pamela J. Kessler | ||||
/s/ TOMMY G. THOMPSON | Chairman | February 28, 2019 | ||
Tommy G. Thompson | ||||
/s/ RICHARD A. WEISS | Trustee | February 28, 2019 | ||
Richard A. Weiss | ||||
113
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
PHYSICIANS REALTY L.P. by: Physicians Realty Trust, its general partner | ||
Dated: | February 28, 2019 | /s/ John T. Thomas |
John T. Thomas | ||
Chief Executive Officer and President | ||
(Principal Executive Officer) | ||
Power of Attorney
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John T. Thomas and Jeffrey N. Theiler and each of them severally, his or her true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his or her name, place and stead, in any and all capacities, to do any and all things and execute any and all instruments that such attorney may deem necessary or advisable under the Securities Exchange Act of 1934 and any rules, regulations and requirements of the Securities and Exchange Commission in connection with this Annual Report on Form 10-K and any and all amendments hereto, as fully and for all intents and purposes as he or she might do or could do in person, and hereby ratifies and confirms all said attorneys-in-fact and agents, each acting alone, and his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
114
Signature | Title | Date | ||
/s/ JOHN T. THOMAS | Chief Executive Officer and | February 28, 2019 | ||
John T. Thomas | President and Trustee (Principal Executive Officer) of Physicians Realty Trust, the general partner of Physicians Realty L.P. | |||
/s/ JEFFREY N. THEILER | Executive Vice President and | February 28, 2019 | ||
Jeffrey N. Theiler | Chief Financial Officer (Principal Financial Officer) of Physicians Realty Trust, the general partner of Physicians Realty L.P. | |||
/s/ JOHN W. LUCEY | Senior Vice President - Chief Accounting and | February 28, 2019 | ||
John W. Lucey | Administrative Officer (Principal Accounting Officer) of Physicians Realty Trust, the general partner of Physicians Realty L.P. | |||
/s/ STANTON D. ANDERSON | Trustee of Physicians Realty Trust, the general partner | February 28, 2019 | ||
Stanton D. Anderson | of Physicians Realty L.P. | |||
/s/ MARK A. BAUMGARTNER | Trustee of Physicians Realty Trust, the general partner | February 28, 2019 | ||
Mark A. Baumgartner | of Physicians Realty L.P. | |||
/s/ ALBERT C. BLACK, JR. | Trustee of Physicians Realty Trust, the general partner | February 28, 2019 | ||
Albert C. Black, Jr. | of Physicians Realty L.P. | |||
/s/ WILLIAM A. EBINGER, M.D. | Trustee of Physicians Realty Trust, the general partner | February 28, 2019 | ||
William A. Ebinger, M.D. | of Physicians Realty L.P. | |||
/s/ PAMELA J. KESSLER | Trustee of Physicians Realty Trust, the general partner | February 28, 2019 | ||
Pamela J. Kessler | of Physicians Realty L.P. | |||
/s/ TOMMY G. THOMPSON | Chairman of the Board of Trustees of Physicians Realty | February 28, 2019 | ||
Tommy G. Thompson | Trust, the general partner of Physicians Realty L.P. | |||
/s/ RICHARD A. WEISS | Trustee of Physicians Realty Trust, the general partner | February 28, 2019 | ||
Richard A. Weiss | of Physicians Realty L.P. | |||
115
EXHIBIT INDEX
Exhibit No. | Title | |
(1) | ||
(2) | ||
(3) | ||
(1) | ||
(4) | ||
(4) | ||
(4) | ||
(5) | ||
(5) | ||
(6) | ||
(7) | ||
(1) | ||
(8) | ||
(8) | ||
(8) | ||
(8) | ||
(8) | ||
(8) | ||
(8) | ||
(9) | ||
(9) | ||
(9) | ||
(9) | ||
(10) | ||
(11) | ||
(11) | ||
(11) | ||
(8) | ||
(12) | ||
(13) | ||
(13) | ||
(13) | ||
(13) | ||
(13) | ||
(14) | ||
(14) | ||
(14) | ||
(14) | ||
(14) | ||
(15) | ||
116
Exhibit No. | Title | |
(16) | ||
(16) | ||
(17) | ||
(18) | ||
101.INS | XBRL Instance Document(†) | |
101.SCH | XBRL Extension Schema Document(†) | |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document(†) | |
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document(†) | |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document(†) | |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document(†) | |
* Filed herewith
** Indicates a management contract or compensatory plan or arrangement.
† | Users of this data are advised pursuant to Rule 406T of Regulation S-T that this interactive data file is deemed not filed or part of a registration statement for purposes of Section 11 or 12 of the Securities Act, is deemed not filed for purposes of Section 18 of the Exchange Act, and otherwise is not subject to liability under these sections. |
(1) | Incorporated by reference to Amendment No. 2 to the Registrant’s Registration Statement on Form S-11 filed with the SEC on June 14, 2013 (File No. 333-188862). |
(2) | Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on February 24, 2017 (File No. 001-36007). |
(3) | Incorporated by reference to the Registrant’s Registration Statement on Form S-3 filed with the SEC on June 17, 2015 (File No. 333-205034). |
117
(4) | Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on March 7, 2017 (File No. 001-36007). |
(5) | Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on December 1, 2017 (File No. 001-36007). |
(6) | Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on February 6, 2015. |
(7) | Incorporated by reference to Amendment No. 3 to the Registrant’s Registration Statement on Form S-11 filed with the SEC on June 20, 2013 (File No. 333-188862). |
(8) | Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on February 28, 2018 (File No. 001-36007). |
(9) | Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on May 7, 2014 (File No. 001-36007). |
(10) | Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on August 7, 2014 (File No. 001-36007). |
(11) | Incorporated by reference to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 12, 2015 (File No. 001-36007). |
(12) | Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on June 13, 2016 (File No. 001-36007). |
(13) | Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on January 12, 2016 (File No. 001-36007). |
(14) | Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on August 11, 2016 (File No. 001-36007). |
(15) | Incorporated by reference to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 12, 2015 (File No. 001-36007). |
(16) | Incorporated by reference to the Registrant’s Quarterly Report on Form 10-Q filed with the SEC on May 6, 2016 (File No. 001-36007). |
(17) | Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on July 7, 2017 (File No. 001-36007). |
(18) | Incorporated by reference to the Registrant’s Current Report on Form 8-K filed with the SEC on August 7, 2018 (File No. 001-36007). |
118